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ABSTRACT 
 
Obesity is known to be associated with obstructive sleep apnoea (OSA) and Type 2 diabetes 
mellitus (T2DM). The effect of OSA in very severely obese individuals is not well 
documented. In this thesis, I compared the effect of OSA in South Asians and white 
Europeans, examined the effect of OSA on glycaemic control among T2DM, and explored the 
relationship between OSA and diabetic retinal and kidney diseases in a severely obese 
population. I also systematically reviewed the effect of OSA on diabetic kidney and retinal 
diseases. Findings from this thesis were 1) severely obese South Asians had greater severity 
of OSA compared to white Europeans and the mechanisms mediating this require further 
investigation, 2) a high OSA prevalence in T2DM individuals with a positive relationship 
between nocturnal hypoxia and glycaemic control, 3) severity of hypoxaemia during sleep 
may be an important factor in the development of diabetic retinal complications, 4) duration 
of hypoxaemia during sleep were inversely associated with renal function in T2DM and 5) 
from the systematic review, there is a need for future large cohort studies with long term 
follow-up data to examine the long-term effects of OSA and other sleep parameters on 
diabetic retinal and kidney diseases.  
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CHAPTER 1 – INTRODUCTION 
 
1.1 Obesity 
1.1.1 Obesity classification: body mass index (BMI) 
Obesity is crudely due to chronic surplus of energy intake with inadequate energy 
expenditure. The term ‘morbid obesity’ was introduced by Scott and Law in 1970 to describe 
individuals with excess weight as well as adverse health issues.
1
 This term is now used in 
parallel with ‘extreme obesity’, ‘clinically severe obesity’ or class III obesity’ in the 
literature.
2
 The lack of a reliable method to determine body fat in a practical, cost-effective 
and reliable way has led to the utilisation of the simple anthropometric measures as 
alternatives to determine the levels of obesity.  
 
The commonest anthropometric definition of obesity is based on the body mass index (BMI). 
Due to the close association between BMI and body fat,
3
 as well as the ability to provide a 
simple and objective measure without bias for comparison between populations, the BMI 
system is endorsed by the World Health Organisation (WHO)
4
 and several other international 
organisations.
5,6
 The BMI system is also cheap and non-labour intensive to measure and 
therefore has been widely used in large epidemiological studies.
7,8
 A BMI of greater or equal 
to (≥) 30Kg/m2 is considered to be obese. Table 1-1 shows the WHO classification of obesity 
for Caucasian adults.
4
 The obesity classification for adult Asians is different as the risk for the 
development of co-morbidities is at a lower weight.
9
 This is summarised in Table 1-2. 
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Table 1-1: The WHO classification of obesity for adult white Europeans
 4
 
BMI (Kg/m
2
) Classification Risk of co-morbidities 
25 – 29.9 Pre-obese Increased 
30 – 34.9 Obese I Moderate 
35 – 39.9 Obese II Severe 
≥ 40 Obese III Very severe 
 WHO = World Health Organisation, BMI = body mass index 
  
Table 1-2: The WHO classification of obesity for adult Asians 
9
 
BMI (Kg/m
2
) Classification Risk of co-morbidities 
23.0 – 27.5 Overweight Increased 
27.5 – 32.5 Obese I Moderate 
32.5 – 37.5 Obese II Severe 
≥37.5 Obese III Very severe 
 WHO = World Health Organisation, BMI = body mass index 
 
BMI has been found to have a ‘U’ shape relationship with morbidity and mortality.10,11 
Several studies have shown that there is an increased risk of premature cardiovascular 
events,
12,13
 stroke
14
 and mortality
11,15-17
 in overweight and obese individuals based on BMI 
calculations, compared to those who have a healthy weight. Although BMI is a widely used 
measurement for obesity, it has limitations, as it is a measurement of both fat and fat free 
mass including muscle, body fluids and organs. For muscular individuals such as body 
builders or rugby players, the BMI system may misclassify them to be either overweight or 
obese because it takes into account both lean mass as well as fat mass therefore it is a poor 
measure of obesity on an individual level. One study found that BMI lacked accuracy 
(sensitivity of 44% in males and 52% in females) in identifying obese individuals when 
compared to body fat percentage.
18
 BMI however, is highly accurate in excluding obesity.
18
 
The National Institute for Health and Care Excellence (NICE) has therefore recommended 
that BMI should be interpreted with caution as it is a surrogate measurement of adiposity.
19
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1.1.2 Other anthropometric measurements 
Adipose tissue is usually deposited either in the subcutaneous or visceral tissues. A high level 
of visceral adipose tissue (VAT) has been found to be associated with increased metabolic 
risk.
20
 Because of this, waist circumference (WC) and waist-to-hip ratio (WHR) are now 
increasing being used as an indirect measurement of visceral adiposity. Similar to BMI, 
population studies have shown that both WC and WHR are predictors for hypertension, Type 
2 diabetes mellitus (T2DM), cardiovascular diseases (CVD) and all-cause mortality.
10,21-24
 
Currently, two major guidelines are using WC as part of the diagnosis for metabolic 
syndrome.
25,26
 However, both guidelines implement different cut off points for WC.
25,26
  
 
The U.S. National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP 
III) for the treatment of dyslipidaemia defines central obesity as ≥102cm for males and ≥88cm 
for females.
25
 The International Diabetes Federation (IDF) uses ethnic-specific levels for WC 
as shown in Table 1-3.
26
 For white Caucasians, the NCEP and IDF cut points differs because 
the NCEP uses a level corresponds to a BMI ≥30Kg/m2 whilst the IDF uses a cut point 
corresponds to BMI ≥25Kg/m2.26 If an individual has a BMI of ≥30Kg/m2, then central 
obesity can be assumed based on the IDF guideline.
26
 Diagnosis of metabolic syndrome based 
on the NCEP and IDF guidelines are shown in Table 1-4.  
 
Table 1-3: The IDF waist circumference cut off points according to ethnicity
26
 
Ethnicity Male Female 
- White Caucasians  
- Sub-Saharan African 
- Eastern Mediterranean  
- Middle East (Arab) populations 
≥ 94 cm 
≥ 94 cm 
≥ 94 cm 
≥ 94 cm 
≥ 80 cm 
≥ 80 cm 
≥ 80 cm 
≥ 80 cm 
- South Asians 
- South and Central American 
≥ 90 cm 
≥ 90 cm 
≥ 80 cm 
≥ 80 cm 
- Chinese  
- Japanese 
≥ 90 cm 
≥ 90 cm 
≥ 80 cm 
≥ 80 cm 
IDF = International Diabetes Federation  
 4  
 
 
Table 1-4: Diagnosis of metabolic syndrome based on the IDF
26
 and NCEP
25
 guidelines 
 Obesity Lipid Blood 
pressure 
Glucose 
IDF  – 
Obesity  plus 
2 factors 
 
Waist 
circumference 
(ethnic specific) 
or  
BMI ≥30Kg/m2 
 
Raised Tg 
≥150mg/dl or 
HDL-chol <50 
(M) or <40mg/dl 
(F) or  on therapy  
≥130/85 
mmHg or on 
therapy 
Fasting glucose 
> 100mg/dl or 
known T2DM 
NCEP -any 3 
criteria 
Waist 
circumference 
>102cm (M) 
or 
>88cm (F) 
Raised Tg 
≥150mg/dl or 
HDL-chol 
<40mg/dl (M) or 
<50mg/dl (F) or 
on therapy 
≥130/85 
mmHg or on 
therapy 
Fasting glucose 
>110mg/dl or 
known T2DM 
IDF=International Diabetes Federation, NCEP= National Cholesterol Education Programme, 
BMI=body mass index, M=Male; F=Female, Tg=triglycerides, HDL-chol=high-densitiy- lipoprotein 
cholesterol, T2DM=type 2 diabetes mellitus. 
 
 
 
1.1.3 Classification based on obesity related complications 
Although both BMI and WC are good surrogate measures in population-based studies, they 
lack accuracy to stratify patient’s risk individually for obesity related co-morbidities.2 This 
has led to the proposed adoption of a clinical staging system to identify high risk obese 
individuals for weight management treatment. The aim of the clinical staging is similar to that 
of utilising the tumour, node and metastasis (TNM) staging system for individual cancer 
care
27
 or the New York Heart Association (NYHA) functional classification for heart failure 
patients.
28
 This approach adopts a standardised framework in order to describe individuals’ 
risk and to ease communication between healthcare practitioners. Currently, there are four 
staging systems available in the literature and they are: the Edmonton Obesity Staging System 
(EOSS),
29
 the Cardiometabolic Disease Staging (CMDS) system,
30
 the King’s Obesity 
Staging Criteria
31
 and the Dudley Bariatric Surgery Comorbidity (DUBASCO) score.
32
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The EOSS assessed 3 components with each component rated using a 5-point ordinal scale 
(please refer to Table 1-5).
2
 The components are categorised into medical, mental and 
functional. Stage 0 applies to asymptomatic patients with no obesity-related health risk 
factors, a full functional capacity and absence of mental health issues. Stage 1 consists of 
individuals with either a sub-clinical risk factor (e.g. borderline hypertension, impaired 
glucose tolerance), the presence of mild physical symptoms such as breathlessness on 
moderate exertion, mild psychopathology or the presence of mild functional limitation. 
Individuals with established obesity related co-morbidity such as hypertension or presence of 
moderate psychopathology/functional limitation causing an impact on well-being are classify 
in to Stage 2.  
 
Stage 3 includes patients with disease specific end-organ damage such as renal impairment or 
significant psychopathology or function impairment. The final stage, Stage 4 involves 
individuals with debilitating illness either from chronic disease, mental health or severe 
functional impairments. Using data from three large population survey data: the National 
Health and Human Nutrition Examination Surveys (NHANES) III (1988 to 1994), NHANES 
1999-2004
29
 and the Aerobics Centre Longitudinal Study,
33
 the EOSS classification system 
had been shown to be a better predictor of mortality compared with the BMI system.  
 
Using the EOSS stage 0 and 1 as the reference, the results from the NHANES data 
demonstrated a step-wise increase in mortality (please refer to Figure 1-1): EOSS stage 2 HR 
1.62 (95% CI: 1.19 to 2.21) and EOSS stage 3 HR 2.78 (95% CI: 2.07 to 3.74). This is 
compared to using the BMI system whereby overweight individuals were used as reference, 
there are no difference in the risk for mortality according level of obesity: class I obesity HR 
 6  
 
1.26 (95% CI: 1.03 to 1.55), class II obesity HR 1.81 (95% CI: 1.27 to 2.57) and class III 
obesity HR 1.61 (95% CI: 1.02 to 2.56).
29
 Due to this reason, the Royal College of Physicians 
have recently recommended the use of EOSS to stratify individual patients’ risk in their report 
Action on obesity: comprehensive care for all.
34
  
 
Figure 1-1: The prediction of all-cause mortality for overweight and obese individuals based 
on the Edmonton obesity staging system and the body mass index system.  
“Using the Edmonton obesity staging system to predict mortality in a population-
representative cohort of people with overweight and obesity” – Reprinted from, Canadian 
Medical Association Journal 2011; (14), (183), E1059-66 by permission of the publisher. ©2014 
Canadian Medical Association  
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Table 1-5: The Edmonton Obesity Staging System. Reprinted by permission from Macmillan 
Publishers Ltd: [International Journal of Obesity],
2
 copyright 2009 
Stage  Description  Management 
0 No apparent obesity-related risk factors 
(e.g., blood pressures, serum lipids, 
fasting glucose, etc. within normal range), 
no physical symptoms, no 
psychopathology, no functional 
limitations and/or impairment of well 
being 
 
Identification of factors contributing to 
increased body weight. Counselling to 
prevent further weight gain through 
lifestyle measures including healthy eating 
and increased physical activity 
1 Presence of obesity-related subclinical 
risk factors (e.g., borderline hypertension, 
impaired fasting glucose, elevated liver 
enzymes, etc.), mild physical symptoms 
(e.g., dyspnoea on moderate exertion, 
occasional aches and pains, fatigues, etc.), 
mild psychopathology, mild functional 
limitations and/or mild impairment of 
well being 
 
Investigation for other (non-weight related) 
contributors to risk factors. More intense 
lifestyle interventions, including diet and 
exercise to prevent further weight gain. 
Monitoring of risk factors and health status. 
2 Presence of established obesity-related 
chronic disease (e.g., hypertension, type 2 
diabetes, sleep apnoea, osteoarthritis, 
reflux disease, polycystic ovary 
syndrome, anxiety disorder, etc.), 
moderate limitations in activities of daily 
living and/or well being 
 
Initiation of obesity treatments including 
considerations of all behavioural, 
pharmacological and surgical treatment 
options. Close monitoring and management 
of comorbidities as indicated. 
3 Established end-organ damage such as 
myocardial infarction, heart failure, 
diabetic complications, incapacitating 
osteoarthritis, significant 
psychopathology, significant functional 
limitations and/or impairment of well 
being 
 
More intensive obesity treatment including 
considerations of all behavioural, 
pharmacological and surgical treatment 
options. Aggressive management of 
comorbidities as indicated. 
4 Severe (potentially end-stage) disabilities 
from obesity-related chronic diseases, 
severe disabling psychopathology, severe 
functional limitations and/or severe 
impairment of well being 
Aggressive obesity management as deemed 
feasible. Palliative measures including pain 
management, occupational therapy and 
psychosocial support.  
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Similar to the EOSS, the CMDS system has been shown to predict all-cause mortality using 
the NHANES III and the Collaborative Assessment of Research Data Infrastructure and 
Objectives (CARDIO) data.
30
 However, the CMDS system is a very recent classification and 
there is no study which compares its predictability for mortality with the BMI or other 
anthropometric systems. The CMDS system is devised from the criteria used for metabolic 
syndrome and the diagnosis of type 2 diabetes mellitus (T2DM). Individuals in Stage 0 have 
no metabolic risk factors. Criteria for Stages 1, 2, 3 and 4 are shown in Table 1-6.  
 
 
Table 1-6: The Cardiometabolic Disease Staging (CMDS) system. Adapted from Guo et al.
30
  
Stage  Description  Components 
0 Metabolically healthy No metabolic risk factors 
1 One or two risk factors (a) Waist circumference ≥112cm in men or ≥88cm 
in women 
(b) Blood pressure (systolic ≥130mmHg and/or 
diastolic ≥85mmhg) or on antihypertensive 
medication 
(c) Low serum HDL-cholesterol (<1.0 mmol/l in 
men or <1.3mmol/l in women) or on lipid 
lowering medication 
(d) Raised fasting serum triglycerides 
(≥1.7mmol/l) or on lipid lowering medication 
2 Metabolic syndrome or 
prediabetes state 
Any one of the following conditions: 
(a) Metabolic syndrome: based on the ≥3 of the 
above risk factors 
(b) Impaired fasting glycaemia (fasting serum 
glucose ≥5.6mmol/l) 
(c) Impaired glucose tolerance (post-prandial 
glucose ≥7.8mmol/l) 
3 Metabolic syndrome with 
prediabetes state 
Have two of the Stage 2 conditions 
4 Type 2 diabetes mellitus 
and/or cardiovascular disease 
(CVD) 
Have either one of the following:  
(a) Type 2 diabetes mellitus or on anti-diabetic 
treatment 
(b) Active CVD (angina pectoris or post CVD 
event) 
HDL= high-density-lipoprotein, CVD = cardiovascular disease 
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Both the Kings Obesity Staging system
31
 and the DUBASCO score
32
 are devised to aid 
decision making for bariatric surgery taking into account adiposity levels as well as co-
morbidities. Similar to the CMDS system, there is no research comparing the predictive 
performance (on mortality and morbidity risks) for both the scoring systems with other 
anthropometry measurements. The Kings Obesity Staging system
31
 contains 9 components 
with 4 ordinal score for each component. The nine components in alphabetical order are 
airways, BMI, cardiovascular disease, diabetes, economic complications, functional 
limitations, gonadal axis, health status, and image (body) as shown in Table 1-7.  
 
 
Table 1-7: The King’s Obesity Staging Criteria. Adapted from Aaesheim et al.31 
 Stage 0 
‘Healthy’ 
Stage 1 
‘At risk’ 
Stage 2 
‘Established 
disease’ 
Stage 3 
‘Advanced 
disease’ 
Airway Normal Snorer On CPAP  Cor pulmonale 
BMI (Kg/m
2
) <35 35 – 40 40 – 60 >60 
Cardiovascular <10% risk 10-20% risk Heart disease Heart failure 
Diabetes No diabetes IGT/IFG T2DM Uncontrolled 
T2DM 
Economic Normal  Expensive 
travel/clothes 
Workplace 
discrimination 
Unemployed due 
to obesity 
Functional Manage 3 flights 
of stairs 
1/2 flights of 
stairs 
Walking 
aids/wheel chair 
House bound 
Gonadal No problem PCOS Infertility Sexual 
dysfunction 
Health  Normal Low QoL or 
mood 
Poor QoL of 
depression  
Severe 
depression 
Image (body) Normal Dislikes own 
body 
Body image 
dysphoria 
Eating disorder  
CPAP=continuous positive airway pressure, BMI=body mass index, IGT=impaired glucose tolerance, 
IFG=impaired fasting glycaemia, T2DM=type 2 diabetes mellitus, PCOS=polycystic ovarian 
syndrome, QoL=quality of life 
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The DUBASCO score
32
 contained 5 components, each with a four level ordinal scale as 
shown in Table 1-8. The researchers for DUBASCO score have recommended the cut point of 
≥10 as a cut-off for considering bariatric surgery. The benefit of using a scoring system is that 
the level of cut point can be altered depending on the available resources. The scoring system 
also aids healthcare professionals in the prioritisation of patients who have the greatest needs 
for bariatric surgery in the face of the current NHS with limited healthcare access and scarce 
resources.  
 
 
Table 1-8: The Dudley Bariatric Surgery Comorbidity (DUBASCO) score. Adapted from 
Labib et al.
32
 (with permission from Dr M. Labib) 
Component 1 2 3 4 
Age (years) >60 51-60 41-50 ≤40 
BMI (Kg/m
2
) ≥35.0 to 40.0 >40.0 to 50.0 >50.0 to 60.0 60.0 
Comorbidities: 
T2DM 
 
IFG/IGT 
 
HbA1c ≤7.0% 
 
HbA1c 7.1-9.0% 
 
HbA1c >9.0% or 
on insulin 
Hypertension Well-controlled 
on one drug 
Well-controlled 
on 2 drugs 
Poorly controlled 
on 2 drugs 
Poorly controlled 
on >2 drugs 
Dyslipidaemia No treatment Well-controlled 
on 1 drug 
Well-controlled on 
2 drugs 
Poorly controlled 
on 2 drugs 
OSA Neck 
circumference 
>43 cm or snorer 
ODI 5-14 
events/hour 
ODI 15-30 
events/hour 
ODI >30 
events/hour or on 
CPAP 
BMI = body mass index, T2DM= type 2 diabetes mellitus, IFG=impaired fasting glycaemia, 
IGT=impaired glucose tolerance, HbA1c=glycosylated haemoglobin A1c, OSA=obstructive sleep 
apnoea, ODI=oxygen desaturation index assessed by 2 overnight oximetry readings, 
CPAP=continuous positive airway pressure 
 
 
1.1.4 Epidemiology of obesity 
The prevalence of obesity is increasing in both developing and developed countries. A report 
using data from 199 countries and territories with 9.1 million participants found that the mean 
BMI has risen by 0.4Kg/m
2
 per decade (95% uncertainty interval: 0.2 to 0.6) for males and 
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0.5Kg/m
2
 per decade increase (95% uncertainly interval: 0.3 to 0.7) for females from 1980 to 
2008.
35
 Moreover, the report estimated that the age-standardised prevalence of obesity is 9.8% 
(95% CI: 9.2 to 10.4) for men and 13.5% (95% CI: 13.1 to 14.7) for women in 2008. 
Recently, the WHO estimated that globally over 1.4 billion adults are now considered obese.
36
  
In the UK, The 2012 Health Survey for England reported that 24% of adult men and 25% of 
adult women over the age of 16 were obese.
37
 Furthermore in 2030, it is projected that an 
extra 11 million adults will be obese
38
 and the Foresight report estimated that by 2050, more 
than half of the UK population will be obese.
39
 The Foresight report also evaluated that in 
2050, both the obese and overweight adults, will cost the country £50 billion per year
39
 if 
weight preventative measures are not successful.  
 
1.1.5 Obesity related diseases 
It is well-recognised that obese individuals suffer from premature mortality,
17,40
 have 
increased risk for cardiovascular disease (CVD)
41-43
 and several different types of 
malignancy.
44
 The National Institute of Health-American Association of Retired Persons 
(NIH-AARP) Diet and Health study followed-up 527,265 US individuals aged between 50 
and 71 years old for a maximum of 10 years reported a ‘J’ shaped relationship between BMI 
and death.
40
 The Framingham Heart Study followed-up 3457 individuals from 1948 to 1990 
demonstrated that a 40-year-old obese non-smoker female loses 7.1 years while a 40-year-old 
obese non-smoker male loses 5.8 years of their respective life expectancy compared to their 
normal weight (BMI between 18.5 and 24.9Kg/m
2
) counterparts.
17
 The premature mortality is 
likely to be related to the increase risk in both malignancy
44
 and CVD.
42
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A systematic review of 141 studies which included 282,137 cancer cases demonstrated an 
association between BMI and several carcinomas.
44
 For example, a 5Kg/m
2
 increase in BMI 
was associated with a higher risk of colon (RR1.24, 95% CI: 1.15 to 1.34), thyroid (RR 1.33, 
95% CI: 1.04 to 1.70) and oesophageal (RR 1.52, 95% CI: 1.33 to 1.74) malignancies in men. 
In women, a 5Kg/m
2
 increase in BMI was associated with a higher risk of oesophageal (RR 
1.51, 95% CI: 1.31 to 1.74), gallbladder (RR 1.59, 9% CI: 1.02 to 2.47) and endometrial (RR 
1.59, 95% CI: 1.50 to 1.68) carcinomas. A Swedish longitudinal study (n=22,025, 26 year 
follow-up) reported that obese men had a 76% higher risk (RR 1.76, 95% CI: 1.49 to 2.08) of 
CVD compared to those with normal BMI.
42
 
 
One of the mechanisms linking obesity with CVD as well as premature death is the 
association of obesity with several cardiovascular risk factors. The NHANES (1999 to 2004) 
study consisted of 13,745 US individuals, and found that when compared to individuals with 
normal BMI, those with BMI ≥40Kg/m2 had a higher risk of hypertension (OR 4.8, 95% CI: 
3.8 to 5.9), dyslipidaemia (OR2.2, 95% CI: 1.7 to 2.4), metabolic syndrome (OR 2.0, 95% CI: 
1.4 to 2.8) and diabetes mellitus (DM) (OR 5.1, 95% CI: 3.7 to 7.0).
45
 Moreover, treatment 
for obesity especially bariatric surgery has been shown to result in improvements in these 
cardiovascular risks, especially T2DM. The Swedish Obese Subjects study followed-up 1703 
participants who had had bariatric surgery and shown that after 10 years, improvements in 
hypertriglyceridaemia (OR 2.56, 95% CI: 1.85 to 3.57), hypertension (OR 1.68, 95% CI: 1.09 
to 2.58) and T2DM (OR 3.45, 95% CI: 1.64 to 7.28)
46
 occurred in bariatric patients compared 
with those medically managed patients. Another chronic condition associated with obesity is 
obstructive sleep apnoea (OSA). The association between obesity and OSA will be discussed 
in section 1.3.  
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1.2 Type 2 diabetes mellitus  
Type 2 diabetes mellitus (T2DM) is a condition characterised by a chronic hyperglycaemic 
state secondary to insulin resistance and beta cell dysfunction. The International Diabetes 
Federation (IDF) estimates that there are at least 366 million individuals with diabetes 
mellitus (DM) worldwide and this is projected to rise to 552 million in 2030.
47
 In the UK, 
there are over 3 million individuals known to have DM and an approximately 850,000 people 
with undiagnosed DM
48
 making the overall prevalence of diabetes in the UK to be 4.5%.
48
 
DM is an important chronic condition partly because it is associated with a considerable 
economic burden to the healthcare system. A recent report from the London School of 
Economics (LSE) estimated that DM costs the UK economy at least £13.8 billion annually 
and the cost of each DM patient was estimated to be £3,717
49
 with a large proportion of the 
cost attributed to the treatment and management of T2DM complications.  
 
Apart from economic cost, T2DM also is associated with increased morbidity and premature 
mortality secondary to the macro- and micro-vascular complications.
50,51
 Macro-vascular 
complications of DM include ischaemic heart disease, cerebrovascular disease and peripheral 
vascular disease. A recent meta-analysis on 26 studies compared mortality risk of DM and 
non-DM individuals. There was a total of 220,689 participants with a mean follow-up of 10.7 
years and DM was found to be an independent predictor for all-cause mortality (RR 1.85, 
95% CI: 1.79 to 1.92).
52
 The UK Prospective Diabetes Study (UKPDS) recruited 4585 newly 
diagnosed T2DM participants found that each 1% rise of glycosylated haemoglobin A1c 
(HbA1c) was associated with 21% (95% CI: 15% to 27%) increase in DM related deaths, 14% 
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increase in  myocardial infarction (95% CI: 8% to 21%) and 37% increase in microvascular 
complications (95% CI: 33% to 41%).
51
  
 
1.2.1 Natural history of Type 2 diabetes mellitus (T2DM) 
The underlying pathophysiology of T2DM is chronic hyperglycaemia and this disturbance in 
glucose homeostasis is likely to have started several years before the onset of DM.
53
 A study 
which recruited T2DM from the US and Australia to investigate the prevalence of retinopathy 
found that by extrapolating the linear relationship between the diagnosis of diabetic 
retinopathy and the duration of T2DM, it was estimated that onset of T2DM most likely 
occurred 9 to 12 years before a clinical diagnosis was made.
53
 The combination of hereditary 
influences and other environmental factors such as sedentary lifestyle leading to obesity have 
contributed to the development of insulin resistance state in which normal glucose tolerance is 
maintained through a compensatory greater production of insulin by the pancreatic beta-cell 
resulting in a hyperinsulinaemic state. Studies on high risk pre-diabetes individuals have 
revealed that insulin resistance is most likely the initial pathognomonic phase for the 
development of T2DM.
54
 Over time, insulin resistance progressively worsened and the 
pancreas is not able to supply the required amount of insulin to match demand from the 
insulin resistant organs. This causes elevation of glucose level commonly known as the 
impaired fasting and glucose tolerance (IGT) state.  
 
The chronic excess glucose from the IGT state induced excess formation of reactive oxygen 
species (ROS) causing oxidative stress. Pancreatic beta-cells are very sensitivity to the insult 
from oxidative stress. Therefore, this leads to damage and subsequently dysfunction of the 
pancreatic beta cells. The term glucotoxicity has been utilised to describe this process. 
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Furthermore, excess glucose also affects intracellular lipid synthesis with accumulation of 
metabolic products causing lipotoxicity. Together, gluco- and lipotoxicity impose deleterious 
effects to insulin signalling, expression and apoptosis of the pancreatic beta-cells.
54,55
 Indeed, 
it has been demonstrated that at the onset of T2DM, there is at least 50-60% loss of beta-cell 
function.
54
 The progressive decompensation of pancreatic beta-cell ultimately led to overt 
T2DM. Although beta-cells continue to secrete some insulin in T2DM state, over time, insulin 
production decreases. At this stage, without the adequate inhibitory action of insulin, hepatic 
gluconeogenesis ensues causing a greater level of hyperglycaemia. This process is 
summarised in Figure 1-1. 
 
 
Figure 1-2: Pathogenesis of beta-cell failure 
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Apart from beta-cell dysfunction, a reduction in incretin effect also plays a role. The ability of 
gastrointestinal system to secrete incretin hormones after a meal, especially after a high 
carbohydrate meal, is termed the incretin effect. The incretin hormones are glucagon-like 
peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones 
are released after a meal and exert different effects on several target organs. GIP inhibits beta 
cell apoptosis and increase beta-cell replication. It also increases glucagon secretion as well as 
lipogenesis. On the other hand, GLP-1 stimulates insulin release, suppresses glucagon 
secretion, increase beta-cell replication and inhibits beta-cell apoptosis. It also promotes 
satiety by acting on the central nervous system, delays gastric emptying thus promoting early 
satiety and helps in weight reduction. In addition, it also has been found to reduce post-
prandial fatty acid levels. Collectively, these effects help in insulin sensitivity and secretion
56
 
as summarised in Table 1-9. In T2DM, it has been proposed that a progressive ineffective 
response to the incretin hormones occur leading to the decline in incretin effect.
57,58
  
 
Table 1-9: Effect of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP) actions in Type 2 diabetes mellitus 
 
Action  GIP GLP-1 
Insulin secretion  No effect Increased  
Glucagon secretion  Increased Reduced  
Beta-cell  Reduced apoptosis 
Increased replication  
Reduced apoptosis 
Increased replication  
Obesity Increased lipogenesis Early satiety via appetite 
centre, reduced in body weight 
Gastric emptying No effect Decreased rate of gastric 
emptying 
Insulin resistance No effect Increased insulin sensitivity 
GIP = glucose-dependent insulinotropic polypeptide; GLP-1 = glucaton-like peptide-1 
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1.2.2 Obesity and Type 2 diabetes mellitus 
As mentioned in section 1.1.5, T2DM is one of the cardiometabolic risk factors associated 
with obesity leading to premature death. Additional information on the effect of obesity on 
T2DM will be covered in the introduction section of Chapter 3 to avoid repetition. 
 
1.3 Obstructive sleep apnoea (OSA) 
1.3.1 Obstructive sleep apnoea: definition and symptoms  
Obstructive sleep apnoea (OSA) is characterised by the intermittent repetitive complete or 
partial collapses of the upper airway or pharynx. It is an increasingly common chronic 
respiratory disorder. It has been recognised as a significant health problem from the late 20
th
 
century. The term ‘Picwickian’ was first used to describe this syndrome in the 19th century 
after Charles Dickens’ description of the character Fat Boy Joe in ‘The Posthumous Papers of 
the Pickwick Club (1837)’. Fat Boy Joe is a remarkably obese boy with an inclination to fall 
asleep at any time of the day in any situation. This has led to the detailed depiction of the 
Picwickian syndrome by Bickelmann and colleague in 1956,
59
 referring to an obese individual 
who has hypersomnolence with hypercapnia which may result in cor pulmonale and 
erythrocytosis.
59
 Currently, this syndrome is redefined as obesity hypoventilation syndrome, 
which represents between 9% and 20% of OSA patients.
60
 OSA is characterised by the 
intermittent repetitive complete or partial collapses of the upper airway or pharynx. The 
collapses lead to increase in airflow resistance, raised intra-thoracic pressure, reduction in 
arterial oxygenation, hypercapnia and subsequently arousal from sleep to re-establish 
ventilation. These respiratory disturbances result in sleep fragmentations as well as activation 
of sympathetic activities.
61,62
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Evaluation of OSA as in many other diseases involves history taking, physical examination 
and laboratory investigations. There are several symptoms found to be associated with OSA, 
most commonly, snoring. In the Sleep Heart Health Study (SHHS) with 5615 participants, 
61% of OSA individuals were habitual snorers, defined as snoring between 3 to 7 nights per 
week.
63
 Snoring may gradually progress to be significantly worse over time and can be 
aggravated by alcohol intake or sedative medications. In some situations, snoring may even 
disrupt relationships as some bed partners are compelled to sleep in a separate bedroom. One 
issue with snoring is that it is also a very common presentation within the general population. 
The Health Improvement Network (THIN) database, a longitudinal UK primary care 
database, found that of the 1,073,116 individuals, 0.6% (6,527 individuals) had a diagnosis of 
OSA while 1.2% (12,499 individuals) was reported to be snorers.
64
 A recent meta-analysis of 
6 studies investigating the accuracy of clinical examination in the diagnosis of OSA 
concluded that snoring alone was not a predictive factor for OSA individuals with an AHI ≥10 
events/hr (likelihood ratio 1.1, 95% CI: 1.0 to 1.1).
65
  
 
Apart from snoring, episodes of breathing pauses during sleep witnessed by bed partners have 
also been associated with OSA. In a study of 394 hypertensive individuals, witnessed apnoeas 
were reported in 18% (95% CI: 11 to 25) of individuals with mild OSA and 11% (95% CI: 28 
to 45) of those with moderate to severe OSA.
66
 A clinical study of 250 patients who were seen 
in a sleep centre found that those with OSA (n=134) had double the risk for observed apnoeas 
(OR 2.0 95% CI: 1.1 to 3.8) compared with those who did not have OSA.
67
   
 
In addition, the Wisconsin Sleep Cohort Study included 388 women found that up to 6% of 
females within the general population may report apnoea episodes.
68
 Other non-specific 
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symptoms have also been shown to be associated with OSA and can be categorised into 
nocturnal or daytime symptoms. Nocturnal symptoms besides snoring and apnoeas include 
dyspnoea which may present as choking or gasping sensation and usually results in arousal, 
nocturia, gastro-oesophageal reflux, dry mouth and restless sleep. Daytime symptoms include 
excessive daytime somnolence, impairment in neurocognition such as poor concentration and 
memory impairment, mood change, headache upon waking as well as sexual dysfunction 
including decrease in libido and impotence. A summary of the OSA symptoms is shown in 
Table 1-9.  
 
Table 1-10: Nocturnal and daytime symptoms of obstructive sleep apnoea 
Nocturnal symptoms Day time symptoms 
Snoring Excessive daytime somnolence 
Observed apneoas  Poor concentration 
Dyspnoea  Memory impairment 
Nocturia Mood change 
Gastro-oesophageal reflux Early morning headache 
Dry mouth Sexual dysfunction  
Restless sleep  
 
 
Not only are symptoms for OSA non-specific, but physicians’ impression based on symptoms 
and signs, has also been shown to have poor predictive ability for OSA. In an observational 
study of 594 patients referred to the sleep clinic in Canada with standard sleep-related 
questions, subjective physician impression had a 60% sensitivity and 63% specificity for the 
diagnosis of OSA compared to the gold standard.
69
 In another study of 37 patients who had 
had polysomnography (PSG), which is the gold standard investigation for OSA, the 
researchers found that a brief clinical assessment had 65% sensitivity and 70% accuracy for 
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the diagnosis of OSA.
70
 Therefore, screening tools may be useful in identifying high risk 
individuals.  
 
1.3.2 Screening and diagnosis of obstructive sleep apnoea 
As symptoms for OSA and clinicians’ impression have lower accuracy for OSA, several 
screening questionnaires have been developed. Screening for OSA usually involves 
administrating validated questionnaires such as the Epworth’s Sleepiness Score (ESS)71 and 
the Berlin Questionnaire.
72
 ESS was first designed to assess daytime somnolence
71
 and has a 
maximum score of 24. A total of 184 adults which consisted of 150 patients with sleep 
disorders were compared with 30 normal individuals. All participants rated the probability of 
falling asleep in eight different situations. An ESS score of ≥16 was found to be present only 
in patients with excessive daytime somnolence (idiopathic hypersomnia, moderate-to-severe 
OSA and narcolepsy).
71
 The correlation between ESS and apnoea-hypopnoea index (AHI), a 
measure for OSA (see below for further explanation), was reported to be (r=0.55, p<0.001).
71
 
However, another study of 54 OSA patients from a sleep clinic found that the correlation 
between ESS and AHI was (r=0.28, p<0.05).
73
 The inconsistencies in the results limit the use 
of the ESS screening, rather than a diagnostic test for OSA.  
 
The Berlin questionnaire is an alternative questionnaire for OSA. It contains 3 categories; 
namely snoring, wake time sleepiness or drowsy driving and hypertension or obesity.
72
 The 
presence of persistent symptoms in at least 2 of the categories indicates a patient has a high 
risk of OSA. The Berlin questionnaire was designed based on the consensus of 120 U.S. and 
German primary care physicians on the Conference on Sleep in Primary Care held in Berlin, 
Germany in 1996.
72
 The questionnaire was subsequently tested on 744 adults from 4 primary 
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care centres in Cleveland, Ohio.
72
 Compared to a portable home monitoring device, the Berlin 
questionnaire was found to have a sensitivity and specificity of 0.17 and 0.97, respectively for 
AHI >30 events/hr. For AHI >15 events/hr, sensitivity was 0.54 and specificity was 0.97 and 
for AHI >5 events/hr, sensitivity was 0.86 with specificity of 0.77.  
 
Another study of 2,467 elective surgical patients compared the Berlin questionnaires with in-
hospital full polysomnography, and  reported an area under the receiver operating 
characteristic curve (AUC) of 0.668 in those with AHI >30 events/hr, AUC of 0.672 in those 
with AHI >15 events/hr and AUC of 0.690 for AHI >5 events/hr.
74
 The sensitivity for Berlin 
questionnaire was 87.2% (95% CI: 72.6 to 95.7), 78.6% (95% CI: 67.1 to 87.5) and 68.9% 
(95% CI: 59.8 to 76.9) for AHI >30 events/hr, >15 events/hr and >5 events/hr respectively. 
The specificity was 46.4% (95% CI: 37.9 to 55.1) for AHI >30 events/hr, 50.5% (95% CI: 
40.6 to 62.3) for AHI >15 events/hr and 56.4% (95% CI: 42.3 to 69.7) for AHI >5 events/hr.  
 
The questionnaires are ideal for stratifying OSA risk and for screening, but they are not 
designed to diagnose OSA. According to the American Academy of Sleep Medicine (AASM) 
guidelines for OSA diagnosis, a diagnosis of OSA is based on apnoea-hypopnoea index 
(AHI).
75
 An apnoea occurs when there is a complete absence of airflow for at least 10 seconds 
while hypopnoea occurs when there is at least 30% reduction in airflow in conjunction with at 
least 4% arterial oxygen desaturation with evidence of abdominal or thoracic movement.
75
 
AHI is the calculated as the average number of apnoea or hypopnoea episodes occurring per 
hour of sleep. An AHI cut off point of greater or equal (≥) to 5 is diagnostic of OSA. AHI is 
further used to classify OSA into mild, moderate and severe disease: AHI of between 5 and 
14events per hour (events/hr) is classified as mild; AHI between 15 and 29 events/hr is 
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moderate and AHI ≥30 events/hr is classified as severe OSA.61,76 OSA syndrome is a 
diagnosis of OSA with sleep symptoms.
77
  
 
The gold standard and the recommended test to diagnose OSA is overnight sleep 
polysomnography (PSG) which includes electroencephalogram (EEG), electroculogram 
(EOG), chin electromyogram, electrocardiography, oxygen saturation, respiratory airflow, 
thoracic-abdominal movements, monitoring for episodes of snoring and body position.
61,76
 A 
basic sleep study should consist of at least assessment of respiration, snoring and abdominal-
thoracic movement.
76
 A full PSG is costly and needs special technical expertise to perform 
therefore some sleep centres might not offer it routinely to patients.
78
 Portable home sleep 
monitors such as a Level III device with data available for oxygen saturation, respiratory 
airflow and thoracic-abdominal movement, provide an alternative option for sleep studies.  
 
1.3.3 Complications of obstructive sleep apnoea 
Apart from the association with obesity, OSA has been linked to and is likely an important 
risk factor for type 2 diabetes mellitus (DM),
79,80
 hypertension,
81-83
 CVD
84,85
 and premature 
mortality either due to road traffic accidents (RTA)
86,87
 or through CVD-related death.
84,85
 
The SHHS
79
 has 2656 patients with fasting blood glucose (FBG) results, 1930 patients with 
prandial blood glucose (PBG) results and 1144 data on fasting insulin levels. The study found 
those with moderate to severe OSA have greater insulin resistance as measured by the HOMA 
index after adjustment for age, gender, ethnicity, BMI, waist circumference, smoking status 
and sleep duration. Individuals with abnormal FBG (includes impaired fasting glycaemia and 
DM) had a 46% (OR 1.46, 95% CI: 1.09 to 1.97) increase in the risk for moderate and severe 
OSA. Similarly, PBG (includes impaired glucose tolerance and DM) is associated with 44% 
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(OR 1.44, 95% CI: 1.11 to 1.87) increase in the risk for experiencing AHI ≥ 15, independent 
of confounding factors.
79
 A recent meta-analysis of 6 cohort studies aims to assess the 
association between T2DM and OSA severity, found that of a total of 5953 participants, there 
was 332 incident cases of DM.
80
 The follow-up period was between 2.7 to 16.0 years. The 
researchers concluded that patients with moderate and severe OSA have a 63% (RR 1.63, 
95% CI: 1.09 to 2.45) increase in risk of DM compared to those without OSA.
80
  
 
Several studies have examined the associations between OSA and hypertension, this includes 
large population studies,
81-83
 sleep clinics
4,88,89
 and case control studies.
90
 Large cross-
sectional population studies such as the SHHS,
81
 the Wisconsin Sleep Cohort Study
82
 and the 
Pennsylvania study
83
 have all reported strong associations between hypertension and OSA. 
Longitudinal research has strengthened the association further. Wright et al. examined 82 
patients with OSA with 5 years follow-up and found a linear relationship between AHI and 24 
hour mean arterial BP (β=0.18, SE=0.09, p=0.04) and maximum systolic BP (β=0.56, 
SE=0.24, p=0.02).
91
 Wisconsin Sleep Cohort group followed 706 patients up for 4 years and 
found a stepwise increase in risk of hypertension: OR 1.42 (95% CI: 1.13 to 1.78) for AHI 
between 0.1 and 4.9 events/hr, OR 2.03 (95% CI: 1.29 to 3.17) for AHI between 5.0 and 14.9 
events/hr, OR 2.89 (95% CI: 1.46 to 5.64) for AHI >15 events/hr.
92
  
 
OSA also results in an increased risk of stroke. An observational cohort study of 697 patients 
followed up over 3.4 years with mean AHI of 35 events/hr found that the hazard ratio for 
stroke is 1.97 (95% CI: 1.12 to 3.48).
93
 There is also a trend (p=0.005) towards a dose 
response relationship between severity of OSA and risk of stroke: HR 1.75 (95% CI: 0.88 to 
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3.49) for AHI between 4 and 12 events/hr, HR 1.74 (95% CI: 0.87 to 3.51) for AHI between 
13 and 36 events/hr and HR 3.30 (95% CI: 1.74 to 6.26).  
 
Apart from stroke, OSA also increases risk of fatal as well as non-fatal cardiovascular 
events.
84,85
 A study from Spain
85
 followed up 264 healthy men, 377 simple snorers, 403 
untreated mild-moderate OSA, 235 untreated severe OSA, 372 treated severe OSA with 
CPAP for 10 years. Patients were age matched. They found that those with untreated severe 
OSA had a markedly increased risk for non-fatal CVD after adjusting for potential 
confounders (OR 3.17, 95% CI: 1.2 to 7.51). This study also reported a higher risk for CVD 
related death for the untreated severe OSA group (OR 2.87, 95% CI: 1.17 to 7.51). Another 
study followed 168 OSA patients up for 7.5 years; CVD death was significantly higher in the 
untreated OSA group compared to those treated with CPAP (14.8% vs. 1.9%).
84
 The total 
CVD events and death were also greater in the untreated group (31% vs. 18%).
84
 
 
Other than death from premature CVD events, OSA is also associated with higher risk of road 
traffic accidents (RTA), likely due to sleepiness. A Canadian group compared the RTA data 
of 783 patients with suspected OSA with sleepiness and 783 controls matched for age and 
gender.
86
 They reported an increased risk for RTA in mild (RR 2.6, 95% CI: 1.7 to 3.9), 
moderate (RR 1.9, 95% CI: 1.2 to 2.8) and severe (RR 2.0, 95% CI: 1.4 to 3.0) OSA 
compared to age and gender matched controls. Of those patients who had RTA, the likelihood 
of personal injury from the RTA was also examined.
86
 Unsurprisingly, the risk of personal 
injury was also increased with RR of 4.8 (95% CI: 1.8 to 12.4), 3.0 (95% CI: 1.3 to 7.0) and 
4.3 (95% CI: 1.8 to 8.9) for mild, moderate and severe OSA, respectively.
86
 A case-control 
study of 102 drivers with OSA and 152 aged and sex-matched controls found that those with 
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AHI of 10 and above had a 6 fold increase in risk (OR 6.3, 95% CI: 2.4 to 16.2) for RTA after 
adjustment for several confounders.
87
 As OSA is associated with these potentially life-
threatening complications, it is important for the clinician to be aware and initiate appropriate 
treatment when necessary.  
 
1.3.4 Obesity and obstructive sleep apnoea 
Several risk factors are linked to the development of OSA. Documented risk factors in the 
literature for OSA include male gender,
94-99
 increasing age,
97,100-102
 and smoking.
103,104
 
Obesity is also one of the well-recognised risk factors for OSA.
63,94,105,106
 The Wisconsin 
Sleep Cohort documented that a 1 standard deviation (SD) increase in BMI was associated 
with a three times increased risk of OSA.
94
 Davies and colleagues studied 66 OSA patients 
and shown a moderate to high correlation between OSA and obesity (r=0.54, 95% CI: 0.39 to 
0.69).
106
  
 
Further evidence on the influence of adiposity on OSA has also been shown in longitudinal 
studies.
92,107
 In the longitudinal Sleep Heart Health cohort study, 2968 middle and older age 
patients were followed up for 5 years. The study reported a weight gain of ≥10Kg led to a 
significant rise in the risk (OR for males 5.21, 95% CI: 2.35 to 11.53) of AHI ≥15 
events/hr.107 The Wisconsin Sleep Cohort Study followed up 690 patients for 4 years and 
found that a 10% weight gain resulted in 32% (95% CI: 20% to 45%) increase in AHI and a 
six-fold increase in the risk for moderate-to-severe OSA (95% CI: 2.2 to17.0).92  
 
Likewise, weight reduction improves the severity of OSA.108-114  The impact of weight loss on 
AHI is seen after lifestyle intervention,110,111 drug therapy112 as well as post bariatric 
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surgery.109,113,114  The Sleep AHEAD study, a randomised control trial (RCT) of 264 DM 
obese patients with OSA received either intensive lifestyle intervention (ILI) or diabetes 
support and education (DSE). After 4 years of follow-up, ILI group lost 5.2Kg and the DSE 
group lost <1Kg in weight with a 5 fold greater remission of OSA in ILI compared to DSE 
group (20.7% vs. 3.6%).110 A recent meta-analysis of dietary interventions for weight loss on 
OSA found that a pooled mean reduction of 4.8Kg/m2 (95% CI: 3.8-5.9) in BMI resulted in a 
weighted mean difference of 14.3 events/hr (95% CI: -23.5 to-5.1) reduction in AHI.111 A 
small RCT on 22 obese patients receiving phentermine/topiramate, medication for weight 
reduction (licensed in the US), and 23 obese patients on placebo found that after 28 weeks, 
there was a 10% weight reduction in those receiving phentermine/topiramate compared to 
4.3% (p=0.0006) in the placebo group. This was associated with a 31.5 events/hr reduction in 
AHI for the drug treatment compared to a reduction of 16.6 events/hr (p=0.0084) in the 
placebo group.112  
 
Bariatric surgery is currently the most effective means for weight reduction and has been 
shown to improve OSA.
109
 Common procedures performed for bariatric surgery are 
laparoscopic Roux-en-Y gastric bypass (RYGB), laparoscopic adjustable gastric band 
(LAGB) and laparoscopic sleeve gastrectomy (LSG). A study comparing 59 patients with an 
ILI and 74 in RYGB resulted in 8% and 30% weight reduction respectively after 1 year found 
a reduction in AHI of 6 and 13 events/hr (p=0.017) respectively. There is also significant 
difference in the remission of OSA (40% vs. 66% in RYGB, p=0.028).
113
 A RCT including 
30 obese individuals who received a lifestyle intervention and 30 on LAGB found a 5.1Kg 
and 27.8Kg (p<0.001) reduction in weight after 2 years, respectively. AHI reductions were 
14.0 and 25.5 events/hr (p=0.18) for lifestyle and LAGB, respectively.
114
 A systematic review 
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of 69 studies on the effect of bariatric surgery on OSA found that RYGB results in 79% 
remission or improvement in OSA compared to 77% in LAGB and 86% in LSG.
109
 Overall, 
these data support that obesity is a risk factor for OSA, and weight reduction is an effective 
treatment for OSA.  
 
Studies on patients with OSA have provided insight into the mechanisms behind the link 
between obesity and OSA.
106,115
 These may involve adverse anatomical changes and airway 
collapsibility. Imaging studies on the pharyngeal anatomy has revealed specific anatomical 
characteristics of OSA individuals, including narrow pharyngeal airway space either due to 
larger soft tissue area or a smaller skeletal enclosure,
116
 which may be accentuated in 
obesity.
117
 Excess fat deposition at the upper airway has been shown in OSA patients when 
compared to matched non-OSA individuals (matched for BMI, neck circumference and 
age).
118
 Therefore a greater neck circumference, which may be a surrogate marker for fat 
deposition within the airway or on the lateral pharyngeal wall, is a feature of OSA.
106,115
  
 
Apart from pharyngeal adiposity, truncal adiposity may also play a part. Obesity is associated 
with lower functional residual capacity, lung compliance
119
 and lung volume.
120
 Hoffstein and 
colleagues showed that in obese OSA patients, changes in the cross-sectional pharyngeal area 
is associated with changes in lung volume.
120
 This may signifies that obese individuals with 
lower lung volumes are more prone to greater collapsibility of the airway impeding airflow. 
Likewise, an improvement in lung volume improves OSA. Heinzer and colleagues studied 12 
OSA patients exposed to negative extra-thoracic pressure at 3 different levels (no negative 
pressure, CPAP-like negative pressure and 500ml above CPAP-like pressure) and found that 
greater lung volume reduces AHI events.
121
 During inspiration, negative thoracic pressure 
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produced by the diaphragm and intercostal muscles causes the trachea to be pulled caudally 
and this increases the upper airway traction therefore making it less collapsible. However, the 
diaphragm of an obese individual with high truncal fat level is more likely to be pushed 
upwards in a supine position compared with a non-obese person and this reduces the intra-
thoracic pressure resulting in less traction and increases the collapsibility of the upper 
airway.
121
  
 
1.4 Aim and objectives 
The effect of OSA in very severe obesity individuals (BMI ≥40Kg/m2), however, is not well 
documented in the literature. South Asians have an increased cardio-metabolic risk with BMI 
of 30Kg/m2 compared with their white European counterparts therefore lower BMI cut points 
were introduced. As OSA is also a risk factor for cardiovascular disease and there is no 
research on how South Asians ethnicity might impact on the prevalence and severity of OSA 
amongst extreme obese individuals, we aim to address that in this thesis. For individuals with 
diabetes mellitus with extreme obesity, there is also limited evidence on the effect of 
nocturnal hypoxaemia on glycaemia, and more importantly on the microvascular 
complications. The aim of this thesis is therefore to improve the understanding of the effect of 
OSA in very severe obese individuals. The following are the objectives of the thesis:  
 
1. Chapter 2 of the thesis will aim to compare the prevalence and severity of OSA, 
co-morbidities and glycaemic control in two different ethnic groups with severe 
obesity. Part of the chapter will also demonstrate the difference in sleep parameters 
between genders; 
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2. Chapter 3 aim to examine the effect of OSA on glycaemia among DM with severe 
obesity; 
3. Chapter 4 aim to investigate the prevalence, risk factors and relationship between 
OSA and diabetic retinal disease in a severely obese population; 
4. Chapter 5 will aim to demonstrate the prevalence and relationship between OSA 
and diabetic kidney disease in severe obesity; and 
5. Chapter 6 will aim to systematically review the effect of OSA on diabetic kidney 
and retinal diseases. 
 
In summary, the rise in the prevalence of obesity globally has significant impact on healthcare 
services worldwide. One of the condition associated with obesity is OSA, this thesis aims to 
describe the effect of OSA on people with extreme obesity. 
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CHAPTER 2 - THE PREVALENCE AND SEVERITY OF 
OBSTRUCTIVE SLEEP APNOEA IN SOUTH ASIANS WITH 
SEVERE OBESITY 
 
2.1 Introduction  
2.1.1 Prevalence of obstructive sleep apnoea (OSA) 
Several reports from the literature described the prevalence of OSA
94,96,97,100,102,122-135
 in the 
Western,
94,100,123-125,131,133-135
 Middle Eastern
122,129
 and Asian populations.
96,97,102,126-128,130,132
 
As PSG is not easily performed and is costly for health services, a variety of approaches were 
utilised including using questionnaires;
100,122,124,128-130
 screening questionnaires followed by 
PSG later;
94,123,126,127,131
 portable home overnight sleep monitoring device.
134,135
 In those 
studies which performed PSG, the criterion for the diagnosis of OSA based on AHI cut off 
points varied including AHI ≥5 events/hr94,126,127,134 or 15 events/hr.131 No data are available 
on the incidence of OSA. In this chapter, we described OSA prevalence in the general 
population, effect of age on OSA prevalence, OSA prevalence in obese populations and 
prevalence of OSA in South Asians.  
 
2.1.2 Prevalence of OSA in the general populations  
The prevalence of OSA in Western populations has been reported to be between 1 and 
28%.
94,123-125,134
 The large difference in the prevalence rate is likely to be due to heterogeneity 
on the diagnosis of OSA and populations studied. For example, some studies reported the 
prevalence rate of OSA while others reported prevalence of OSA syndrome. A diagnosis of 
OSA with sleep symptoms has been referred to as OSA syndrome in some studies.
77
 The 
Wisconsin Sleep Cohort study reported a prevalence of 16.5% amongst middle-age adults 
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(24% in males and 9% in females).
94
 The prevalence is lower at about 3% (about 4% in males 
and 1 to 2% in females) for OSA syndrome.
94,98
 A review of 12 studies performed by Davies 
and colleagues concluded that the prevalence of OSA syndrome in Western population is 
likely to be between 1 and 5% in males but much lower rate amongst females (effect size not 
reported) in the general population.
125
 Possible reasons for the gender variation include 
anatomical differences and hormonal influences. The effects of gender on OSA will be 
elaborated further in the discussion section.   
 
Two studies from Australia reported very different prevalence rates: 3.6% by Olson et al.
131
 
and 26% by Bearpark and colleagues.
135
 This wide difference can be explained by the cut off 
points of AHI as the diagnosis of OSA. Olson et al. used AHI ≥15 events/hr131 while Bearpark 
et al. engaged AHI ≥5 events/hr.135 A study from Spain showed a prevalence of 27% for AHI 
≥5  events/hr.134 Therefore, the true prevalence of OSA in the general population is likely to 
be between 16 and 27% while OSA syndrome is likely to be 1 and 5%.  
 
2.1.3 Prevalence of OSA and the effect of aging 
The prevalence of OSA increases with aging and peaks at middle-age as illustrated in Table 2-
1. A Spanish study performed PSG on 555 individuals aged between 30 and 70 years.
134
 OSA 
was defined as AHI ≥5 events/hr. The researchers reported a gradual increase in the 
prevalence of OSA as age rises. The SHHS study however, demonstrated a gradual increase 
in OSA prevalence until the age 60 years whereby the prevalence plateaued.
63
 The San Diego 
study conducted PSG on 420 individuals aged ≥65 years.136 Based on the diagnosis of AHI 
≥10 events/hr, overall prevalence was 62% (70% in men and 56% in women). Also, the 
prevalence of OSA remains almost stagnant across age group 60-69, 70-79 and 80-89 years.  
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Table 2-1: Age-specific prevalence of OSA from four different studies 
 
Prevalence of OSA 
 
Study 
 
Spain*
ǂ 134
 SHHS* 
63
 San Diego
⌠ 136
 Pennsylvania
ǂ ǁ 123
 
Age group (years) 
    20-29  - - - 0.4% 
30-39 9% - - 1.5% 
40-49 46% 29% - 2.8% 
50-59 28% 40% - 5.5% 
60-69 52% 51% 61% 4.1% 
70-79 - 54% 62% 2.5% 
80-99 - 56% 65% - 
OSA = obstructive sleep apnoea, SHHS = Sleep Heart Health Study.  
ǂ
Percentage represents the males only
 
*OSA diagnosis based on AHI ≥5 events/hr 
⌠
OSA diagnosis based on AHI ≥10 events/hr 
ǁ OSA diagnosis based on AHI ≥10 events/hr with sleep symptoms (OSA syndrome) 
 
 
The Pennsylvania study was specifically designed to examine the effect of age on OSA 
syndrome.
123
 Only men were recruited and a total of 741 PSG were performed. Prevalence of 
OSA increases as age increases (AHI ≥10 events/hr). For the age group 20 and 44 years, OSA 
prevalence was 3.2% (95% CI: 1.6 to 6.4); for age group 45 to 64 years, prevalence was 
18.8% (95% CI: 15.4 to 22.8) and age ≥65 years, prevalence was 24.8% (95% CI: 16.3 to 
35.7). However, there seems to be a quadratic relationship between age and OSA syndrome. 
Prevalence of OSA syndrome was 1.2% (95% CI: 0.4 to 3.8), 4.7% (95% CI: 3.1 to 7.1) and 
1.7% (95% CI: 0.3 to 9.1%) for age groups 20 to 44 years, 45 to 64 years and ≥65 years, 
respectively. In addition, the severity of hypoxaemia based on minimum oxygen saturation 
also shares the quadratic relationship as shown in Figure 2-1. The slope for AHI ≥20 events/hr 
was 0.22 (95% CI: 0.01 to 0.43) after adjusted for BMI, this suggests that younger men with 
OSA were more hypoxic compared to older men.  
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Figure 2-1: Relationship between minimum oxygen saturation (SaO2) and age based on 4 
apnoea-hypopnoea indexes. AHI represents apnoea-hypopnoea index and lower minimum oxygen 
saturation indicates greater hypoxaemia. Reprinted with permission of the American Thoracic Society. 
Copyright © 2014 American Thoracic Society. Reference: Bixler EO, Vgontzas AN, Ten Have T, 
Tyson K, Kales A. 1998. Effects of age on sleep apnoea in men: I. Prevalence and severity. American 
Journal of Respiratory and Critical Care Medicine;157:144-8. Official Journal of the American 
Thoracic Society. 
 
 
The mechanisms of the quadratic effect of age on OSA remain unclear. It may be that 
individuals with OSA suffered from premature mortality and those who live past 65 years 
might be a ‘fitter population on the whole’ based on Darwin’s theory on survival of the 
fittest.
123
 Also, it may be that the influence of obesity or weight gain in the elderly might be 
less significant compared to middle aged individuals.
137
 Another possibility is that since 
hereditary diseases tend to be more severe in the young and in middle aged, OSA may be 
associated with some form of genetic predisposition.
123
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2.1.4 Prevalence of OSA in the obese populations 
Unsurprisingly, the prevalence of OSA amongst obese individuals is much higher.
138,139
 All 
epidemiological studies of OSA in this group of individuals were performed in a 
hospital/clinic setting using PSG. The largest study based on data collected from 22 European 
centres reported a prevalence of 79.4%
138
 in individuals with a mean BMI of 31Kg/m
2
 and 
mean age of 51.8 years.
138
 The Sleep Ahead study reported a higher OSA prevalence of 86% 
in obese (mean BMI 36.5Kg/m
2
), older (mean age 61years) DM patients.
139
  
 
Amongst very severe obese individuals (BMI ≥40Kg/m2), the prevalence of OSA has been 
found to be between 61 and 98%.
95,140-145
 The majority of these studies were on patients who 
needed bariatric surgery.
95,143-145
 The two largest studies were from the USA (349 patients)
145
 
and Singapore (350 patients).
144
 They reported an OSA rate of 83%
145
 and 65%
144
, 
respectively. The discrepancy may be due to the latter population being generally young (9 
year age difference) and less obese (10Kg/m
2
 lower BMI)
144
 compared to the US study.
145
  
Indeed, a stepwise relationship has been shown by Lopez and colleagues that the prevalence 
of OSA rises as BMI increases: 71% in those with severe obesity (BMI between 35 and 
39.9Kg/m
2
), 74% in those with BMI between 40 and 49.9Kg/m
2
, 77% in those BMI between 
50 and 59.9Kg/m
2
 and 95% in those with BMI ≥60Kg/m2.146 
 
 
2.1.5 Prevalence of OSA in South Asians  
Epidemiological studies performed in South Asians countries (predominantly India) have 
found a prevalence of OSA to be between 14 and 27%
96,102,147
 which is consistent with the 
studies from Western countries. However, compared to white Europeans, South Asians (those 
of Indian/Pakistani/Bangladeshi/Sri Lankan origin) residing in Western countries, have a 
 35  
 
higher prevalence of DM, dyslipidaemia, and CVD.
148
 Considering these conditions 
commonly accompany OSA, it is possible that South Asians who live in Western countries 
are at greater risk of OSA compared to white Europeans. This potential ethnic difference has 
not, however, been comprehensively examined, particularly in very severely obese 
individuals. A recent UK study compared the prevalence of OSA in South Asians and white 
Europeans but found no difference between groups.
124
 This study, however, characterised 
OSA based on subjective responses to the Berlin questionnaire, which has not previously 
demonstrated a high level of diagnostic specificity
149
 and does not provide an objective 
measure of OSA. 
 
We therefore sought to assess potential differences in objectively-determined OSA prevalence 
and severity between severely obese South Asians and white Europeans. We specifically 
assessed a severely obese patient population since this group is at increased risk of CVD. 
Based on the evidence that South Asians have a higher prevalence of metabolic and 
cardiovascular morbidities, we hypothesised that severely obese South Asians would have a 
higher prevalence and more severe OSA compared to white Europeans.  
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2.2 Aim and objectives  
The aim of this chapter is to examine the prevalence and severity of OSA, co-morbidities and 
glycaemic control in two different ethnic groups with severe obesity. The following are the 
objectives of the study:  
1. To estimate the prevalence of OSA in South Asians and white Europeans with very 
severe obesity; 
2. To compare the severity of OSA amongst South Asians and white Europeans with 
very severe obesity; 
3. To examine the range and number of co-morbidities and glycaemic control between 
South Asians and white Europeans with very severe obesity; and 
4. To demonstrate potential differences in respiratory parameters between males and 
females. 
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2.3 Methods 
2.3.1 Study design and study participants 
Routine clinical data were prospectively collected from consecutive adults with age greater or 
equal to 18 years who were attending a West Midlands regional specialist weight management 
service from January 2009 to December 2011 at the Heart of England NHS Foundation Trust, 
Birmingham, UK. Over 10% of the West Midlands inhabitants with an estimated total of 5.5 
million individuals are South Asians.150 The majority of South Asian patients local to the 
specialist weight management service originate from the Mirpur region in Pakistan. All 
patients were referred to the service based on the following criteria:  
 
1) BMI ≥35Kg/m2 with at least one co-morbidity, or  
2) BMI ≥40Kg/m2 without a comorbidity.  
 
The aim of the specialist service is to provide a comprehensive clinical assessment of patients 
with obesity and the associated co-morbidities, and the development of a therapeutic plan that 
may include bariatric surgery. Patients and referring physicians are informed of the pathways 
and processes within the service and the treatment options available. 
 
In the specialist service, all patients are formally assessed for sleep-disordered breathing 
(SDB). Anonymised data from patients attending the service with OSA assessment were 
included. Data available included age, gender, ethnicity, objective anthropometry (height, 
weight, BMI), systolic and diastolic blood pressure (BP), and the presence of obesity-related 
co-morbidities. The co-morbidities recorded included presence or absence of type 2 diabetes 
(DM), hypertension and coronary artery disease (CAD). 
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2.3.2 Respiratory sleep monitoring 
 The Embletta
TM
 (Embla systems) home sleep portable monitoring device was employed as 
part of the trust’s clinical service protocol. Patients were given a demonstration of the 
equipment by a trained sleep physiologist on the afternoon of the test night. Measurement 
channels included airflow using a nasal pressure sensor device, chest and abdominal 
movements (inductance plethysmography), oxygen saturation (O2), and heart rate using a 
finger oximetry probe. The sleep physiologist observed the patient undergoing self-
application of the equipment before leaving the sleep centre. Patients also completed a diary 
of sleep-wake times for the test night, which was completed the morning after the test night. 
This was used to determine sleep onset and wake times as well as subjectively confirming that 
the patient achieved at least four hours sleep duration. South Asian and white European 
patients did not differ in the interpretation of sleep diaries, which were in agreement with the 
respiratory data as seen by movement artefacts. Equipment and diaries were returned the next 
day, and data were downloaded and reviewed. Studies with at least 4 hours of good quality 
respiratory signals were considered acceptable. A retest was offered if data were inadequate. 
All respiratory data were manually scored by blinded trained sleep-respiratory physiologists 
and rescored by a sleep physician and author DB for confirmation. All scoring was blinded to 
patient characteristics including name and ethnicity. 
 
 
All respiratory parameters were scored based on the standard American Academy of Sleep 
Medicine guidelines.
151
 To summarise, an apnoea was defined as a complete cessation of 
airflow for at least 10 seconds while hypopnoea was defined as a reduction of at least 30% of 
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airflow accompanied by at least 4% reduction in oxygen saturation with the presence of 
thoracic and abdominal movement. Central events were characterised by the absence of 
thoracic and abdominal movements. The AHI was calculated as the average number of 
episodes of apnoea and hypopnoea per hour of sleep. AHI was calculated for the whole night 
and was not differentiated for supine and non-supine positions.  
 
Respiratory parameter data collected included: AHI, mean and minimum oxygen saturation 
during sleep (%), and percentage of time spent under 90% oxygen saturation while asleep 
(%TST<90). OSA was defined using the standard AHI cut-point of at least 5 events/hr.73 
Mild, moderate and severe OSA were defined as AHI of between 5 and 15 events/hr, 15 and 
30 events/hr, and ≥30 events/hr, respectively.  
 
The anonymised data collected for analysis was conducted as part of service evaluation and 
did not require formal ethical committee approval, as recommended by the UK National 
Research Ethics Service.152 This study used the current available database from the weight 
management service and was designed to evaluate the characteristics of the patients referred 
to our local service. The results of the study will provide valuable insights on current clinical 
need and care of very severe obese individuals. We also hope to provide more information to 
assist in the improvement and design of the weight management services within the NHS.  
 
2.3.4 Statistical analysis 
Statistical analysis was performed using Statistical Package for Social Sciences version 19 
(SPSS, Chicago, IL).  Normality of continuous data was ascertained through visual inspection 
and the Kolmogorov-Smirnov test. Normally distributed data are reported as mean ± standard 
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deviation (SD), while non-normally distributed variables are reported as median with inter-
quartile range (IQR). Mann Whitney U-tests and independent t-tests were used for non-
parametric and normally distributed data, respectively. Differences between categorical 
variables were analysed using chi-square test.  We ran a series of Mann Whitney U-tests to 
assess the potential difference in AHI, mean O2 saturation, minimum O2 saturation, and 
%TST<90 according to ethnicity.  
 
Natural log transformation was performed for variable AHI to make it normally distributed 
prior to multivariate linear regression analysis. As some of the AHI results were zero, the 
natural log transformation was performed on AHI+1. As AHI was in the form of a continuous 
data, three models were explored using linear regression analysis. The base model was 
unadjusted; Model 1 adjusted for age, sex, ethnicity (white Europeans/South Asians) and/or 
BMI, as appropriate; Model 2 further adjusted for the presence/absence of co-morbidities 
(presence of type 2 diabetes, hypertension, CAD and insulin treatment). The factors adjusted 
included in the adjusted models were those that are considered to be clinically important and 
the rationale for including each factor is discussed elsewhere (see table 2-2). Clinically 
relevant results from log-transformed data were back-transformed and results are reported as 
unstandardised beta coefficients () along with 95% confidence intervals (CI), for 
AHI+1.  Results were considered statistically significant when p<0.05. No subgroup or 
sensitivity analysis was carried out.  
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Table 2-2: Factors adjusted and the appropriate sections discussing the rationales behind  
Factors Sections 
Age Introduction of Chapter 2 (section 2.1.3) 
Gender Chapter 2’s discussion (section 2.5.5) 
Body mass index Chapter 1 (section 1.3.4) 
Type 2 diabetes  Chapter 3 (section 3.5.2) 
Insulin treatment  Chapter 4 (section 4.5.5) 
Hypertension  Chapter 1 (section 1.3.3) and chapter 4 (section 
4.5.3) 
Coronary artery disease Chapter 1 (section 1.3.3) 
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2.4 Results 
2.4.1 Study characteristics 
A total of 343 consecutive patients referred to the Specialist Weight Management Clinic 
underwent overnight sleep assessment during the study period. Data from four patients were 
not analysable, seven patients had missing anthropometry data, and 24 patients were from 
another ethnic group and were excluded, leaving complete data on 308 patients for subsequent 
analyses (Figure 2-2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2: Flow diagram of the number of referrals seen at HEFT Specialist Weight Management 
Clinic, and those included in the study 
HEFT – Heart of England NHS Foundation Trust 
 
 
 
Consecutive patients seen at HEFT 
Specialist Weight Management 
Clinic 
(January 2009 to December 2011) 
 
N = 343 
Included patients for analysis 
N = 303 
Excluded:  
 
24 = Other ethnic groups 
7   = Missing anthropometry data 
4   = Respiratory data unable to 
analyse 
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Table 2-3: Patient characteristics in 308 obese patients according to ethnic group 
  White 
European 
(n=268) 
South Asians 
 
(n=40) 
p value 
Age (years) 
Sex n (%) 
Male  
Female 
46.6 ± 12.2 
 
75 (27.3) 
200 (72.7) 
43.8 ± 10.9 
 
16 (40.0) 
24 (60.0) 
0.17 
0.10 
Weight (Kg) 
BMI (Kg/m2) 
133.2 ± 24.9 
48.6 ± 8.0 
134.9 ± 30.9 
49.8 ± 10.9 
0.71 
0.42 
Systolic BP (mmHg)* 
Diastolic BP (mmHg)* 
142 ± 18 
87 ± 12 
142 ± 15 
82 ± 14 
0.99 
0.09 
Overall prevalence of OSA  
     (AHI ≥5) n (%) 
OSA severity n (%) 
No OSA (AHI <5)  
Mild OSA (AHI 5-15)  
Moderate OSA (AHI 15-30)  
Severe OSA (AHI >30)  
AHI (per hour) 
 
177 (66.0) 
 
91 (34.0) 
77 (28.7) 
42 (15.7) 
58 (21.6) 
9.0 (3.4, 26.6) 
 
34 (85.0) 
 
6 (15.0) 
10 (25.0) 
7 (17.5) 
17 (42.5) 
24.0 (9.3, 57.6) 
 
0.017 
0.015 
 
 
 
 
<0.01 
Co-morbidities 
DM % 
HTN % 
CAD % 
 
33.1 
36.6 
7.3 
 
60.0 
42.5 
7.5 
 
<0.01 
0.48 
0.96 
Presence of co-morbidities  
       (DM, HTN or CAD) 
None % 
One % 
Two % 
Three % 
 
 
50.9 
28.7 
16.4 
4.0 
 
 
27.5 
37.5 
32.5 
2.5 
0.02 
HbA1c (%) 
HbA1c (mmol/mol) 
% on glucose-lowering medication 
6.3 (5.8, 7.3) 
45 (40, 56) 
25.1 
7.4 (6.3, 8.6) 
57 (45, 71) 
50.0 
<0.01 
<0.01 
<0.01 
Number of DM medications 
None % 
One % 
Two % 
Three or more % 
 
74.9 
10.5 
10.2 
4.4 
 
50.0 
10.0 
30.0 
10.0 
<0.01 
Data are reported as mean ± standard deviation or median (IQR), unless otherwise stated.  
BMI=body mass index; BP=blood pressure; AHI = apnoea-hypopnoea index; DM=diabetes mellitus; 
HTN=hypertension; CAD=coronary artery disease, HbA1c=glycosylated haemoglobin A1c. 
* Blood pressure data presented were available in 212 patients. 
p values were calculated using either independent t-test, Mann Whitney U-test or chi-square, as 
appropriate. 
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The study sample characteristics are shown in Table 2-3. The majority of the sample was 
white European (87.3%) reflecting the ethnic composition of the local Birmingham 
population.150 The majority of patients were female (71.1%), in agreement with attendance at 
services catering for severely obese patients.153 There was no statistical significant gender 
difference between the ethnic groups (60.0% females in South Asians vs. 72.2% in White 
Europeans, p=0.10). No significant differences were found between ethnic groups for age 
(mean age 43.8±10.9years for South Asians vs. 46.6±12.2years for white Europeans, p=0.17), 
BMI (49.8±10.9 vs. 48.6±8.0Kg/m2, p=0.42) or body weight (134.9±30.9 vs. 133.2±24.9Kg, 
p=0.71). The measured BP in both groups was also similar: 142±15 vs. 142±18mmHg for 
systolic BP (p=0.42) and 82±14 vs. 87±12mmHg (p=0.09) for diastolic BP.  
 
2.4.2 Co-morbidities and glycaemic results 
The percentage of South Asians with type 2 diabetes mellitus was, however, almost double 
that observed in white Europeans (60.0% vs. 33.1%, p<0.01) as shown in Table 2-3. A greater 
proportion of the South Asian group also took glucose-lowering medication (50.0% vs. 
25.1%, p<0.01) and had significantly worse glycaemic control compared to white Europeans 
(HbA1c 57 vs. 45mmol/mol, p<0.01). Poor glycaemic control was also reflected in the total 
number of hypoglycaemic medications required in the South Asians group (p<0.01). Although 
the prevalence of hypertension (42.5% vs. 36.6%, p=0.48) or coronary artery disease (7.5% 
vs. 7.3%, p=0.96) alone were not significantly different, South Asians had a significantly 
greater prevalence of total number of co-morbidities compared to white Europeans (p=0.02). 
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2.4.3 Prevalence and severity of OSA 
The prevalence of OSA (AHI ≥5 events/hr) in our study population was 69%. The South 
Asian group had a significantly higher AHI compared to white Europeans (24 [IQR: 9.3, 57.6] 
vs. 9 [IQR: 3.4, 26.6] events/hr, p<0.01). South Asians had significantly greater prevalence of 
OSA (85% vs. 66%, p=0.017) and more severe OSA (p=0.015) compared to white Europeans 
as shown in Figure 2-2. In those with severe OSA (AHI >30 events/hr), South Asians were 
significantly younger (45±13years) than white Europeans (52±11years), p=0.04. 
 
 
Figure 2-3: The prevalence and severity of obstructive sleep apnoea in South Asians and Caucasians. 
 
 
Table 2-4 highlights a number of statistically significant differences according to ethnic group 
in relation to three of the four SDB measures. South Asians had a greater AHI (p<0.01). They 
also spent more time under 90% oxygen saturation (8.4% [IQR: 1.0, 24.3] vs. 2.4% [IQR: 0.2, 
16.0], p=0.03) and had significantly lower minimum oxygen saturation (76% [IQR: 64, 84] 
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vs. 83% [IQR: 77, 87], (p<0.01) compared to white Europeans. The mean oxygen saturation 
was not significantly different between the two ethnic groups (93% [IQR: 91, 95] vs. 93% 
[IQR: 92, 95], p=0.41). 
 
Table 2-4: Comparison of AHI, mean oxygen saturation, time under 90% oxygen saturation and 
minimum oxygen saturation between white Europeans and South Asians 
      
 White European 
(n=268) 
South Asian 
(n=40) 
 
p value 
AHI (events per hour) 
 
9 (3.4, 26.6) 24 (9.3, 57.6) <0.01 
Mean O2 saturation (%) 93 (92, 95) 93 (91, 95) 0.41 
 
% time spent under 90% O2 
saturation 
 
2.4 (0.2, 16.0) 8.4 (1.0, 24.3) 0.03 
Minimum O2 saturation (%) 83 (77, 87) 76 (64, 84) <0.01 
 
Data are presented as median (IQR). 
IQR = inter-quartile range; AHI = apnoea-hypopnoea index; O2 = oxygen, % = percentage. 
p values were calculated using Mann Whitney U-test.  
 
 
Table 2-5 demonstrates a significant positive association between South Asian ethnicity. 
Without any adjustments, regression analysis showed a 95% increase in AHI+1 (=1.95, 95% 
CI: 1.29 to 2.95) in South Asians compared to white Europeans. This association remained 
after adjusted for age, sex and BMI (=1.83, 95% CI: 1.28 to 2.63), and, after further 
adjustment for DM, insulin usage, hypertension and coronary artery disease was =1.84 (95% 
CI: 1.27 to 2.65) compared to white Europeans. Thus, South Asian ethnicity was significantly 
associated with an 84% (95% CI: 27% to 165%) increase in AHI+1, after adjustment for 
potential confounders.  
 
 47  
 
As expected, male gender was also an independent predictor of increasing AHI+1. The 
unadjusted model showed a 131% (95% CI: 72% to 211%) increase in AHI+1 for males 
compared to females. The association persisted after adjustment for age, BMI and ethnicity 
(=2.38, 95% CI: 1.81 to 3.12) as well as with addition adjustment for comorbidities in 
Model 3 (β=2.42, 95% CI: 1.84 to 3.20).   
 
Similarly, positive linear relationships were observed for age and BMI with AHI+1.  In the 
unadjusted model, for every increment increase in age and BMI, there was an expected 3% 
(95% CI: 2% to 4%) and 3% (95% CI: 2% to 5%) increase in AHI+1, respectively. The 
associations persisted for both age and BMI after adjustment for sex and ethnicity: age 
(β=1.03, 95% CI: 1.02 to 1.04) and BMI (β=1.04, 95% CI: 1.03 to 1.06). Further adjustment 
for DM, hypertension, coronary artery disease and insulin as shown in model 3, illustrated the 
expected increase in AHI+1 was 3% (95% CI: 2% to 4%) for each unit increase in age (year) 
and 5% (95% CI: 3% to 6%) for BMI (Kg/m2).  
 
Table 2-5: Independent predictors of AHI+1 in 308 obese patients. Data were presented as 
unstandardised beta coefficients (95% CI) from multivariate linear regression analyses. 
 
Predictor 
 
 
Unadjusted 
Models 
Model 1 
 
Model 2 
 
South Asian 
 
1.95 (1.29-2.95) 
 
1.83 (1.28-2.63) 
 
1.84 (1.27-2.65) 
Age (years) 1.03 (1.02-1.04) 1.03 (1.02-1.04) 1.03 (1.02-1.04) 
Males 2.31 (1.72-3.11) 2.38 (1.81-3.12) 2.42 (1.84-3.20) 
BMI (Kg/m
2
) 1.03 (1.02-1.05) 1.04 (1.03-1.06) 1.05 (1.03-1.06) 
Diabetes Mellitus 1.50 (1.13-2.00) Not applicable 0.83 (0.62-1.12) 
Hypertension  1.70 (1.28-2.26) Not applicable 1.21 (0.91-1.61) 
Coronary Artery 
Disease 
1.49 (0.87-2.55) Not applicable 
 
0.75 (0.46-1.23) 
 
Insulin  2.32 (1.47-3.68) Not applicable 1.51 (0.95-2.38) 
 
Unadjusted: univariate models 
Model : adjusted for age, sex, BMI, ethnicity, as appropriate. 
Model 2: further adjusted for diabetes mellitus, hypertension, coronary artery disease, and insulin. 
BMI = body mass index. 
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2.4.4 Gender differences 
The differences in the patient characteristics between males and females were shown in Table 
2-6. Male patients were slightly but not significantly older than females. There were no 
differences in ethnicity and systolic and diastolic BP between the genders. Females were 
heavier than males (BMI 49.9 vs. 46.3 Kg/m2, p=0.001). A greater proportion of male patients 
suffered with DM as well as CAD with significant proportion of males having two or more 
co-morbidities compared to females. Males were also more likely to be on glucose-lowering 
medications compared to females (p=0.009).  
 
A greater proportion of males have OSA compared to females (87% vs. 61%, p<0.001). Males 
were also more likely to have moderate and severe OSA compared to females (p<0.001). The 
AHI was significantly higher in males (19.1, IQR: 8.0, 55.0 vs. 7.9, IQR: 3.0, 20.0 events/hr, 
p<0.001) with a lower minimum oxygen saturation (80%, IQR: 71, 84 vs. 84%, IQR: 77, 88, 
p<0.001). The time spent under 90% oxygen saturation during sleep (p=0.002) as shown in 
Table 2-7. 
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Table 2-6: Patient characteristic differences between males and females with OSA 
 Males 
N = 90 
Females 
N = 218 
P value 
Age (years) 48 ±13 45 ±12 0.52 
BMI (Kg/m
2
) 46.3 ± 7.6 49.9 ± 8.5 0.001 
Systolic BP (mmHg) 146 ± 15 141 ±19 0.83 
Diastolic BP (mmHg) 86 ±9 86 ±13 0.85 
Ethnicity (%) 
White Europeans 
South Asians 
 
82.2% 
17.8% 
 
90.0% 
3.9% 
 
0.108 
Diagnosis of OSA (%) 61% 87% <0.001 
Classification of OSA 
Mild 
Moderate 
Severe 
 
25.6% 
21.1% 
40.0% 
 
29.4% 
13.8% 
17.9% 
 
<0.001 
Co-morbidities (%) 
DM  
HTN 
CAD 
 
53.9% 
43.8% 
13.5% 
 
29.4% 
24.8% 
4.8% 
 
<0.001 
0.139 
0.008 
Presence of co-morbidities 
None  
One 
Two  
Three 
 
0% 
33.3% 
31.1% 
35.6% 
 
0% 
53.2% 
29.4% 
17.4% 
 
0.001 
% on DM Medications 42.2% 23.4% 0.001 
Number of DM medications 
(%) 
None 
One  
Two 
Three or more 
 
57.8% 
14.4% 
18.9% 
8.9% 
 
76.6% 
9.2% 
10.6% 
0.4% 
 
0.009 
Data are reported as mean ± standard deviation, unless otherwise stated. 
BMI=body mass index; BP=blood pressure; OSA = obstructive sleep apnoea; DM=diabetes mellitus; 
HTN=hypertension; CAD=coronary artery disease. 
* Blood pressure data presented were available in 212 patients. 
p values were calculated using either independent t-test, Mann Whitney U-test or chi-square, as 
appropriate.  
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Table 2-7: Comparison of apnoea-hypopnoea index, mean oxyhaemoglobin saturation, time under 
90% saturation and minimum oxygen saturation between genders 
  Median (IQR) p value 
     
Apnoea-hypopnoea Index 
(events/hour) 
Males 
 
19.1 (8.0, 55.0) 
 
<0.001 
Females 7.9 (3.0, 20.0)  
   
Mean O2 saturation (%)     
Males 93.0 (91.0, 93.7) <0.001 
Females 93.9 (92.0, 5.0)   
     
Time under 90% O2 saturation (%)     
Males 4.4 (1.0, 25.4) 0.002 
Females 1.8 (0.1, 16.0)   
     
Minimum O2 saturation (%)     
Males 80 (71, 84) <0.001 
Females 84 (77, 88)   
      
Data are presented as median (IQR). 
IQR = inter-quartile range; AHI = apnoea-hypopnoea index; O2 = oxygen. 
p values were calculated using Mann Whitney U-test. ** signify p value of < 0.01 
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2.5 Discussion  
2.5.1 Patient demographics  
In this study of very severe obese patients attending a specialist weight management clinic, 
majority of patients were females. This is consistent with the data observed in other weight 
management services which offer bariatric surgeries.
46,153-155
 Indeed, the Health Survey for 
England reported that in 2011, there were at least twice as many females with Class III 
obesity compared to males (3.5% vs. 1.5%)
156
 which is reflected in the higher female 
population seen in weight management services. An observation study of the Hospital 
Episode Statistics database from April 2000 to March 2008 on the laparoscopic bariatric 
surgery performed in England also found that the majority of the patients who had had 
bariatric surgery were females (80.8%).
157
  
 
In our study, there were no difference in the weight and BMI in both our ethnic groups. The 
mean BMI was 48.8Kg/m
2
 for our patients and this is at the higher end of the mean BMI 
range between 45 and 51Kg/m
2
 found in most OSA prevalence studies in very severely obese 
individuals.
95,140-143
  Although white Europeans were slightly older (47years) compared to 
South Asians (44years) in our study, this was not statistically significant. Other prevalence 
studies on OSA in very severely obese individuals have slightly younger patients with age 
ranging between 37 and 43 years.
95,140-143
 
 
2.5.2 Prevalence of obstructive sleep apnoea 
The general prevalence of OSA has been reported to be between 16 and 27%
94,123,131,134
 and is 
significantly lower than our study (68.5%), which has only Class III obese patients. 
Moreover, the OSA prevalence for South Asians ethnic group in our study is 3 times higher 
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than the general population studies from India.
96,102,147
 Studies by Reddy et al. and Sharma et 
al. generated a random list of participants using information from their respective electoral 
rolls in South Delhi.
96,102
 Udvadia and colleagues recruited a random sample of healthy males 
who presented to Hinduja National Hospital for health check-ups.
147
 All three Indian studies 
were conducted in a 2 stage process: Stage 1 consists of screening population to identify 
habitual and non-habitual snorers, and Stage 2 involves random selection of a sample from the 
screened population for PSG. A proportion of habitual snorers (between 15% and 100%) and 
non-habitual snorers (between 5% and 25%) were invited for PSG. Subsequently, overall 
population prevalence of OSA was estimated. Apart from the differences in recruitment, 
obesity levels between the Indian populations studies (mean BMI ranges from 24.3 to 
27.0Kg/m
2
)
96,102,147
 and our South Asians sample, which only included vey severely obese 
patients, may partially explained the differences in OSA prevalence. The mean age of our 
patients (44years) is similar to the Indian studies which range from 41 to 48 years.
96,102,147
 Our 
study also differed in gender distribution when compared to the Indian population studies as 
we have a greater proportion of females.  The study by Udwadia and colleagues only consists 
of urban Indian males
147
 while the other 2 Indian studies are slightly skewed towards higher 
proportions of males.
96,102
 
 
 
OSA is increasingly appreciated as an important contributor for CVD
93,158,159
 risk and 
mortality.
93,160,161
 The prevalence and severity of OSA in the South Asian population, a group 
at increased risk of CVD, have not been comprehensively examined. Our study is the first to 
objectively investigate prevalence and severity of OSA in severely obese South Asians 
residing in the west. Our results demonstrated that South Asians have a significantly greater 
prevalence of OSA with more severe OSA compared to white Europeans. To date, only one 
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Western study has investigated ethnic differences in OSA, which reported no significant 
ethnic differences.
124
 The UK study by Brady and colleagues recruited participants from a 
community setting consists of urban, suburban and rural areas.  As the study by Brady and 
colleagues was a population-based study, obesity was not part of the inclusion criteria. 
Furthermore, diagnosis of OSA was determined through the Berlin questionnaire,
124
 which is 
a screening, rather than a diagnostic tool. Participants who scored high risk in the Berlin 
questionnaire are considered likely to have OSA.
124
 A community-based study on 100 
participants showed that the Berlin questionnaire is very useful for OSA risk stratification 
with a sensitivity of 0.86 for those who have a high risk score and specificity of 0.77 for those 
with a low risk score.
72
 However, a recent Chinese community study of 143 participants 
reported a sensitivity of 0.89 with a specificity of 0.35 for moderate-to-severe OSA using the 
Berlin questionnaire.
162
 No study has investigated the performance of the Berlin questionnaire 
in South Asians population. Therefore, the study by Brady and colleagues
124
 may not 
represent the true prevalence of OSA in South Asians and white Europeans residing in the 
UK. Given that our patient group was very severely obese, a greater prevalence of OSA was 
anticipated compared to the study by Brady and colleagues (69% vs. 28%).
124
  
 
In very severely obese populations (BMI ≥40Kg/m2), prevalence rates of OSA have been 
reported to be between 61% and 98%.95,140-145 In our patients who were attending the regional 
specialist weight management service, the prevalence of OSA was comparable to these 
reports. This is in spite of our patients being slightly older (mean age 46years) compared to 
the other studies (mean age range between 37 and 43years).95,140-143 The prevalence of OSA in 
obese populations is clearly elevated compared to the general population,94,96 which is not 
surprising given the close association of obesity with OSA.94,95,98 The Wisconsin Sleep Cohort 
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which performed PSG in 602 individuals between age 30 and 60 showed that for each 
standard deviation increase in BMI, there was a threefold increase in the risk of development 
of OSA.94 Likewise, Bixler and colleagues assessed 1741 individuals in Pennsylvania and 
reported that obese individuals have a RR of 11.5 (95% CI: 3.3 to 33.8) in females and RR of 
7.0 (95% CI: 3.4 to 13.9) in obese males compared to non-obese counterparts in developing 
OSA.98  
 
2.5.3 Severity of obstructive sleep apnoea 
We showed, after adjustment, that South Asian ethnicity was significantly associated with an 
84% increase in AHI+1. While there were no significant differences in BMI between the 
South Asian and white European groups in our sample, South Asians have greater 
cardiovascular risk for an equivalent BMI.163 This has resulted in adoption of lower BMI cut-
points for overweight/obesity for South Asians by the WHO.163 A marker for adiposity is 
visceral adipose tissue (VAT). The Multicultural Health Assessment Trial (M-CHAT) was a 
cross sectional study aimed to compare adiposity levels between 4 ethnicities: 201 Europeans, 
195 Aboriginals, 219 Chinese and 207 South Asians.164 The South Asians were from 
Bangladesh, India, Nepal, Pakistan and Sri Lanka. The participants were matched for 
ethnicity, sex and BMI range (≤24.9, between 25.0 and 29.9 and ≥30.0Kg/m2). The results 
showed that South Asians have significantly greater VAT compared to Europeans (115.2, IQR: 
87.2 to 159.0 vs. 100.8, IQR: 73.6 to 142.9 cm2, p=0.009). After adjusting for age, sex, BMI, 
total body fat, ethnicity, education, smoking, physical activity and humeral breadth, South 
Asians with ≤37.4Kg total body fat has greater VAT compared to Europeans. In our study, 
both the age and BMI were similar in the two ethnic groups. Nevertheless, the South Asians in 
our study most likely have greater visceral fat for the given BMI.  
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Apart from acting as a marker for adiposity, visceral fat is also found to significantly correlate 
with apnoea index or AHI.67,165,166 Deegan and colleagues assessed 140 males and found that 
waist circumference, as a surrogate marker for visceral adiposity, correlated significantly to 
AHI (r2=0.125).67 A group of Japanese researchers investigated 37 individuals with a mean 
BMI of 36.5Kg/m2 and mean age of 46.5 years through computer tomography (CT) imaging 
to assess visceral fat.166 They reported that all individuals with visceral fat greater than 220 
cm2 have OSA syndrome while those with visceral fat less than 120 cm2 do not suffer with 
OSA syndrome. The correlation between visceral adiposity and AHI was found to be 
significant at 0.63 in this study.166 Another small study by Schafer and colleagues assessed 81 
patients with a mean BMI of 30Kg/m2 and mean age of 55 years.165 Nuclear magnetic 
resonance imaging (MRI) was used to assess abdominal fat in 60 patients and they found a 
statistical significant correlation between AHI and visceral fat (r=0.29).165 This greater 
propensity to visceral adiposity and the association with AHI may explain the greater 
prevalence and severity of OSA in South Asians.  
 
It was also observed that in those with moderate to severe OSA, 58% of OSA was attributable 
to excess body weight.167 While this percentage is likely to be much higher in those with very 
severe obesity, other factors including craniofacial anatomy and airway structure168 and 
tone169 may also be important. Cephalometric features associated with OSA include inferior 
position of the Hyoid bone,170,171 greater mandibular prognathism,170-172 larger tongue170,173 
and longer soft palate.172 A few studies have reported ethnic differences in craniofacial 
morphology between Chinese/Far East and Caucasians,168,174 which may predispose to OSA, 
especially in very severe obese individuals. Lam and colleagues examined participants from 2 
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regional sleep disorder centres: 164 Chinese in Hong Kong and 74 white Caucasians from 
Vancouver, British Columbia. They found that Chinese participants have a greater 
thyromental angle and smaller thyromental distance compared to Caucasians (p<0.05). The 
researchers also performed multivariate analysis and reported that larger thyromental angle is 
associated with OSA diagnosis adjusted for ethnic group, BMI and neck circumference 
(p<0.05).168 Li and colleagues compared Far East Asian (Chinese, Korean and Japanese) and 
Caucasian men craniofacial profile. Participants were recruited from Stamford University. The 
researchers found that in Far East Asians, crowding of the retropalatal region due to reduction 
in cranial base dimensions as compared to more influence from the retroglossal region in 
Caucasians may explain the differences in prevalence and severity of OSA between these two 
ethnicities.174 No studies have compared or studied the craniofacial morphology in South 
Asians. However, if South Asians have a similar profile as those from the Far East, as they do 
with adiposity increased for a given BMI,175 South Asians may also have increased fat 
depositions in the palatal or upper airway region that may predispose these individuals to 
OSA.  
 
In the South Asian with diabetes, it is also plausible that airway tone could have been altered 
through greater severity of diabetes and potential diabetic autonomic neuropathy. In a cross 
sectional study of 25 diabetes patients with autonomic neuropathy (AN) and 23 diabetes 
patients without AN, the prevalence of OSA was 26% in AN group and 0% in non-AN group 
(p<0.01).176 In another recent cross sectional study of diabetic participants recruited randomly 
from two UK Birmingham hospitals, the researchers assessed diabetic peripheral neuropathy 
(DPN) using the Michigan Neuropathy Screening Instrument questionnaire and 10g 
monofilament test. OSA was assessed using a home portable device.  Logistic regression 
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analysis demonstrated that OSA was associated with diabetic neuropathy (OR 2.72, 95% CI: 
1.44 to 5.52) after adjusting for recruitment site, age, sex, ethnicity, DM duration, alcohol and 
smoking status, lipid profiles and medications for diabetes, hypertension, lipids and 
antiplatelets.177 This suggests that neuropathy may cause pharyngeal collapsibility. Future 
studies could incorporate assessment of visceral obesity, craniofacial and airway anatomy. 
Whether there is also a genetic basis for the observed ethnic differences in OSA also requires 
exploration. 
 
 
2.5.4 Obstructive sleep apnoea and co-morbidities 
2.5.4.1 Hypertension and obstructive sleep apnoea 
Although no significant differences were found in systolic BP between South Asians and 
white Europeans, the mean systolic BP (142mmHg) in our study was above the threshold for 
further investigation based on NICE guidance on the Clinical Guidance 127: Clinical 
management of primary hypertension in adults.
178
 There was also a non-significant 4mmHg 
difference in diastolic BP between the two ethnic groups. A not significant higher proportion 
of South Asians had a diagnosis of hypertension compared to white Europeans (42.5% vs. 
36.6%, p=0.48). These results are unsurprising because OSA is well known to be 
independently associated with systemic hypertension.
81-83,88-91,158,179-181
 
 
Several general population and hospital/clinic based studies have concluded that there is an 
association between hypertension and OSA
81-83,88,89,158,179-181
 except one study by Stradling 
and colleagues.
182
  The study by Stradling and colleagues was performed in Oxford using 
overnight pulse oximetry and not PSG on 752 patients.
182
 They found no correlation between 
hypertension and overnight hypoxaemia.
182
 This Oxford group later performed a small case 
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control study with 45 matched OSA and control patients.
90
 Individuals were matched for age, 
BMI, alcohol and smoking status, history of ischaemic heart disease and treated 
hypertension.
90
  They reported a higher day and night time diastolic BP, greater night-time 
systolic BP and smaller nocturnal BP reduction.
90
 The Sleep Heart Health Study,
81
 a 
multicentre cohort study based in the US examined 6135 middle and older age individuals 
using a portable home device. Individuals had a 37% increase in risk for hypertension if they 
had AHI of ≥30 events/hr compared to an AHI <1.5 events/hr.81  They also found dose-
response relationship between AHI and the risk of hypertension.
81
 This dose-response 
relationship is echoed by the Wisconsin Sleep Cohort Study, which investigated 1060 
individuals using questionnaire and subsequently performed PSG in 305 participants with a 
mean BMI 29Kg/m
2
 and mean age of 45 years.
82
 Another large community study based in 
Pennsylvania performed PSG on 1741 individuals concluded that there was a strong 
association between hypertension and OSA especially in younger subjects.
83
  
 
Several clinic based studies have also reported an association between BP and AHI.4,88,89,179,180 
Lavie et al. examined 2677 patients with PSG, mean age and BMI of 48.6 years and 
30.5Kg/m2, respectively and found that every unit increase in AHI event was associated with 
a 1% increase in the risk of hypertension while every 10% decrease in oxygen saturation is 
associated with 13% increase in risk of hypertension.4 These studies4,81-83,88-90,181 all support 
the existence of an association between AHI and BP. Longitudinal studies have also reported 
on the effect of OSA on the risk of development of hypertension.91,158 The Wisconsin Sleep158 
Cohort Study followed up 706 patients for 4 years with baseline mean age of 46 years and 
mean BMI 29Kg/m2. Although mean BP was lower after 4 years from 125/82 to 
123/79mmHg, the prevalence of hypertension increased from 28% to 31%. The proportion of 
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individuals needing antihypertensive medications are also increased from 10% to 17%.158 The 
odds ratio for hypertension in those with an AHI ≥15 events/hr was 2.89 (95% CI: 1.46 to 
5.64) after adjustment for baseline hypertension status, body habitus, non-modifiable risk 
factors, alcohol and smoking status.158 Wright et al. followed up 82 patients for 5 years and 
reported that increase in AHI was associated with higher 24 hour mean BP, and systolic BP.91  
Our study showed that the patients had elevated mean clinic systolic BP in clinic and this 
could be related to a concomitant diagnosis of OSA.  
 
2.5.4.2 Metabolic syndrome, glycaemic control and obstructive sleep apnoea 
Studies in predominantly white populations have found that OSA is associated with premature 
mortality85,93,160,161 and obese individuals have a lower life expectancy compared to normal 
BMI counterparts.17,183 This study found that South Asians not only had an elevated risk of 
severe OSA, but that those with severe OSA were seven years younger compared to white 
Europeans. This suggests that earlier exposure to intermittent hypoxia may contribute to more 
severe CVD and premature mortality, particularly in obese South Asian populations. The 
mechanisms involved in the link between OSA and ethnicity are still unknown and require 
detailed investigation.  
 
Several studies have suggested that the metabolic syndrome is associated with OSA.184,185 
Although our study did not assess metabolic syndrome per se, we demonstrated that South 
Asians had a significantly higher prevalence of DM, a major risk factor for CVD, compared to 
white Europeans. The Southall and Brent Study followed up 1787 white Europeans and 1420 
South Asians in those residing in the UK over a median of 16 years.186 There were significant 
differences in the demographic between the ethnic groups. The South Asian ethnic group was 
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2 years younger with a lower BMI (26.2 vs. 25.9Kg/m2) and had better cardiovascular risk 
profile with 0.1mmol/l lower total cholesterol level and more than half were non-smokers 
when compared to white Europeans.186 Despite these differences, the researchers found that 
the prevalence of the combination of existing and newly diagnosed DM was significantly 
greater in prevalence amongst South Asians (22.1%) compared to white Europeans (7.2%).186 
Moreover, HOMA-IR analysis also showed greater insulin resistance (2.9% vs. 1.8%) and a 
higher prevalence of metabolic syndrome (44.6% vs. 23.1%) in South Asians compared to 
white Europeans.186 This was consistent with our study finding of a greater proportion of DM 
amongst South Asians.  
 
Whilst OSA has been linked with increased risk of mortality85,93,160,161 and CVD,85,93,187 the 
majority of the studies have been performed in white Europeans, although not exclusively. A 
small study from India of 134 patients of whom 62 were obese individuals with concomitant 
OSA, 46 obese controls and 26 lean controls with no diagnosis of OSA.187 Subjects were 
matched for age and the obese subjects were matched for BMI, body fat percentage, fasting 
and prandial blood glucose levels.187 This study examined high sensitivity C-reactive protein 
(hsCRP) level,187 which is a surrogate marker for increased CVD risk.188-190 The study found 
that Indians with co-existing OSA had significantly higher hsCRP (3.6mg/dl) followed by 
obese individuals without OSA (1.4mg/dl) and lean subjects (0.93mg/dl).187 The recent study 
from Brady and colleagues reported that South Asians had a 2.8% greater body fat percentage 
(p=0.016), 0.08mmol/l lower HDL-cholesterol level (p=0.06) and are 9 years younger 
(p<0.0001) upon initial presentation/investigations for OSA compared to white Europeans.124 
The study also found a 0.3% (p=0.001) higher in HbA1c level in South Asians suggesting 
greater risk for the development of DM.124  Our observations are also suggestive of greater 
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CVD risk in South Asians, which may be an important consideration in clinical practice. 
 
A Norwegian primary care study involving 11 GP practices and a total of 1653 DM patients 
compared the quality of DM care received between ethnic groups. The study shown that age 
of DM diagnosis was significantly younger for South Asians (45years) compared to 
indigenous Norwegians (60years).  South Asians living in Norway with DM also had greater 
adiposity as measured by BMI compared to Caucasian Norwegians (30.1 vs. 29.8Kg/m2) and 
had the greatest risk of needing to be treated with either oral hypoglycaemic medications 
(OHA) or combination OHA treatment with insulin. A total of 25.8% of South Asians were on 
either OHA alone or OHA with insulin compared to 17.4% of Norwegians. The study also 
found that the risk of poor glycaemic control (defined as HbA1c above 9.0%) was 3 fold 
higher in South Asians.191 Allsworth and colleagues examined DM care in 50,427 nursing 
home residents in 5 US cities and found that the use of glucose-lowering medication was 
more prominent in Asians.192 Our study is consistent with these findings, where DM 
prevalence was significantly higher in South Asians compared to white Europeans. Glycaemia 
was also less well controlled and more anti-diabetes medications were required for South 
Asians, suggesting that this population had significantly more severe and more challenging 
diabetes mellitus.  
 
2.5.5 Gender and obstructive sleep apnoea 
Several epidemiological studies have shown that male gender is a risk factor for OSA.
94,96-
98,102
 Although we have a higher proportion of females in our study, we found that male 
gender was associated with an increased severity of OSA. This is consistent with findings 
from general community and sleep clinic studies.
94,95,98,99,193-195
 The Wisconsin Sleep Cohort 
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found that the male to female ratio for OSA diagnosis is 3:1.
94
  A similar ratio was found by 
the Pennsylvania study (3.3:1),
98
 which performed PSG on 1741 individuals. A study by the 
Mayo Clinic on 406 individuals referred for sleep studies found a lower 2:1 ratio for OSA 
diagnosis despite a higher proportion of obese females (64.5% vs. 74.8%).
99
 Mean age was 
similar for both genders.
99
 Males were more likely to consume alcohol (49.4% vs. 30.1%) and 
have a greater AHI (26.6 vs. 22.1 events/hr) than females.
99
 Another sleep clinic study from 
Toronto with 839 patients reported the same ratio of 2:1.
195
 However, the ratio for males to 
every female was a lot higher for severe OSA (ratio 7:1).
195
 Although the males in this study 
are 2 years younger than the females, it was not statistically significant. Females had a higher 
BMI compared to males (35.1 vs. 32.1Kg/m
2
) in this study.
195
  
 
In very severely obese individuals the gender difference was reduced with a ratio of between 
1.4 and 1.7 in males to every female.
95,194
 A study from Brazil examined 132 patients with 
very severe obesity; OSA is diagnosed in 77.4% males and 55.7% females.
95
 Despite higher 
proportion of males with OSA, they were younger (42 vs. 48years), had more severe OSA 
(AHI 66.1 vs. 30.5 events/hr) with greater visceral adiposity (waist circumference 137 cm vs. 
121 cm) and higher neck circumference (48.5 vs. 40.8cm) compared to female counterparts.
95
 
Unsurprisingly, this study also reported a higher ratio for moderate and severe OSA 
(2.3:1.0).
95
 A Singaporean study investigated 176 obese patients and found that 92.5% of 
males and 54.2% of females had OSA.
194
 They also found that the a neck circumference 
greater than 43 cm had a 80% sensitivity, 83% specificity, 80% positive predictive value and 
75% negative predictive value for a diagnosis of OSA.
194
 Our study found that 61% of 
females and 87% of males were diagnosed with OSA giving a ratio of 1.4:1, which is 
consistent with the studies for Class III BMI individuals.
95,194
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The gender differences in OSA parameters could partly be explained by anatomical 
difference, discrepancies in airway responsiveness and hormonal influence.
98,196,197
  Studies 
have found that men have a higher neck circumference when compared to females
193,198
 and 
this could represent a higher fat deposition in the pharynx resulting in higher incidence of 
upper airway obstructions. Mohsenin
199
 examined the effect of the differences in airway size 
and sleep positions between genders and found that men had a lower upper airway diameter 
and greater changes in mandibular movement. Our results also showed a lower minimum 
oxyhaemoglobin saturation in males as well as a twofold increase in time spent below 90% 
oxyhaemoglobin saturation compared to females.  This may be partly due to variations in 
pharyngeal muscular tone between the sexes.
169
 
 
Hormonal differences in gender may also influence airway responsiveness. The Pennsylvania 
study conducted PSG in 1000 women.
98
 OSA was diagnosed if AHI was ≥15 events/hr. 
Interestingly, there was a significant difference in the risk of OSA between post-menopausal 
women who were taking hormonal replacement treatment (HRT) (RR 1.9, 95% CI: 0.4 to 
10.1) and those who were not (RR 9.3, 95% CI: 2.6 to 25.8) when compared to pre-
menopausal women. The effect remained in post-menopausal women without HRT (OR 4.3, 
95% CI: 1.1 to 17.3) after adjustment for confounders. Studies also found that females with 
polycystic ovarian syndrome (PCOS) have a greater risk and severity of OSA. PCOS is a 
condition characterised by hyper-androgenism, menstrual disturbance and obesity. A study 
compared 53 females with PCOS to 452 healthy premenopausal females reported a 30-fold 
(OR 30.6, 95% CI: 7.2 to 139.4) higher OSA prevalence in PCOS group.
200
 Another study 
compared age and weight matched 18 PCOS females with those without PCOS found that 
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PCOS females had greater AHI (22.5 vs. 6.7 events/hr, p=0.008) and AHI was also correlated 
with free testosterone (r=0.50, p<0.05).
201
 Furthermore, excess androgens administration in 
either males or females results in worsening OSA.
202,203
  
 
2.5.6 Limitations  
Whilst our study is the first to report on the ethnic differences of OSA prevalence and severity 
in severely obese individuals, it is important to acknowledge the limitations. Our population 
was recruited from the specialist weight management service and may be subject to selection 
bias with findings only being representative of very severely obese individuals attending such 
a service. Furthermore, ethnic differences in those who initially present with obesity and those 
who are referred by physicians are unknown, and may have produced further selection bias in 
our sample.  
 
Although all UK residents have access to the National Health Service, we cannot rule out the 
possibility of ethnic group differences for the presentation of obesity. However, as previously 
noted, the West Midlands South Asian population is approximately 10% of the total 
population.152 Our patient population of South Asian’s referred to our Specialist Weight 
Management Clinic was 13% and thus may be representative of this minority group in the 
West Midlands. Referral bias may explain the greater prevalence of co-morbidities and a 
younger age of presentation of South Asians. We acknowledge that referral bias may play a 
role, however a recent assessment that utilised the National Bariatric Surgery Registry and 
census data from the UK and Ireland, demonstrated that ethnic minority groups have equal 
access to this type of service/procedure.204  
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One further limitation is that sleep was not assessed using full polysomnography, which is 
impractical and not cost-effective in large clinical populations. Validated instruments for 
assessment of sleep apnoea were however used.205 We did not assess or collect data for OSA 
symptoms as most of our patients are referred to us are for considerations of bariatric surgery. 
Since OSA increases the risks of peri-operative complications, prolonged apnoeic periods are 
associated with risk of respiratory arrest,206 we routinely assess potential SDB prior to 
consideration for bariatric surgery. Moreover, Kapur et al. found that subjective sleepiness 
was not present in more than half of the individuals with moderate to severe OSA.207 Carneiro 
et al.95 also found the Epworth Sleepiness Score was not a useful predictor of OSA in such 
obese populations. Whilst our study benefitted from adjustment for a range of potential 
confounders, we did not consider smoking and alcohol consumption as this data was 
unavailable. Cigarette smoking had a positive correlation with OSA although no causal 
association has been established.104  
 
2.6 Conclusions 
In summary, OSA prevalence and comorbidities were greater in these severely obese South 
Asians compared with equivalent white Europeans. South Asians also had more severe OSA 
compared to BMI-matched white Europeans. Our data also support previously confirmed risk 
factors for AHI severity including higher BMI, older age and male gender. The precise 
mechanisms involved in these ethnic differences are still to be explored and understood 
although we hypothesise that visceral adiposity and different fat depositions play a role. Other 
potential contributory factors may be genetically mediated and include craniofacial structure 
and differences in pharyngeal muscular tone. Further exploration of mechanisms underlying 
ethnic differences in OSA severity is likely to extend the current understanding of OSA. 
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CHAPTER 3: OBSTRUCTIVE SLEEP APNOEA AND 
GLYCAEMIC CONTROL IN TYPE 2 DIABETES MELLITUS 
WITH EXTREME OBESITY 
 
3.1 Introduction  
3.1.1 Obesity and Type 2 diabetes mellitus (T2DM)  
Obesity is a well-established risk factor for T2DM. A hospital-based study on 3637 UK 
patients with T2DM showed that 86% of the individuals are either overweight or obese.
208
 
The Health Professional Follow-up Study which consists of 51,529 male participants 
demonstrated that those with a BMI ≥35Kg/m2 has a greater risk of T2DM (RR 42.1, 95% CI: 
22.0 to 80.6) compared with those with a BMI <23.0Kg/m
2 
over 5 years of follow-up.
209
 
Likewise, the Nurses Health Study with 114,281 participants with 1.49 million person-years 
follow-up ascertained that those who gained >5 Kg in weight had a higher risk of developing 
T2DM: weight gain between 5.0-7.9 Kg had RR 1.9 (95% CI: 1.5 to 2.3); and weight gain 
between 8.0-10.9Kg had RR 2.7 (95% CI: 2.1 to 3.3).
210
  
 
Several intervention studies of obese individuals have shown that weight reduction improved 
insulin sensitivity and lower the risk of developing T2DM. The landmark Diabetes Prevention 
Programme with 2.8 years of follow-up established that in pre-diabetic individuals, lifestyle 
interventions with a 4Kg weight reduction significantly reduced the risk of T2DM incident 
(RR 0.42, 95% CI: 0.52 to 0.44) compared to placebo.
211
 Additionally, the Look AHEAD 
(Action for Health and Diabetes) study showed that after 4 years of intensive lifestyle 
intervention, mean weight loss was 6.15% with a mean reduction in HbA1c of 0.36%.
212
 
Additionally, a recent meta-analysis of 11 RCTs showed that bariatric surgery, a treatment for 
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obese T2DM patients, resulted in a 26Kg (95% CI: -31 to -21) weight reduction and a greater 
T2DM remission (RR 22.1, 95% CI: 3.2 to 154.3) compared to non-surgical treatment.
213
  
 
3.1.2 Obstructive sleep apnoea and glycaemia  
Both obesity and diabetes are related to multiple co-morbidities that may contribute to the 
perpetuation of obesity and deterioration of glycaemic control. A common co-morbidity that 
accompanies both obesity and DM is obstructive sleep apnoea (OSA).
80,139,142
 Several studies 
have shown that OSA is associated with DM.
80,139,142
 The Sleep AHEAD study reported that 
the prevalence of OSA (AHI ≥5 events/hr) can be as high as 86% amongst obese DM 
individuals.
139
 A recent meta-analysis of 6 cohort studies over a follow-up period of between 
2.7 to 16 years with 5653 participants and 332 incident cases of DM found that moderate-to-
severe OSA conferred a relative risk of 1.63 (95% CI: 1.09 to 2.45) for DM.
80
  
 
OSA has been found to affect insulin sensitivity and worsen glycaemia in non-DM 
individuals.
214,215
 In a study of 52 young healthy lean individuals with similar characteristics 
(age, BMI, DM risk, family history of DM and physical activity levels) and normal blood 
pressure (BP) as well as lipid profile; individuals with OSA were noted to have greater insulin 
secretion suggesting lower insulin sensitivity.
214
 The Sleep Heart Health Study (SHHS) also 
reported a significantly higher risk for impaired fasting glucose as well as impaired glucose 
tolerance in OSA compared to non-OSA participants independent of adiposity.
215
 Another 
study of 98 non-DM obese Italian women demonstrated that insulin sensitivity and fasting 
glucose levels correlated with both nocturnal mean and minimum oxygen saturation 
saturations.
216
 The Sleep Extension Study which consists of 96 participants, showed that the 
respiratory disturbances index is a predictor of fasting glucose concentration (mean 5.8, 95% 
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CI: 0.3 to 11.3) after adjusted for potential confounders.
217
 The pathophysiological link 
between OSA and glucose regulation will be described in detail in the discussion section to 
minimise repetition.  
 
Currently, the management of glycaemia mainly consists of lifestyle advice, and 
pharmacotherapy, and in those with extreme obesity, bariatric surgery is increasingly 
advocated. Although bariatric surgery has been shown to be very effective in treating DM,
213
 
not all severely obese individuals fulfil the criteria for bariatric surgery and these patients tend 
to be managed on high doses of insulin treatment in conjunction with oral therapies. As DM 
has been shown to be associated with OSA, the purpose of the current evaluation was to 
explore if OSA is an important factor for the management of challenging insulin resistance in 
individuals with extreme obesity. The impact of nocturnal hypoxia caused by OSA on 
glycosylated haemoglobin A1c (HbA1c) levels were investigated in this high risk patient group.  
 
 
3.2 Aim and objectives  
The aim of this chapter is to examine the effect of OSA on glycaemia amongst DM with 
severe obesity. The following are the objectives of the study:  
 
1. To compare the prevalence of OSA in extremely obese individuals with  and without 
diabetes, and 
2. To explore the relationship between OSA and glycosylated haemoglobin A1c  
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3.3 Methods 
3.3.1 Study Design 
The methodology had been described in Chapter 2. The participants; however, were 
consecutive patients from January 2009 to April 2013. The recruitment period was longer 
compared with chapter 2 as this study was carried out at a later date. Respiratory sleep 
monitoring was also described in Chapter 2. 
 
3.3.2 Statistical analysis 
All data (including those with and without DM) were anonymised prior to any statistical 
analysis. However, for the multivariate linear regression analysis, only individuals with DM 
were included.  Distribution of the data was determined through visual inspection. Normally 
distributed data was reported as mean ± standard deviation whilst non-normally distributed 
data was reported as median with inter-quartile range (IQR). T-test and Mann Whitney U-
tests were used for parametric and non-parametric data, respectively. Chi-squared test was 
utilised for categorical data.  
 
The association between respiratory parameters and HbA1c was carried out using multivariate 
linear regression analysis in DM patients only. The base model was unadjusted, Model 1 was 
adjusted for age, gender, BMI and ethnicity (white Europeans vs. non-white Europeans) while 
further adjustments for number of DM medications were performed in Model 2. The factors 
included in the adjusted models were those that are considered to be clinically important, and 
the rationale for including each factors is discussed elsewhere (see table 3- 1). Results are 
reported as beta coefficient with 95% confidence interval (95% CI). A p value of <0.05 was 
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considered significant. All statistical analyses were performed using Stata 13 (StataCorp LP, 
College Station, Texas). 
 
 
Table 3-1: Factors adjusted and the appropriate sections discussing the rationales behind  
Factors Sections / rationale 
Age Introduction of Chapter 2 (section 2.1.3) 
Gender Chapter 2’s discussion (section 2.5.5) 
Ethnicity  Chapter 2’s discussion (section 2.5.3) 
Body mass index Chapter 1 (section 1.3.4) 
Number of anti-diabetes medications Can influence HbA1c level  
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3.4 Results 
3.4.1 Study characteristics  
There were a total of 433 patients. However, 145 patients had missing HbA1c results, four 
patients did not have analysable results from the overnight sleep study, and one patient had 
missing BMI data. Therefore a total of 283 eligible patient records were examined, including 
161 with DM (56.9%).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1: Flow diagram of referrals seen at the HEFT Specialist Weight Management Clinic, and 
those included in the study 
HEFT – Heart of England NHS Foundation Trust 
 
 
Consecutive patients seen at HEFT 
Specialist Weight Management 
Clinic 
(January 2009 to April 2013) 
 
N = 433 
Included patients for analysis 
N = 283 
Excluded:  
 
143 = No HbA1c results 
4     = Respiratory data unable to 
analyse 
1     = Missing anthropometry data 
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Table 3-2 describes the characteristics of non-DM and DM individuals in this study. DM 
patients were 10 years older compared to non-DM patients (51.1±10.2 vs. 41.8±12.5 years, 
p<0.0001). There were also more males (40.4% vs 23.8%, p=0.003) and a lower proportion of 
white Europeans (75.2% vs. 92.6%, p=0.010) amongst the DM patients. However, there were 
no significant differences in BMI (48.8±9.1 vs. 49.59±8.4Kg/m
2
, p=0.47), systolic 
(145.4±20.1 vs. 141.1±18.0mmHg, p=0.12) and diastolic BP (87.0±11.1 vs. 86.6±12.6, 
p=0.84) between the two groups. As expected, there were greater proportions of DM patients 
with HTN (57.8% vs. 23.8%, p<0.001) and CAD (10.6% vs. 2.5%, p=0.008) when compared 
to non-DM individuals.  
 
There were also significant differences in the respiratory parameters (p<0.05). The overall 
OSA prevalence (AHI ≥5 events/hr) was 72.8%; and it was significantly more common in 
DM (80.1%) compared with non–DM individuals (63.1%, p=0.001). There were also greater 
proportions of DM individuals with moderate and severe AHI (47.2% vs. 34.4%, p=0.015). 
DM individuals had higher median AHI (14.0 [IQR: 6.0, 36.0] vs. 8.0 [IQR: 3.5, 24.5] 
events/hr, p=0.009), lower median minimum O2 saturation (82% [IQR: 74, 85] vs. 83% [IQR: 
78, 88], p=0.01), mean oxygen saturation (93% [IQR: 91, 95] vs. 94% [IQR: 92, 95%], 
p=0.026) and significantly longer median time spent under 90% O2 saturations (4.0% [IQR: 
0.7, 15.8] vs. 1.0% [IQR: 0.1, 13.2], p=0.007) compared with non-DM patients.   
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Table 3-2: Characteristics of obese individuals with and without diabetes mellitus 
 
 
Overall 
N=283 
Non-DM 
N = 122 
DM 
N = 161 
P value 
Age (years) 47.1 ± 12.1 41.8 ± 12.5 51.1 ± 10.2 <0.001 
Sex n (%) 
Females 
Males 
 
189 (66.8%) 
93 (33.2%) 
 
99 (81.1%) 
29 (23.8%) 
 
96 (59.6%) 
65 (40.4%) 
 
0.003 
Ethnicity 
White European 
South Asian 
Afro-Caribbean 
 
230 (81.3%) 
39 (13.8%) 
14 (4.9) 
 
113 (92.6%) 
10 (8.2%) 
4 (3.2%) 
 
121 (75.2%) 
30 (18.6%) 
10 (6.2%) 
 
0.010 
 
BMI (Kg/m
2
) 
 
49.2 ± 8.8 
 
49.59 ± 8.38 
 
48.8 ± 9.1 
 
0.467 
Systolic BP (mmHg) 143.5 ± 19.3 141.1 ± 18.0 145.4 ± 20.1 0.123 
Diastolic BP (mmHg) 86.8 ± 11.7 86.6 ± 12.6 87.0 ± 11.1 0.838 
     
Co-morbidities  
Hypertension 
Coronary artery 
disease 
 
122 (43.1%) 
20 (7.1%) 
 
29 (23.8%) 
3 (2.5%) 
 
93 (57.8%) 
17 (10.6%) 
 
<0.001 
0.008 
     
Respiratory 
parameters 
AHI (events/hr) 
Mean O2 sat (%) 
Min O2 sat (%) 
%TST<90% 
 
OSA (AHI > 5/hr) 
 
Classification of OSA 
Mild 
Moderate 
Severe 
 
11.8 (4.0, 31.8) 
93.4 (91.6, 95.0) 
83.0 (76.0, 87.0) 
2.3 (0.2, 15.0) 
 
206 (72.8%) 
 
 
87 (30.7%) 
45 (15.9%) 
74 (26.1%) 
 
8.0 (3.5, 24.5) 
94.0 (92.0, 95.0) 
83.0 (78.0, 88.0) 
1.0 (0.1, 13.2) 
 
77 (63.1%) 
 
 
34 (26.6%) 
17 (13.3%) 
26 (21.1%) 
 
14.0 (6.0, 36.0) 
93.0 (91.2, 95.0) 
81.5 (74.0, 85.0) 
4.0 (0.7, 15.8) 
 
129 (80.1%) 
 
 
53 (32.9%) 
28 (17.4%) 
48 (29.8%) 
 
0.009 
0.026 
0.011 
0.007 
 
0.001 
 
 
0.015 
     
Data presented as mean ± standard deviation (SD), median (interquartile range) or number (%). DM = 
Type 2 diabetes mellitus, BMI = body mass index, BP = blood pressure, AHI = apnoea-hypopnoea 
index, O2 sat = oxygen saturation, %TST<90% = % time spent below 90% oxygen saturation, OSA = 
obstructive sleep apnoea. 
 
 
3.4.2 Respiratory parameters and glycaemia 
The univariate model of linear regression showed that AHI was not associated with glycaemic 
levels (β=0.0018, 95% CI: -0.0079 to 0.0115) as shown in Table 3-3. The result remained 
non-significant after adjustment for age, gender, ethnicity and BMI (β=0.003, 95% CI: -
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0.0099 to 0.0106) as well as further adjustment for the number of diabetic medications 
(β=0.0011, 95% CI: -0.0088 to 0.0109). Similarly, mean oxygen saturation did not show any 
significant association with HbA1c in the univariate (β=-0.0577, 95% CI: -0.1441 to 0.0287), 
Model 1 (β=-0.0690, 95% CI: -0.1637 to 0.0256) and Model 2 (β=-0.0688, 95% CI: -0.1598 
to 0.0221). Minimum oxygen saturation also was not associated with the level of glycaemia in 
the univariate model (β=-0.0267, 95% CI: -0.0542 to 0.0008). However, the association 
became significant after adjustment for age, gender, ethnicity and BMI (β=-0.0320, 95% CI: -
0.0622 to -0.0018) and remained significant with further adjustments for the number of 
glucose-lowering medications (β=-0.0304, 95% CI: -0.0595 to -0.0013). The final model 
(Model 2) showed that each 1% increase in the minimum oxygen saturation was associated 
with 0.03% reduction in HbA1c. In other words, a 0.3% increase in HbA1c was associated with 
a 10% reduction in minimum O2 saturation. 
 
Likewise, univariate linear regression analysis showed a positive relationship between 
%TST<90 and HbA1c levels (β=0.0155, 95% CI: 0.0026 to 0.0284). The association persisted 
after adjustment for age, gender, BMI and ethnicity (Model 1: β=0.0189, 95% CI: 0.0050 to 
0.0237) and further adjustments for diabetic medication (Model 2: β=0.0177, 95% CI: 0.0043 
to 0.0310). This demonstrated a 0.02% increase in HbA1c with each 1% increase in 
%TST<90.  Non-significant associations with HbA1c were found for AHI and mean O2 
saturations.  
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Table 3-3: Independent predictors of HbA1c in DM patients (n=161)  
Predictors Models 
Beta coefficients (95% confidence intervals) 
 Univariate analyses Model 1 Model 2 
AHI 
0.0018 (-0.0079 to 
0.0115) 
0.0003 (-0.0099 to 
0.0106) 
0.0011 (-0.0088 to 
0.0109) 
Mean O2  
-0.0577 (-0.1441 to 
0.0287) 
-0.0690 (-0.1637 to 
0.0256) 
-0.0688 (-0.1598 to 
0.0221) 
Min O2 
-0.0267 (-0.0542 to 
0.0008) 
-0.0320 (-0.0622 to     
-0.0018) 
-0.0304 (-0.0595 to  
-0.0013) 
%TST<90 
0.0155 (0.0026 to 
0.0284) 
0.0189  (0.0050 to 
0.0327) 
0.0177  (0.0043 to 
0.0310) 
Age 
-0.0219 (-0.0476 to 
0.0038) 
-0.0258 (-0.0520 to 
0.0005)* 
-0.0258 (-0.0510 to -
0.0005)* 
Male 
0.6754 (0.1478 to 
1.2031) 
0.7586 (0.1837 to 
1.3334)* 
0.6858 (0.1311 to 
1.2404)* 
BMI 
-0.0043 (-0.3345 to 
0.0250) 
0.0047 (-0.0268 to 
0.0362)* 
0.0116 (-0.0190 to 
0.0421)* 
Non WE 
0.0484 (-0.4055 to 
0.5023) 
-0.0051 (-0.4454 to 
0.4461)* 
-0.0491 (-0.4841 to 
0.3858)* 
No. DM 
medications 
0.4604 (0.2187 to 
0.7021) Not applicable 
0.4487 (0.2063 to 
0.6912)* 
Analysis performed using linear regression. HbA1c = glycosylated haemoglobin A1c, AHI = apnoea-
hypopnoea index, O2 = oxygen saturation, Min O2 = minimum oxygen saturation, %TST90 = % time 
spent below 90% oxygen saturation, BMI = body mass index, Non WE = Non White Europeans, No. 
DM medications = Number of diabetes mellitus medications  
*Adjusted for apnoea-hypopnoea index only to avoid multi-collinearity 
 
Univariate analyses = unadjusted models 
Model 1 = adjusted for age, gender, body mass index and ethnicity 
Model 2 = adjustments for gender, body mass index, ethnicity, number of glucose-lowering 
medications  
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3.5 Discussion  
3.5.1 Prevalence of obstructive sleep apnoea in the diabetes mellitus populations  
Our study showed that the prevalence of OSA was significantly higher in DM individuals 
with extreme obesity. As discussed in Chapter 2, the general prevalence of OSA has been 
reported to be between 16 and 27%
94,123,131,134
 whilst in the extremely obese populations, 
between 61 and 98% had OSA.
95,140-145
 However, one of the limitations of the prevalence 
studies in obese population is the underreporting of chronic diseases therefore inclusion of 
multiple co-morbidities including DM may lead to an overestimation of the prevalence of 
OSA.
95,140,144,145
 In fact, our observations were comparable with the findings from several 
studies involving DM individuals. The Sleep Ahead study, which examined 305 obese DM 
individuals, reported an OSA rate of 86%.
139
 In the Morbid Obesity treatment, Bariatric 
surgery versus Intensive lifestyle intervention (MOBIL) study, the prevalence of OSA was 
78% amongst DM individuals, which was significantly higher than in patients with normal 
glucose tolerance (33%).
142
  
 
Aronsohn and colleagues reported an OSA prevalence of 77% among 60 DM individuals.
218
 
However, the Sleep Heart Health Study (SHHS) found that only 58% of DM patients had 
OSA.
219
 The lower prevalence rate reported by the SHHS study compared to our study may 
be partially due to the differences in adiposity levels (SHHS mean BMI was 31.3±6.0 
Kg/m
2
).
219
 Also, our study included ‘undiagnosed’ DM individuals with HbA1c results of 
>6.5% as well as known DM in the analysis and this is likely to represent a better OSA 
prevalence rate amongst DM whilst the SHHS study had only recorded self-reported DM 
patients.
207
 Therefore, SHHS is likely to represent an underestimation of the reported OSA 
rate.  
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3.5.2 Obstructive sleep apnoea and glycaemic control   
In the literature, limited studies have examined the relationship between OSA and glycaemic 
control amongst DM individuals.
218,220
 A study from Oxford screened 938 T2DM men using 
the Berlin questionnaire and selected 240 (124 high risk and 116 low risk men) T2DM male 
individuals for overnight pulse oximetry investigation.
220
 They first used the oxygen 
desaturation index (ODI), with an event defined as a drop of oxygen saturation of at least 5% 
and then used 10 events/hr to identify individuals with OSA. This was subsequently 
confirmed using a portable home device to diagnose OSA. Those who had an ODI of less 
than 10 events/hr but had a sleep tracing resembling OSA were also confirmed with the 
portable device for the diagnosis of OSA. The researchers found a correlation between pulse 
oximetry and HbA1c (r=0.2, p=0.0006) in a subgroup analysis of their hospital-recruited DM 
individuals.
220
 The strength of the relationship reduced (coefficient not reported) after 
adjusting for BMI (p=0.03). One limitation of the study is that the authors only adjusted for 
BMI and not other confounding factors such as DM duration, age and diabetic medication. 
Moreover, the positive correlation, was lost when a larger sample size of both community and 
hospital-recruited DM individuals were included
220
 suggesting the correlation might be 
spurious.  
 
Another study by Aronsohn and colleagues examined 60 DM individuals with overnight 
laboratory full PSG. Following a mean respiratory recording of 6 hours, mild OSA was 
associated with an increased HbA1c of 1.49%, moderate OSA of 1.93% and severe OSA of 
3.69%.
218
 Aronsohn and colleagues used an AHI ≥5 events/hr for the diagnosis of OSA. In 
contrast, our results did not show any significant association between AHI and the level of 
 78  
 
glycaemia in DM individuals. This could be due to the differences in the minimum duration 
of overnight sleep study recorded. We included all individuals with at least 4 hours of 
respiratory records. Aronsohn and colleagues found that when they used only the first 4 hours 
of sleep data, the association between OSA and HbA1c was no longer significant. One 
hypothesis is that during REM sleep, there is a higher frequency of apnoea and hypopnoea 
episodes compared to other sleep stages
218
 and REM sleep usually becomes more prominent 
as the night progresses.
221
 From our experience, we find that it is difficult to achieve 6 hours 
of quality respiratory recording in our patients mainly due to the discomfort caused by the 
device and in other cases, the loss of connection with part of the device during sleep.  
 
Although our results showed no significant association between AHI and levels of glycaemia 
in Type 2 diabetes mellitus individuals, we found a significant relationship between minimum 
O2 saturation as well as %TST<90 and HbA1c levels in these individuals. To our knowledge, 
no study has assessed the association between the levels and duration of hypoxia and 
glycaemic control in the obese DM population. In a non-DM study of 116 hypertensive 
individuals, a significant correlation was identified between minimum O2 level and HbA1c (r=-
0.25, p<0.001)
222
 as did another study from Japan non-DM individuals (β=-0.29, p<0.001).223 
This suggests that in DM individuals with limited respiratory recordings, nocturnal hypoxia, 
and not AHI, may be a useful indicator of greater insulin resistance and might contribute to 
poor glycaemic control. Moreover, our previous studies have also shown that the severity and 
duration of nocturnal hypoxaemia may be an important factor for DM micro-vascular 
complications, such as progression of diabetic retinal complication
224
 (please refer to Chapter 
4), and diabetic nephropathy
225
 (please refer to Chapter 5).  
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This suggests that apart from using usual glucose-lowering medications, correcting nocturnal 
hypoxia may be beneficial in the reduction of HbA1c notably amongst severely obese patients. 
The current CPAP trials on glycaemia have been inconclusive. A recent meta-analysis of 8 
observational studies and 1 RCT found that CPAP treatment had no significant impact on 
glycaemia (mean change in HbA1c was -0.08, 95% CI: -0.26 to 0.42%).
226
 However, there 
were several limitations present in the meta-analysis especially in the quality of the included 
studies. Three of the observational studies included performed a repeated HbA1c in less than 
90 days: 1 after 41 days, 1 after 4 weeks, 1 after 2 months.
50,227,228
 In vivo, lifespan of 
erythrocytes is between 2 to 3 months therefore the American Diabetes Association (ADA) 
has recommended that HbA1c should be monitored approximately 3 monthly.
229
  
 
Furthermore, some of the studies had problems with CPAP adherence. Since the development 
of CPAP, compliance with the device has been a major issue in the treatment of OSA. A 
study which examined the ‘threshold’ of CPAP usage which was likely to provide 
improvements for sleepiness symptoms suggested that at least 4 hours was needed.
230
 This 
study examined 137 participants with complete baseline and 3 month follow-up data. 
Response was judged using the ESS, Multiple Sleep Latency Test (MSLT) and functional 
status using the Functional Outcomes of Sleep Questionnaire (FOSQ). The ‘threshold’ for 
improvement in sleep symptoms based on ESS, MSLT and FOSQ were 4 hours, 6 hours and 
7.5 hours respectively at study end. Therefore, this suggests that at least a minimum duration 
of 4 hour CPAP usage is required to be beneficial. The only RCT
231
 included in the meta-
analysis had only 20 participants in the CPAP group and the mean CPAP usage was 3.6 hours 
compared with 22 in placebo group with 3.3 hours of CPAP per night. Unsurprisingly, the 
result from the RCT was not statistically significant for improvement in HbA1c after 3 months 
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of treatment. Apart from the relatively small sample size, the minimum level of CPAP 
adherence was not achieved by West and associates (mean hours used 3.6±2.8 hours).  
 
Finally, 4 small studies from the meta-analysis which provided at least 4 hours of compliance 
with CPAP showed statistically significant correlations between CPAP usage and HbA1c 
reduction.
232
 Babu et al compared 12 participants with <4 hours and 12 with >4 hours of 
CPAP usage for between 30 and 90 days and showed that those with >4 hours had significant 
correlation between glycaemia and days of CPAP use (r=0.74, p=0.006).
232-235
 Another study 
from Greece had 21 non-DM individuals with CPAP use of 4.71±0.55 hours expressed a 
HbA1c reduction from 5.55±0.4 to 5.38±0.45% (p=0.004) after 6 months of treatment.
233
 A 
prospective cohort study found that out of 19 participants with severe OSA being followed up 
for between 3 to 5 months, 12 had a least 4 hours of CPAP usage and the mean HbA1c 
decreased from 6.47±0.67% to 6.28±0.51% (p=0.038).
234
 Moreover, a cross-sectional study of 
29 patients with mean of 4±3 hours use per day demonstrated a drop of HbA1c from 7.8±1.4% 
to 7.3±1.3% (p<0.001) at least 3 months apart.
235
 Consequently, future well designed RCTs 
with appropriate sample size and good adherence of CPAP of at least 6 hours amongst DM 
individuals are required to enhance our understanding on the effect of treating nocturnal 
hypoxia.  
 
3.5.2.1 Pathophysiology between OSA and glycaemia 
The effect of OSA on glucose may be caused through several mechanisms as shown in Figure 
3-2. Sleep disturbances (arousal, sleep fragmentation, sleep deprivation and napping), chronic 
intermittent hypoxaemia and hypercapnia are likely play a part in affecting insulin sensitivity 
and beta cell function. The elevated sympathetic drive
236-238
 alters glucose and fat metabolism 
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causing an increase in hepatic gluconeogenesis, inhibition of insulin secretion hence lowering 
of glucose uptake by insulin-dependent tissue such as muscle.
239
 Likewise, greater release of 
cortisol was demonstrated to have similar effects on hepatic glucose production 
(gluconeogenesis and glycogenolysis) and inhibition of insulin secretion.
238
 OSA also 
activates the renin-angiotensin-aldosterone system (RAAS).
240
 Recent emerging evidence 
suggests that RAAS plays a role in glucose metabolism via inhibition of insulin signally in 
skeletal muscles thus insulin resistance.
241
 Additionally, angiotensin receptors were found in 
pancreatic islet cells and angiotensin II appears to suppress glucose-induced insulin secretion 
and lowers islet blood flow affecting insulin production.
241
 In addition, drugs which inhibit 
the RAAS system seems to improve glucose tolerance and insulin sensitivity
242,243
 in animal 
studies. Furthermore, a systematic review and meta-analysis of 11 RCTs on the effect of 
angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) 
demonstrated a reduction in risk of the development of T2DM (OR 0.78, 95% CI: 0.73 to 
0.83) compared to placebo.
244
  
 
Insulin resistance caused by OSA may also partly be explained through activation of oxidative 
stress pathways.
245
 Excess of reactive oxygen species (ROS) either from overproduction or 
ineffective removal can alter cellular function and activates greater oxidative stress and 
inflammatory reactions resulting in endothelial dysfunction.
245
 Indeed, several studies have 
demonstrated greater levels of inflammatory markers such as interleukin-6 (IL-6), tumour 
necrosis factor-alpha (TNFα) as well as other inflammatory markers in individuals with 
OSA.
246-248
 In severely hypoxic OSA individuals, there seems to be an up-regulation of the 
hypoxia-inducible factor-1 alpha (HIF-1α) expression,249 HIF-1a in turn has been found to 
down-regulate insulin signalling pathways and the synthesis of glucose transport proteins
250
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which will contribute to the fall in insulin sensitivity. Humoral modulations also occurred 
with OSA as leptin levels was found to be elevated while adiponectin levels were 
significantly reduced.
142,247
 Leptin has been shown to inhibit glucose-induced insulin 
secretion from the pancreatic islet cells
251
 whilst adiponectin has been found to stimulate 
insulin secretion, suppress hepatic gluconeogenesis and increase glucose uptake in skeletal 
muscles.
252
   
 
Collectively, these mechanisms play a vital role in the impairment of pancreatic beta cell 
function and insulin sensitivity. The pancreatic beta cell is very sensitive to oxygen 
deprivation. Hypoxia in mice has been shown to result in impairment in beta cell function
253
 
and also cell apoptosis.
254
 Indeed, it has been shown in several islet cells transplantation 
studies for type 1 diabetes mellitus that reduction in oxygenation is one of the main factors 
resulting in transplant failure.
255,256
 Alternatively, it is plausible that DM may lead to the 
development of OSA. The possible pathophysiology of DM causing OSA will be discussed in 
detail in Chapter 4.  
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Figure 3-2: Pathogenic mechanisms linking OSA to diabetes mellitus. OSA=obstructive 
sleep apnoea, HPA=hypothalamic-pituitary-adrenal axis, RAAS=renin-angiotensin-
aldosterone system, IL-6=interleukin-6, TNF-alpha= tumour necrosis factor alpha 
 
 
3.5.3 Limitations and benefits of the study 
There were several limitations to our study. Firstly, it only examined extremely obese 
individuals, which are an especially high-risk group of individuals for health complications 
and mortality. Secondly, the limitations of observational studies apply to our study and it is 
difficult to exclude reverse causality. Thirdly, there was no data on smoking and alcohol 
status. However, this study had a large number of patients and is representatives of the local 
population with extreme obesity. The analyses were also adjusted for multiple potential 
confounders in the regression analyses.  
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3.6 Conclusion 
This study observed an inverse relationship between nocturnal hypoxaemia and glycaemia 
control among extremely obese DM individuals. It was also observed that the prevalence of 
OSA amongst DM individuals, especially in those who needed insulin therapy, was very high. 
This supports the notion that OSA, in particular hypoxaemia, may have an adverse effect on 
glucose metabolism. Further well-designed, adequately powered studies on the impact of 
correcting nocturnal hypoxaemia on glycaemia are needed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 85  
 
CHAPTER 4 – THE POTENTIAL ASSOCIATION BETWEEN 
OBSTRUCTIVE SLEEP APNOEA AND DIABETIC 
RETINOPATHY IN SEVERE OBESITY  
 
4.1 Introduction  
4.1.1 Diabetic retinal disease 
The chronic hyperglycaemic state is associated with both macro and micro-vascular 
complications. Macro-vascular complications of diabetes mellitus (DM) are mainly due to 
atherosclerosis of the arteries leading to myocardial infarction, coronary artery disease, stroke 
and peripheral vascular disease. DM micro-vascular complications include nephropathy, 
neuropathy and diabetic retinal disease. The most common diabetic retinal disease is diabetic 
retinopathy (DR). Stages of DR include background, pre-proliferative and proliferative 
retinopathy disease. The initial stage - background retinopathy involves presence of micro-
aneurysm lesions whereby the lining of the retinal vessels weakened leading to leakage of 
lipoproteins (termed hard exudates) or blood. Presence of the blood in the retina has been 
described to be either dot (small dots of blood) or flame (larger blotches of blood) 
haemorrhages.
257
   
 
The next stage - pre-proliferative DR involves large pools of blood leakage from the vessels 
causing large dark blot haemorrhages or multiple blood exudates. At this stage, disruption of 
the blood supply in some areas of the retina can occur leading to micro-infarctions of the 
nerve fibre. Such changes looked are termed ‘cotton-wool’ spots. In order to compensate 
blood supply to these ischaemic areas, abnormal branching or dilatation of retinal capillaries 
occur. These abnormal vessels are called intra-retinal micro-vascular abnormalities 
(IRMA).
257
 The final stage - proliferative DR (PDR) occurs when abnormal new blood vessel 
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are present within the retina. These vessels are different from IRMA as they are finer and 
much more delicate hence easier to rupture resulting in vitreous haemorrhage.
257
 A summary 
of the features of the DR stages are shown in Table 4-1. 
 
 
Table 4-1: Stages of diabetic retinopathy 
Stages Features 
Background diabetic retinopathy Micro-aneurysms 
Hard exudates 
Flame, dot, blot haemorrhages 
Pre-proliferative diabetic retinopathy Large blot haemorrhages 
Cotton wool spots 
Intra-retinal microvascular abnormalities (IRMA) 
Venous beading 
Proliferative diabetic retinopathy Abnormal new vessel on optic disc or retina 
Vitreous haemorrhages 
 
 
The WHO Global Burden of Disease 2000 Project reported that DR accounts for 15% to 17% 
of blindness in developed Western countries.
258
 Although DR is the third most common threat 
to vision after age-related macular degeneration and glaucoma, it is the most common cause 
of blindness in people within the working age group,
259
 making it an important cause for 
disability and morbidity. Apart from the retina, DM also affects the macula. Changes within 
the macula due to diabetes are termed diabetic maculopathy (DMac). DMac can occur at any 
stage of DR and is potentially very serious as it can threaten central vision. Presence of DMac 
include any exudative leak of proteins which causes macula oedema, micro-aneurysms or 
haemorrhages within the central fovea or ischaemic changes to the macula.
260
 Other eye 
diseases associated with DM includes retinal detachment,
260
 glaucoma
261
 and cataract.
262
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4.1.2 Obesity, obstructive sleep apnoea and diabetic retinal disease 
Both observational
263,264
 and longitudinal studies
265,266
 have demonstrated an association 
between obesity and diabetic retinal disease especially DR. The Diabetic Management Project 
based in Australia recruited 492 Type 1 and Type 2 DM participants with a median age of 65 
years demonstrated that obesity with BMI ≥30Kg/m2 had a 3-fold greater risk of DR (OR 
3.12, 95% CI: 1.20 to 8.16) compared to normal BMI individuals after adjustment for a range 
of confounders.
263
 Similarly, the Hoorn study,
264
 a population study from the Netherlands also 
reported that DM patients with higher BMI were at increased risk of DR (OR 3.52, 95% CI: 
1.05 to 11.8 in those with BMI between 28.4 and 45.7Kg/m
2
 compared with BMI between 
15.0 and 20.1Kg/m
2
) after adjusted for age and gender. Longitudinal study from the Diabetes 
Incidence Study in Sweden (DISS)
265
 followed up 627 participants for 10 years. The 
incidence of DR was 39% and BMI was found to be predictor for DR (HR 1.11, 95% CI: 1.04 
to 1.18).  
 
Frequent episodes of hypoxaemia during sleep in OSA have been reported to be associated 
with raised inflammatory mediators.
267
 In DM, inflammatory mediators are also elevated,
268
 
and are contributory to diabetic micro-vascular complications such as diabetic retinal 
disease.
259
 More recently, literature has emerged to suggest that concomitant OSA in DM 
patients might be associated with significantly more DR cases, and more advanced sight-
threatening DMac, with the suggestion that OSA is an independent risk factor for diabetic 
retinal complications.
269,270
 These studies used oxygenation as part of their definition of OSA, 
suggesting that the intermittent hypoxaemia and re-oxygenation episodes in OSA lead to a 
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greater oxidative stress and inflammatory responses, and hence deterioration of diabetic 
retinal disease.
271
 
  
There is very little information, however, regarding the association between sleep-disordered 
breathing as defined by apnoea-hypopnoea frequency and diabetic retinal complications, or 
whether other hypoxaemia parameters are important, particularly the degree of hypoxaemia 
during sleep (e.g. minimum oxygen saturation (O2) or time spent under 90% oxygen 
saturations [%TST<90]). Furthermore, little has been studied in patients with severe obesity, a 
high-risk group for OSA and DM. We hypothesised that DM patients with severe obesity and 
moderate-to-severe OSA (as defined by AHI) will have a higher prevalence of diabetic retinal 
disease compared to those without OSA and that OSA is associated with more severe diabetic 
retinal disease. We therefore undertook a cross-sectional evaluation of a cohort of consecutive 
severe obese patients with DM undergoing assessment with routine clinical retinal screening 
and overnight respiratory sleep monitoring.  
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4.2 Aim and objectives 
The aim for this chapter is to examine the prevalence, risk factors and relationship between 
OSA and diabetic retinal disease in a severely obese population. The following are the 
objectives for the study:  
1. To explore the prevalence of diabetic retinal disease amongst DM individuals who are 
very severely obese  
2. To examine the relationship between nocturnal hypoxaemia and diabetic retinal 
disease in very severely obese DM participants, and  
3. To investigate the risk factors for diabetic retinal disease amongst very severely obese 
DM individuals. 
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4.3 Methods  
4.3.1 Study design and study participants 
A cohort of consecutive patients attending the regional specialist weight management service 
at Birmingham Heartlands Hospital, UK between January 2009 and December 2011 was 
studied. This study was carried out at the same period as Chapter 2 hence the identical study 
period. Only DM individuals were included. Routine clinical data collected included age, 
gender, self-reported ethnicity, weight, BMI, cardiovascular co-morbidities (hypertension and 
coronary artery disease), duration of DM, DM medications, HbA1c (DCCT-aligned and 
IFCC), and renal function (creatinine and estimated glomerular filtration rate (eGFR)). 
 
 
4.3.2 Respiratory sleep monitoring methods 
Overnight sleep recording had been described in detail in Chapter 2. OSA in this chapter was 
classified into participants 2 groups: those with AHI of <15 events/hr was regarded as the 
‘OSA– group’ while those with the presence of AHI ≥15 events/hr was in the ‘OSA+ group’. 
The cut-off point for AHI of 15 events/hr was selected as it signifies moderate-to-severe OSA 
and forms part of the clinical decision making determining whether or not to treat with 
continuous positive airway pressure (CPAP). The AHI was used as the diagnostic parameter 
for OSA and not oxygen desaturation index (ODI) as ODI was not measured in this study.  
 
4.3.3 Retinal screening methods 
DR data were obtained from routine local screening program based on the English National 
Screening Programme for Diabetic Retinopathy (ENSPDR) in Birmingham Heartlands 
Hospital.  The ENSPDR was implemented from 2003.
156
 The screening programme aims to 
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offer regular eye examinations in order to detect DR at an early stage so appropriate and 
effective eye treatment can be provided to diabetes patients.
156
 Digital photographs of two 45º 
fields per eye (1 fovea-centre-ed, 1 disc-centre-ed) are obtained annually. ENSPDR also 
developed guidance on the classification of the severity of diabetic retinopathy in England and 
Wales.
272
 All diabetes patients attending the clinic underwent annual retinal screening and 
data were acquired from the most recent screening assessment. Presence or absence of DR 
and DMac were recorded. DMac is defined as any evidence of exudate, micro-aneurysm or 
haemorrhage with 1 disc diameter of the centre of the fovea.
272
  
 
4.3.4 Statistical analysis 
All statistical analyses were carried out using the Statistical Package for Social Sciences, 
version 19 (SPSS, Chicago, IL). Data analysis was performed on anonymised patients as part 
of service evaluation. Normally distributed data are reported as mean±standard deviation (SD) 
and analysed using an independent t-test whilst skewed data are reported as median and 
interquartile range (IQR) and the Mann Whitney U-test was used for analysis. Categorical 
data was analysed using the chi-squared test. Statistical comparisons were made for patients 
with and without DR, DMac and OSA.  
 
Univariate analyses were carried out to examine factors associated with diabetic retinal 
disease. Logistic regression analyses were conducted and three models constructed to 
examine associations between 1) AHI (continuous); 2) mean O2; 3) minimum O2; and 4) 
%TST<90; and DR as well as DMac. The base model is unadjusted, Model 1 was adjusted for 
age, gender, BMI and ethnicity (white Europeans vs. non-white Europeans), and Model 2 was 
further adjusted for DM duration, presence/absence of insulin treatment and HbA1c, 
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presence/absence of hypertension, and presence/absence of coronary artery disease. Logistic 
regression analyses were also performed to investigate the associations between other 
variables and DR as well as DMac. The models aimed to adjust factors which were 
considered to be clinically important. To avoid repetition, the influence of these factors has 
been or will be described elsewhere. For the effect of age on OSA, please refer to the 
introduction of chapter 2 (section 2.1.3), the effects of gender (section 2.4.4) and ethnicity 
(section 2.5.3) on OSA have been discussed in details in the chapter 2’s discussion. Please 
refer to Chapter 1 (section 1.3.4) for the effect of body mass index on OSA. The effect of type 
2 diabetes (HbA1c) on OSA was discussed in chapter 3 (section 3.5.2). As for insulin treatment 
and DM duration, these signify severity of diabetes mellitus (please refer to section 4.5.5). 
Hypertension (section 1.3.3 and 4.5.3) and coronary artery disease (section 1.3.3) have been 
shown to be associated with OSA. Results were reported as odds ratio (OR) with 95% 
confidence interval (95% CI). A p value of <0.05 was considered statistically significant.  
 
Table 4-2: Factors adjusted and the appropriate sections discussing the rationales behind  
Factors Sections 
Age Introduction of Chapter 2 (section 2.1.3) 
Gender Chapter 2’s discussion (section 2.5.5) 
Ethnicity Chapter 2’s discussion (section 2.5.3 
Body mass index Chapter 1 (section 1.3.4) 
Type 2 diabetes  Chapter 3 (section 3.5.2) 
Insulin treatment  Chapter 4 (section 4.5.5) 
Hypertension  Chapter 1 (section 1.3.3) and chapter 4 (section 
4.5.3) 
Coronary artery disease Chapter 1 (section 1.3.3) 
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4.4 Results 
There were a total of 121 eligible DM patients, but two patients’ sleep respiratory data were 
not analysable, and 26 patients did not have the complete retinopathy screening data 
available; therefore, a total of 93 eligible patients were included in the study (Figure 4-1). No 
patient had a diagnosis of central sleep apnoea.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1: Flow diagram of referrals seen at the HEFT Specialist Weight Management Clinic, and 
those included in the study  
HEFT – Heart of England NHS Foundation Trust 
DM = Diabetes Mellitus 
 
 
Consecutive patients seen at 
HEFT Specialist Weight 
Management Clinic 
(January 2009 to December 2011) 
 
N = 121 DM individuals 
Included patients for analysis 
N = 93 DM individuals 
Excluded:  
 
26   = Incomplete retinopathy 
screening data 
 
2     = Respiratory data unable to 
analyse 
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4.4.1 Study characteristics 
The mean±SD age of the patients was 52±10 years and 59% of the patients were females. The 
majority of patients were of white European origin (69%) and 23% were of South Asian 
origin. The mean±SD for weight and BMI were 130.4±25.3Kg and 47.3±8.3Kg/m
2
, 
respectively.  Sixty-three per cent of patients suffered with hypertension. Median duration for 
DM was 6 years (IQR: 2, 10) with a median HbA1c of 62mmol/mol (IQR: 51, 77) or 7.8% 
(IQR: 6.8, 9.2). The majority of patients were on diabetic lowering medications (81.7%) and 
33% of the patients were on insulin treatment.  
 
Median AHI was 14 events/hr (IQR: 7, 36) with a median minimum O2 of 82% (IQR: 74, 85) 
and median %TST<90 of 3% (IQR: 1, 12) for the total sample. The mean O2 was 93% (IQR: 
92, 95).  Results for creatinine and estimated GFR were 72micromol/l (IQR: 63, 87) and 
86ml/min/1.73m
2
 (IQR: 71, 90).  The overall prevalence of DR and DMac were present in 
38.7% (95% CI: 29.2 to 49.1) and 17.2% (95% CI: 10.7 to 26.5), respectively.  
 
4.4.2 Diabetic retinopathy 
A total of 36 patients had a diagnosis of DR. Characteristics of patients with and without DR 
was shown in Table 4-3 below.  No significant differences were found for mean age (53±10 
vs. 51±11years, p=0.228), BMI (46.2±7.8
 
vs. 48.1±8.5Kg/m
2
, p=0.276), systolic BP (144±24 
vs. 143±17mmHg, p=0.819) and diastolic BP (83±15 vs. 84±8mmHg, p=0.734) between 
those with and without DR. There were also no significant differences in gender distribution 
between the groups (p=0.759).  
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Significant differences were present for all diabetic parameters. Glycosylated haemoglobin 
A1c for patients with DR were significant higher at 8.5% (IQR: 7.3, 9.9) when compared to 
those without the disease (7.5% IQR: 6.6, 8.7). The duration of DM was also significantly 
longer in the diseased group (10 [IQR: 5, 15] vs. 5 [IQR: 2, 9]years, p=0.003). Even though 
there was a slightly greater proportion of DM patients on medications for non-DR group 
(82.5% vs. 80.6%), majority of the patients were only on single DM medications (35.1%). In 
comparison, more than half of the DR patients received 2 or more DM medications (69.4%, 
p=0.012). Significant differences were also present for those treated with insulin between DR 
and non-DR groups (69.4% vs. 15.8%, p<0.001).  
 
There were no significant differences found for all respiratory parameters between individuals 
with and without DR (p>0.05). For the renal parameters, both creatinine and eGFR reached 
statistical significance when compared in both groups. Both creatinine and eGFR had a 
10µmol/l (p=0.013) and 10ml/min/1.73m
2
 (p=0.006) difference respectively between the 
groups.  
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Table 4-3: Comparison of patients with and without diabetic retinopathy 
 Diabetic 
retinopathy absence 
(n=57) 
Diabetic retinopathy 
presence 
(n=36) 
p value 
Age (years)  51 ± 11 53 ± 10 
 
0.228 
Gender 
Female 
Male 
 
33 (57.9%) 
24 (42.1%) 
 
22 (61.1%) 
14 (38.9%) 
 
0.759 
 
Ethnicity 
White Europeans 
South Asians 
Afro-Caribbean 
 
40 (70.2%) 
12 (21.1%) 
5 (8.8%) 
 
24 (66.7%) 
9 (25.0%) 
3 (8.3%) 
 
0.906 
 
Weight (Kg) 134 ± 26 124 ± 24  
BMI (Kg/m
2
) 48.1 ± 8.5 46.2 ± 7.8 0.276 
Systolic BP (mmHg) 143 ± 17 144 ± 24 0.819 
Diastolic BP (mmHg) 84 ± 8 83 ± 15 
 
0.734 
Diabetes parameters 
HbA1c (%) 
Insulin 
DM duration (years) 
DM medications 
None 
1 
2 
>3 
 
7.5 (6.6, 8.7) 
9 (15.8%) 
5 (2,9) 
 
10 (17.5%) 
20 (35.1%) 
16 (28.1%) 
11 (19.3%) 
 
8.5 (7.3, 9.9) 
25 (69.4%) 
10 (5, 15) 
 
7 (19.4%) 
4 (11.1%) 
21 (58.3%) 
4 (11.1%) 
 
 
0.020 
<0.001 
0.003 
 
0.012 
Respiratory parameters 
AHI (events/hr) 
Mean O2 sats (%) 
Min O2 sats (%) 
Time < 90% (%) 
 
14 (6, 30) 
93 (92, 95) 
82 (77, 84) 
2 (1,9) 
 
15 (7, 61) 
93 (91, 95) 
81 (71, 85) 
8 (1, 27) 
 
 
0.493 
0.200 
0.292 
0.117 
Renal parameters 
Creatinine (µmol/l)  
eGFR (ml/min/1.73m
2
) 
 
70 (60, 78) 
90 (78, 90) 
 
80 (66, 98) 
80 (59, 90) 
 
 
0.013 
0.006 
Data are presented as mean ± standard deviation, number (%), or median (interquartile range). 
BMI=body mass index; CAD=coronary artery disease; DM=diabetes mellitus; BP=blood pressure; 
eGFR=estimated glomerular filtration rate, HbA1c=glycosylated haemoglobin A1c. 
p values were calculated using either independent t-test, chi square or Mann Whitney U-test. 
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4.4.3 Diabetic maculopathy 
A comparison was made between individuals with presence and absence of diabetic 
maculopathy as summarised in Table 4-4. A total of 16 patients had DMac. There were no 
statistical differences in the recorded age (53±10 vs. 51±11years, p=0.671), BMI (45.8±8.4
 
vs. 
47.6±8.2Kg/m
2
, p=0.420), systolic BP (139±24 vs. 144±20mmHg, p=0.403) and diastolic BP 
(84±21 vs. 84±9mmHg, p=1.000) between those with and without DMac. There was a greater 
proportion of males in DMac compared to those with no DMac (56.3% vs. 37.7%, p=0.777), 
however, it did not reached statistical significance. There were also almost equal proportions 
of White Europeans (62.5% vs. 70.1%), South Asians (25.0% vs. 22.1%) and Afro-Caribbean 
(12.5% vs. 7.8%) in both groups (p=0.777).  
 
Similarly to DR, there were significant differences in diabetes parameters. DMac individuals 
were found to have higher HbA1c (9.2% [IQR: 8.1, 10.3] vs. 7.6% [IQR: 6.7, 8.9], p=0.003) 
and double the duration of DM (12 [IQR: 7, 19] vs. 6 [IQR: 2, 9]years, p=0.003) compared to 
disease free individuals. Although there was a four-fold difference in insulin treatment for 
DMac patients (87.5% vs. 22.1%, p<0.001), no significance were found for the number of 
DM medications (p=0.172). For respiratory parameters, the only significant finding was on 
minimum O2. There was almost a 10% reduction in minimum O2 in DMac vs non-DMac 
patients (71% [IQR: 63, 84] vs. 82% [IQR: 77, 85], p=0.021). Even though there was almost 2 
fold higher in the AHI (29 [IQR: 11, 69] vs. 14 [IQR: 6, 32] events/hr), this did not achieve 
statistical significance (p=0.074). Similarly, no significant difference were found for 
%TST<90 in spite of an almost 4 fold difference between the two groups (11% [IQR: 1, 27] 
vs. 3% [IQR: 1, 11], p=0.239).  Creatinine was found to be significantly different between the 
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groups (88 [IQR: 67, 108] vs. 71 [IQR: 60, 84]µmol/l, p=0.042) while eGFR was not (83 
[IQR: 60, 90] vs. 89 [IQR: 71, 90]ml/min/1.73m
2
, p=0.140).  
 
Table 4-4: Comparison of patients with and without diabetic maculopathy 
 Diabetic maculopathy 
absence 
(n=77) 
Diabetic maculopathy 
presence 
(n=16) 
P value 
Age (years)  51 ± 11 53 ± 10 
 
0.671 
Gender 
Female 
Male 
 
48 (62.3%) 
29 (37.7%) 
 
7 (43.8%) 
9 (56.3%) 
 
0.169 
 
Ethnicity 
White Europeans 
South Asians 
Afro-Caribbean 
 
54 (70.1%) 
17 (22.1%) 
6 (7.8%) 
 
10 (62.5%) 
4 (25.0%) 
2 (12.5%) 
 
0.777 
Weight (Kg) 131 ± 26 125 ± 21  
BMI (Kg/m
2
) 47.6 ± 8.2 45.8 ± 8.4 0.420 
Systolic BP (mmHg) 144 ± 20 139 ± 24 0.403 
Diastolic BP (mmHg) 84 ± 9 84 ± 21 
 
1.000 
Diabetes parameters 
HbA1c (%) 
Insulin 
DM duration (years) 
DM medications 
None 
1 
2 
>3 
 
7.6 (6.7, 8.9) 
17 (22.1%) 
6 (2, 9) 
 
14 (22.1%) 
22 (28.6%) 
27 (35.1%) 
14 (18.2%) 
 
9.2 (8.1, 10.3) 
14 (87.5) 
12 (7, 19) 
 
3 (18.8%) 
2 (11.1%) 
10 (62.5%) 
1 (6.3%) 
 
 
0.003 
<0.001 
0.003 
0.172 
Respiratory 
parameters 
AHI (events/hr) 
Mean O2 sats (%) 
Min O2 sats (%) 
Time < 90% (%) 
 
14 (6, 32) 
93 (92, 95) 
82 (77, 85) 
3 (1, 11) 
 
29 (11, 69) 
93 (90, 95) 
71 (63, 84) 
11 (1, 27) 
 
 
0.074 
0.906 
0.021 
0.239 
Renal parameters 
Creatinine (µmol/l)  
eGFR 
(ml/min/1.73m
2
) 
 
71 (60, 84) 
89 (71, 90) 
 
88 (67, 108) 
83 (60, 90) 
 
0.042 
0.140 
Data are presented as mean±standard deviation, number (%), or median (interquartile range). 
BMI=body mass index; CAD=coronary artery disease; DM=diabetes mellitus; BP=blood pressure; 
eGFR=estimated glomerular filtration rate, HbA1c=glycosylated haemoglobin A1c/ 
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4.4.4 Diabetic retinal diseases (DR and DMac) and obstructive sleep apnoea 
Table 4-5 shows the patient characteristics, according to the presence or absence of OSA, 
determined by AHI. Of the 93 patients, 46 (51%) had an AHI ≥15events/hour with a median 
(IQR) AHI of 37 (23, 74) events/hr (OSA+ group), compared to those with an AHI <15 
events/hr; median (IQR) for AHI was 7 (4 to 11) events/hr (OSA- group). Both OSA+ and 
OSA- groups were well matched for ethnicity (p=0.716), weight (135±27 vs. 127±23Kg, 
p=0.142), BMI (47.6±8.5 vs. 47.1±8.1Kg/m
2
, p=0.776), diastolic BP (85±12 vs. 
83±10mmHg, p=0.446) and coronary artery disease (15% vs. 11%, p=0.510). Although not 
statistically significant, systolic BP (146±23 vs. 139±15mmHg, p=0.177) and hypertension 
(72% vs. 55%, p=0.100) higher in OSA+ group. The OSA+ group were slightly older than 
those without OSA (54±10 vs. 49±10years, p=0.01) with a greater proportion of males (66% 
vs. 25%, p=0.002). 
 
No significant differences were found for diabetes parameters, which includes diabetes 
duration (6 [IQR: 2, 10] vs. 6 [IQR: 3, 11]years, p=0.423), HbA1c (8.1% [IQR: 7.1, 9.2] vs. 
7.7% [IQR: 6.7, 9.3], p=0.267], insulin requirement (41% vs. 26%, p=0.123) and the number 
of DM medications required (p=0.795). As expected, there were significant differences in all 
the respiratory parameters. The AHI was 37 (IQR 23, 74) events/hr for OSA+ group 
compared to 7 (IQR: 4, 11) events/hr for OSA- group. Mean and minimum O2 were 93% 
(IQR: 91, 94) and 76% (IQR: 71, 82), respectively for OSA+ group and 94% (IQR: 92, 95, 
p=0.001) and 84% (IQR: 82 to 88, p<0.001) for OSA- group. Significant higher %TST<90 
were found for OSA+ group (11% [IQR: 2, 25] vs. 1% (IQR: 0, 3], p<0.001). There was 
significant higher renal creatinine level in OSA+ group (78 [IQR: 66, 93]µmol/l) when 
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compared to disease free group (67 [IQR: 57, 79]µmol/l, p=0.002). Non statistical differences 
were reported for eGFR (83 [IQR: 61 to 90]
 
vs. 90 [IQR: 77 to 90]ml/min/1.73m
2
, p=0.068). 
 
Table 4-5: Sample characteristics of 93 patients according to presence/absence of obstructive sleep 
apnoea  
 OSA- 
(n=47) 
OSA+ 
(n=46) 
p value 
Age (years)  49 ± 10 54 ± 10 0.010 
Gender, n (%)   0.002 
   Female, n (%) 35 (75) 20 (43.5)  
Ethnicity, n (%)   0.716 
   White European 34 (72) 30 (65)  
   South Asian 9 (19) 12 (26)  
   Afro-Caribbean 4 (9) 4 (9)  
Weight (kg) 127 ± 23 135 ± 27 0.142 
BMI (kg/m
2
) 47.1 ± 8.1 47.6 ± 8.5 0.776 
Systolic BP (mmHg) 139 ± 15 146 ± 23 0.177 
Diastolic BP (mmHg) 83 ± 10 85 ± 12 0.446 
Co-morbidities, n (%)    
    Hypertension 26 (55) 33 (72) 0.100 
   CAD 5 (11) 7 (15) 0.510 
Diabetes parameters    
   DM duration (years) 6 (3-11) 6 (2-10) 0.423 
DM medications, n (%)   0.795 
   None 9 (19) 8 (17)  
   One 10 (21) 14 (30)  
   Two 20 (43) 17 (37)  
   Three or more 8 (17) 7 (15)  
HbA1c (%) 7.7 (6.7-9.3) 8.1 (7.1-9.2) 0.267 
Insulin treatment 12 (26) 19 (41) 0.123 
Respiratory parameters    
   AHI (/hour) 7 (4-11) 37 (23-74) <0.001 
   Mean O2 saturation (%) 94 (92-95) 93 (91-94) 0.001 
   Minimum O2 saturation (%) 84 (82-88) 76 (71-82) <0.001 
   % Time spent <90% saturation 1 (0-3) 11 (2-25) <0.001 
Renal parameters    
   Creatinine (µmol/l) 67 (57-79) 78 (66-93) 0.002 
  eGFR (ml/min/1.73m
2
) 90 (77-90) 83 (61-90) 0.068 
Retinopathy outcome, n (%)    
   Retinopathy present 18 (38) 18 (39) 0.934 
   Maculopathy present 6 (13) 10 (22) 0.252 
Data are presented as mean±standard deviation, number (%), or median (interquartile range). 
OSA=obstructive sleep apnoea; BMI=body mass index; CAD=coronary artery disease; DM=diabetes 
mellitus; BP=blood pressure; eGFR=estimated glomerular filtration rate, HbA1c=glycosylated 
haemoglobin A1c. 
p values were calculated using either independent t-test, chi square or Mann Whitney U-test. 
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Table 4-6 shows the retinal screening results. Most of the patients did not have DR for those 
with or without OSA (60.9% vs. 61.7%, p=0.765). Background retinopathy was present in 13 
OSA patients and 15 non-OSA patients. Three patients with OSA had pre-proliferative 
retinopathy compared to one in OSA- group. There were 2 patients each in both groups for 
proliferative DR. No significant differences were found between the presence and absence of 
OSA for DR (39% vs. 38%, p=0.765). However more OSA+ patients had DMac compared to 
OSA- patients (22% vs. 13%), but this did not reach statistical significance (p=0.252). A total 
of 5 patients had had photocoagulation therapy.  
 
Table 4-6: Diabetic retinopathy in 93 patients according to presence/absence of obstructive sleep 
apnoea 
 OSA- (n=47) 
n (%) 
OSA+ (n=46) 
n (%) 
p value 
Either eye    
   No retinopathy 29 (61.7) 28 (60.9) 0.765 
   Background  retinopathy 15 (31.9) 13 (28.3)  
   Pre-proliferative  retinopathy 1 (2.1) 3 (6.5)  
   Proliferative retinopathy 2 (4.3) 2 (4.3)  
   Maculopathy 6 (12.8) 10 (21.7) 0.252 
   Photocoagulation 3 (6.4) 2 (4.3) 0.664 
    
Right eye    
   No retinopathy 32 (68.1) 30 (65.2) 0.943 
   Background  retinopathy 12 (25.5) 12 (26.1)  
   Pre-proliferative retinopathy 2 (4.3) 2 (4.3)  
   Proliferative retinopathy 1 (2.1) 2 (4.3)  
   Maculopathy 5 (10.6) 5 (10.9) 0.971 
   Photocoagulation 3 (6.4) 2 (4.3) 0.664 
    
Left eye    
   No retinopathy 33 (70.2) 31 (67.4) 0.777 
   Background retinopathy 11 (23.4) 10 (21.7)  
   Pre-proliferative retinopathy 1 (2.1) 3 (6.5)  
   Proliferative retinopathy 2 (4.3) 2 (4.3)  
   Maculopathy 5 (10.6) 10 (21.7) 0.146 
   Photocoagulation 3 (6.4) 2 (4.3) 0.664 
 
OSA=obstructive sleep apnoea. 
p values derived from chi square test. 
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Univariate logistic regression (Table 4-7) identified factors significantly associated with 
diabetic retinal disease, which was minimum O2 with both DR and DMac. The results of the 
multivariate logistic regression analyses are shown in Table 4-6. We observed, after 
adjustment, no relationship between DR and AHI, mean O2, minimum O2, and %TST<90. 
After adjustment, the presence of DMac was not associated with AHI, mean O2, and 
%TST<90. Minimum O2 was, however, after adjustment, an independent and significant 
predictor for the presence of DMac (OR 0.79 [95% CI: 0.65 to 0.95], p<0.05). This represents 
that each 1% increase in minimum oxygen saturation was associated with 21% reduction in 
the risk of DMac.  
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Table 4-7: Logistic regression analyses assessing the presence of diabetic retinopathy (DR) and 
maculopathy (DMac) with four respiratory parameters 
Predictors of 
thepresence of 
retinopathy (DR) 
 
 
Unadjusted 
Models 
Model 1 
 
Model 2 
AHI 1.01 (0.99-1.02) 1.01 (0.99-1.02) 1.00 (0.98-1.02) 
Mean oxygen
 
saturation 0.89 (0.77-1.03) 0.90 (0.77-1.05) 0.83 (0.67-1.02) 
Minimum oxygen
 
saturation 
0.95* (0.90-1.00) 0.95 (0.89-1.00) 0.93 (0.86-1.01) 
% Time spent <90% 
oxygen
 
saturation 
1.03 (1.00-1.05) 1.03 (1.00-1.06) 1.03 (1.00-1.06) 
 
Age 
Male 
BMI 
Non WE 
DM Duration 
Insulin  
HbA1c 
Hypertension 
CAD 
 
1.03 (0.98-1.07) 
0.88 (0.37-2.05) 
0.97 (0.72-1.02) 
1.08 (0.56-2.06) 
1.12 (1.04-1.21) 
8.21 (3.08-21.83) 
1.32 (1.01-1.73) 
1.54 (0.63-3.72) 
1.70 (0.50-5.75) 
 
1.02 (0.98-1.07)* 
0.54 (0.20-1.45)* 
0.95 (0.90-1.01)* 
1.00 (0.60-1.98)* 
Not applicable 
Not applicable 
Not applicable 
Not applicable 
Not applicable 
 
 
1.01 (0.95-1.06)* 
0.43 (0.12-1.54)* 
0.94 (0.87-1.01)* 
1.08 (0.45-2.56)* 
1.04 (0.94-1.15)* 
6.55 (1.63-26.26)* 
1.36 (0.98-1.90)* 
0.35 (0.09-1.32)* 
3.01 (0.62-14.54)* 
Predictors of the 
presence of 
maculopathy (DMac) 
 
 
Unadjusted 
Models 
Model 1 
 
Model 2 
AHI 1.01 (1.00-1.03) 1.01 (0.99-1.03) 1.01 (0.98-1.04) 
Mean oxygen
 
saturation 0.93 (0.79-1.08) 0.92 (0.77-1.09) 0.80 (0.59-1.07) 
Minimum oxygen
 
saturation 
0.91** (0.85-0.97) 0.90** (0.84-0.97) 0.79* (0.65-0.95) 
% Time spent <90% 
oxygen
 
saturation 
 
Age 
Male 
BMI 
Non WE 
DM Duration 
Insulin 
HbA1c 
Hypertension 
CAD 
 
1.02 (0.99-1.04) 
 
 
1.01 (0.96-1.07) 
2.13 (0.72-6.33) 
0.97 (0.91-1.04) 
1.32 (0.60-2.90) 
1.16 (1.06-1.26) 
24.29 (5.02-117.57) 
1.49 (1.07-2.07) 
4.98 (1.06-23.44) 
0.96 (0.19-4.85) 
 
1.02 (0.99-1.04) 
 
 
1.00 (0.94-1.06)* 
1.61 (0.49-5.33)* 
0.98 (0.91-1.06)* 
1.18 (0.50-2.77)* 
Not applicable 
Not applicable 
Not applicable 
Not applicable 
Not applicable 
1.03 (0.99-1.08) 
 
 
0.95 (0.87-1.04)* 
1.49 (0.27-8.25)* 
0.95 (0.36-1.05)* 
0.83 (0.23-2.97)* 
1.09 (0.97-1.22)* 
10.02 (1.49-67.59)* 
1.41 (0.90-2.20)* 
3.94 (0.28-54.56)* 
0.79 (0.08-8.11)* 
Unadjusted: univariate models. 
Model 1: adjusted for age, gender, body mass index, ethnicity. 
Model 2: further adjusted for diabetes mellitus duration, insulin treatment, HbA1c, hypertension, and 
coronary artery disease. * adjusted for AHI only to avoid multi-collinearity 
AHI = apnoea-hypopnoea index, HbA1c=glycosylated haemoglobin A1c, BMI = body mass index, 
Non WE = non White Europeans, DM = Diabetes mellitus, CAD = coronary artery disease. 
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4.4.5 Factors associated with worsening of diabetic retinopathy and maculopathy 
Apart from respiratory parameters, logistic regression analysis was also performed for other 
factors, namely gender, age, BMI, duration of DM, HbA1c level, hypertension and insulin 
treatment. No associations were found for age, gender and BMI with DR or DMac. Univariate 
analysis showed that DM duration was associated with greater progression of both DR (OR 
1.123, 95% CI: 1.042 to 1.211) and DMac (OR 1.156, 95% CI: 1.060 to 1.260). Similarly, 
DM patients who did not require treatment for insulin were protective of DR (OR 0.122, 95% 
CI: 0.046 to 0.324) and DMac (OR 0.041, 95% CI: 0.009 to 0.199). Greater level of HbA1c 
was associated with presence of DMac (OR 1.481, 95% CI: 1.063 to 2.064) while absence of 
hypertension was protective of DMac (OR 0.201, 95% CI: 0.043 to 0.946).  
 
In Model 1, adjustment for gender, age and BMI were performed. The protective association 
of the absence of insulin treatment with DR (OR 0.111, 95% CI: 0.038 to 0.323) and DMac 
(OR 0.035, 95% CI: 0.007 to 0.188) persisted. Longer duration of DM (OR 1.110, 95% CI: 
1.028 to 1.199) and higher HbA1c level (OR 1.333, 95% CI: 1.003 to 1.771) were associated 
with worsening of DR. The association between hypertension and DMac was no longer 
significant in Model 2. However, the associations between all variables with DR and DMac 
disappeared apart from treatment with insulin after adjustment in Model 2. Only absence of 
insulin treatment was found to be protective of DR (OR 0.163, 95% CI: 0.044 to 0.609) and 
DMac (OR 0.109, 95% CI: 0.018 to 0.668) as shown in Table 4-8. 
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Table 4-8: Logistic regression analyses assessing the presence of diabetic retinopathy (DR) and 
maculopathy (DMac) and other factors 
 
Predictors of the 
presence of 
retinopathy (DR) 
 
 
Unadjusted 
Models 
Model 1 
 
Model 2 
Female 1.143 (0.488–2.679)  1.854(0.577-5.959) 
Age 1.026(0.984-1.069)  1.011(0.960-1.066) 
BMI 0.971(0.921-1.023)  0.952(0.890-1.018) 
DM duration 1.123(1.042-1.211)** 1.110(1.028-1.199)** 1.039(0.942-1.147) 
HbA1c 1.291(0.982-1.699) 1.333 (1.003-1.771)* 1.210(0.863-1.697) 
No Insulin 0.122(0.046-0.324)** 0.111(0.038-0.323)** 0.163(0.044-0.609)** 
No hypertension 
 
0.650 (0.268-1.576) 0.719(0.284-1.824) 2.150(0.624-7.405) 
Predictors of the  
presence of 
maculopathy (DMac) 
 
 
Unadjusted 
Models 
Model 1 
 
Model 2 
Female 0.470(0.158-1.398)  0.474(0.107-2.103) 
Age 1.011(0.960-1.066)  0.965(0.892-1.044) 
BMI 0.972(0.907-1.041)  0.997(0.892-1.070) 
DM duration 1.156(1.060-1.260)** 0.427(0.119-1.534) 1.091 (0.974-1.222) 
HbA1c 1.481(1.063-2.064)* 1.153 (1.061-2.157)* 1.212(0.760-1.932) 
No Insulin 0.041 (0.009-0.199)** 0.035 (0.007-0.188)** 0.109(0.018-0.668)* 
No hypertension 
 
0.201 (0.043-0.946)* 0.211 (0.043-1.029) 0.255 (0.022-2.953) 
BMI = body mass index, DM = diabetes mellitus, HbA1c = glycosylated haemoglobin A1c 
Unadjusted: univariate models 
Model 1: adjusted for age, gender, BMI 
Model 2: further adjusted for hypertension, diabetes mellitus duration, insulin treatment and HbA1c 
* p<0.05; ** p<0.01. 
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4.5 Discussion 
4.5.1 Prevalence of diabetic retinal disease 
Diabetic retinal disease is a well-recognised micro-vascular complication of DM.
273
 There are 
several epidemiological studies on the prevalence of DR for both type 1 and type 2 DM.
274-277
 
However, the scope of the problem has not been studied in the extreme obese population, a 
high risk group of individuals. Our study showed that the overall prevalence of DR amongst 
extreme obese DM patients was 38.7% (95% CI: 29.2 to 19.1%) and for diabetic maculopathy 
was 17.2% (95% CI: 10.7 to 26.5%).  
 
A study on the sample of National Health and Nutrition Examination Survey (NHANES) 
from 2005 to 2008 found that there were 1006 individuals aged 40 and above with DM 
including 795 self-reported DM patients and 211 undiagnosed patients (HbA1c ≥6.5%).
276
 The 
reported estimated crude prevalence for DR was 28.5% (95% CI: 24.9 to 32.5%) and the age 
standardised prevalence was 22.1% (95% CI: 18.4 to 26.35).  DR prevalence was higher at 
32.8% (95% CI: 28.6 to 37.2%) when the 211 undiagnosed DM individuals were excluded. In 
spite of this, the reported prevalence is still lower compared to our study. The estimated crude 
prevalence for diabetic macular oedema was 2.7% (95% CI: 1.8 – 4.0%). The NHANES study 
had a lower mean HbA1c 7.9% (95% CI: 7.6 to 8.1%) for the DR group compared to our study 
of 8.5% and this may partially explain the differences in prevalence. However, the NHANES 
patients are 9 years older in age compared to those in our study - the mean ages for the 
NHANES study are 62 (95% CI: 60 to 63) years for DR patients and 60 (95% CI: 59 to 61) 
years for non-DR individuals.
276
 The duration of DM was also 5 years longer for the 
NHANES DR individuals at 15.0 (95% CI: 13.4 to 16.5) years compared to our DR patients. 
One of the most likely factors contributing to the greater prevalence of DR in our study is the 
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level of adiposity. All our patients were very severely obese with mean BMI of 
47.3±8.3Kg/m
2
 while in the NHANES examined the general population as a whole and only 
57.1% (95% CI: 48.5 to 65.2) with DR have a BMI≥30 Kg/m2.276 
 
4.5.1.1 Different era of diabetes care 
Another report on a pool of 8 population studies of those aged 40 and above with both type 1 
and type 2 DM. The study had 4440 individuals.  The 8 studies included in the report were the 
Barbados Eye study,
278
 Beaver Dam Eye Study,
279
 Blue Mountains Eye Study,
280
 Melbourne 
Visual Impairment Project,
281
 Proyecto Vision Evaluation Research,
282
 San Antonio Heart 
Study,
283
 San Luis Valley Diabetes Study
284
 and Wisconsin Epidemiologic Study of Diabetic 
Retinopathy (WESDR).
285
 The estimated overall crude prevalence for DR was 40.3% (95% 
CI: 38.8 to 41.7). The higher crude prevalence may be partially influenced by the WESDR 
prevalence rate (36.6%) as the WESDR study was conducted between 1980 and 1982.
285
  
 
When the WESDR study was excluded from the analysis, the crude prevalence reported was 
35.8%,
277
 which is comparable to our study’s figure. All the data from the pool of 8 studies 
were collected prior to year 2001 while our data was collected after 2009.
277
 It may be that 
this represents the difference in the standard of care for DM in the 2 eras which consequently 
have an impact on the reported DR prevalence. Since the publication of the landmark studies 
such as Diabetes Control and Complications Trial (DCCT) in 1993 for type 1 DM
286
 and the 
UK Prospective Diabetes Study (UKPDS) in 2001 for type 2 DM,
287
 there has been 
significant focus on the importance of tight glycaemic and BP control to reduce the risk of the 
development and progression of DM micro-vascular complications. These trials have led to 
significant changes in clinical management and care for DM patients and these changes most 
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likely have contributed to the lower DR prevalence in our study despite the high level of 
adiposity.   
 
A recent report by Yau and colleagues examined the global DR prevalence
274
 from a pool of 
35 studies including 22,896 individuals of both type 1 and type 2 DM patients. The mean age 
was 58.1 years with 52% female and median DM duration and HbA1c of 7.9 (IQR 3-16) years 
and 8.0% (IQR 6.7-9.9), respectively. The overall age standardised prevalence was 34.6% 
(95% CI: 34.5 to 34.8) for DR and 6.81% (95% CI: 6.74 to 6.89) for macular oedema. The 
global DR rates were even lower when studies performed before the year 2000 were excluded 
in the subgroup analysis. The reported global age standardised prevalence rate for post year 
2000 for DR was 24.79% (95% CI: 24.57 to 25.00) and 5.46% (95% CI: 5.35 to 5.56) for 
DMac. These figures are lower compared to our study’s result especially for DMac, which is 
at least 3 fold lower.  
 
In addition, despite having a higher prevalence, our patients were also 6 years younger in age 
and have shorter DM duration compared to the study by Yau et al. (median 7.9 with IQR 3 to 
16years).
274
 The study from Yau and colleagues did not report on the number of glucose-
lowering medications or insulin treatment for their participants. Although DM duration may 
be an indicator of the severity of DM, glucose-lowering treatment especially insulin therapy
288
 
may be a better predictor. More than half of our study participants who had DR and DMac 
were on insulin treatment. Moreover, the majority of DR and DMac patients required at least 
2 or more glucose-lowering medications indicating high level of insulin resistance. For our 
DMac patients, HbA1c level was also significantly higher compared to Yau et al. (median 
HbA1c 8.0% [IQR: 6.7 to 9.9]).
274
 All these factors demonstrated that our patients may have 
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more severe DM and as a consequent of this, a greater prevalence of diabetic retinal disease. 
Both the greater severity of DM as well as the greater prevalence of DR and DMac may be a 
result from a combination of high level of adiposity and nocturnal hypoxia. To our 
knowledge, this is the first DR prevalence study on extreme obese individuals suitable for 
bariatric surgery. 
 
4.5.2 Relationship between obstructive sleep apnoea and diabetic retinopathy 
4.5.2.1 OSA and retinopathy in general population 
There has been much interest in the role of OSA in the development of micro-vascular 
complications. The first study to examine the effect is the Sleep Heart Health Study 
(SHHS).
289
 The SHHS examined a total of 2927 participants. Of those 2927 participants, 1867 
participants were from the Atherosclerosis Risk in Communities (ARIC)
290
 and 1060 
participants were from the Cardiovascular Health Study (CHS).
291
 All the participants 
received retinal photography as part of the primary study (within the study protocol of ARIC 
and CHS) while all patients had home sleep monitoring performed as part of SHHS.
289
 The 
majority of the participants were white Caucasians (93%). The median AHI was 4.7 events/hr 
(IQR: 1.5, 11.6) and about 70% of the participants had AHI ≤10 events/hr.  
 
The investigators also reported the median %TST<90 as 0.7% (IQR: 0.1, 6.6%). The presence 
of retinopathy was found in 6.6% of the participants. Unsurprisingly, the proportion of 
retinopathy was higher in DM individuals (19.4%) and hypertensive individuals (9.7%).
289
 
Both AHI and %TST<90 were categorised into four quartiles. Logistic regression was 
performed and no associations were found between retinopathy and AHI as well as %TST<90 
quartiles after adjustment for age, gender, BMI, hypertension, systolic BP, smoking status, 
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DM and primary study.
289
 Compared to the lowest quartile, the fourth quartile for AHI (OR 
1.17, 95% CI: 0.73 to 1.88) and the 4
th
 quartile for %TST<90 (OR 1.21, 95% CI: 0.75 to 1.94) 
did not show any significant increase in risk for any retinopathy. However, there are several 
limiting factors from the SHHS. Although the sample size was large, the numbers of diseased 
individuals for retinopathy (6.6%) were limited. There was a difference in age as ARIC age 
range between 51 to 71 years while CHS age range between 69 to 97 years old, this suggests 
heterogeneity within sample.
289
 Due to these limitations for the SHHS study, even though no 
associations were found, more research is needed especially in the high risk individuals.  
 
4.5.2.2 OSA and diabetic retinopathy 
Limited studies are available in the literature to describe the relationship between OSA and 
DR.
270,271,292,293
 Our study consists of very severely obese DM individuals and our result did 
not show any significant difference in the prevalence of diabetic retinal disease between those 
who had moderate-to-severe OSA compared to those who did not. We also examined the 
relationship between diabetic retinal disease and various respiratory parameters. After 
correcting for multiple confounders, there was no association found between mean oxygen 
saturation, and %TST<90 with DR as well as DMac. Our negative results were consistent 
with two Japanese studies, from the same investigators, which did not find any correlation 
with the above respiratory parameters.
270,271
 The Japanese researchers examined DM 
inpatients who were admitted for retinal surgery such as vitreous surgery for macular oedema, 
cataract surgery, neovascular glaucoma, vitreous haemorrhage or retinal detachment 
surgery.
270,271
 The investigators did not perform a full PSG, instead, they used pulse 
oximetry.
270,271
 The first study had 116 inpatients in which 48 had a diagnosis of non-
proliferative DR and 116 had proliferative-DR (PDR).
270
 No significant association was found 
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between mean oxygen saturation and PDR after adjustment for age, DM duration, BMI, 
HbA1c, hypertension, eGFR and other respiratory parameters.
270
 For the second study, there 
were 219 inpatients of which 68 had non-PDR and 151 had PDR.
271
 Logistic regression 
analysis was performed and again, no association was demonstrated between %TST<90 and 
PDR after adjustment for HbA1c, age, minimum oxygen saturation, 4% oxygen desaturation 
index (ODI) and HbA1c.
271
  
 
Apart from mean oxygen saturation and %TST<90, our study also showed that OSA, when 
measured using AHI, has no association with retinal complications after adjustment for 
confounders. One study investigated the effect of AHI and DR in 98 veterans who were 
predominantly male.
292
 The study used portable home sleep monitors and sleep was 
monitored for 3 nights.
292
 All 98 participants had OSA and good DM control with HbA1c 
levels of 6.5% and below.
292
 The veteran study found a significant difference in the mean AHI 
between those with DR (AHI 44.2 events/hr) and those without DR (AHI 27.2 events/hr).
292
 
The discrepancy in the results between our and the veteran study may be partially explained 
by the differences in the characteristics of both patient groups. The mean age for the veteran 
participants was 61.1±8.8 years,
292
 which was almost 10 years older than our cohort of 
individuals. Almost all the veteran participants suffered from hypertension (95%)
292
 compared 
to less than three quarters in our patients. As expected, there was a great difference in the 
level of adiposity as the mean BMI was 33.7±5.0Kg/m
2
 for the veteran study.
292
 However, the 
main limitation factor was the absence of regression analysis performed to take in to account 
potential confounders.
292
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In a short report by Rudrappa and colleagues described the results of 31 DM individuals who 
received in-hospital PSG.
293
 OSA was diagnosed based on AHI ≥5 events/hr and they found 
that 17 patients had OSA.
293
 Regression analysis performed showed a significant association 
between OSA and total retinopathy score (p=0.008) after adjustment for confounders 
including serum biomarkers.
293
 However, no dose response association was demonstrated 
between severity of OSA and retinopathy scoring.
293
 The relatively small sample size is a 
major limitation for this study. Also, the 17 OSA positive patients probably had more severe 
DM compared to our study as the mean HbA1c was 10.0%,
293
 which is 2% higher than our 
study and mean DM duration of 12 years,
293
 which is 2 fold higher than our OSA patients. 
Furthermore, all recruited patients were Caucasians therefore limiting the generalizability of 
this study.
293
 Other studies have examined ODI instead of AHI.
269,270
  
 
Although AHI is the recommended measurement for OSA, it measured both hypopnoea 
episodes which are associated with 4% oxygen desaturation and apnoea episodes
75
 which may 
not include a dip in oxygen saturation. Therefore, one could argue ODI may be a better 
measure of hypoxia episodes instead of AHI. The Japanese group who compared 116 PDR 
and 48 non-PDR inpatients as described above reported a correlation between ODI and PDR 
(r=0.43, p=0.03).
270
 They also performed regression analysis and found that ODI (β=0.20, t 
value=2.15, p=0.03) was one of the risk factor for PDR after adjustment for age, DM 
duration, BMI, HbA1c, eGFR, hypertension and other respiratory parameters.
270
 Our study 
was not designed to investigate the association between PDR and OSA as we only had 4 cases 
of PDR in our study while the Japanese study consists of DM individuals with either non-
PDR or PDR.
270
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Another study from Oxford performed pulse oximetry on 140 high risk OSA individuals 
assessed using the Berlin questionnaire and 100 low risk OSA individuals between 2004 and 
2005.
269
 All 240 participants were men, of whom 118 had had a retinal screen. Twenty-four 
per-cent (n=28) had a diagnosis of OSA based on ODI.
269
 The proportion of DR in OSA 
participants was 54%
269
 which was significantly higher compared to our OSA+ individuals 
(39%). Multiple regression analysis confirms the association between ODI and retinopathy.
269
 
This study is not comparable to our study on several factors. First, it used ODI rather than 
AHI as a measure of OSA. The Oxford researchers defined ODI episode as having at least 4% 
reduction in oxygen saturation and OSA was diagnosed as having ODI of 10 or more 
events/hr.
269
  
 
Second, the Oxford study recruited and performed pulse oximetry on their participants at a 
much earlier interval (between 2004 and 2005) while digital retinal photographs were most 
likely taken at a later interval. This is because the Oxfordshire Diabetic Eye Screening Service 
(ODESS) was launched only in January 2006
148
 so there was a time lag between the 2 
investigations which may lead to greater progression of DR. Third and finally, the Oxford 
study’s participants were much older when pulse oximetry was first measured (at least 12 
years older compared to our study’s OSA+ group) with a much longer duration of DM 
(10.4±8.2years) and they also have greater proportion of individuals with DR in their OSA 
individuals (54%).
269
 In addition, all the participants were male in the Oxford study
269
 and it 
is well known that males have a greater risk of developing OSA compared to females
195
 as 
discussed in Chapter 2.  
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Since our study was part of a service evaluation, and the current clinical recommendation
75
 is 
the measurement of AHI, we do not have results for ODI. However, we attempted to 
compensate for the apnoea episodes by using AHI ≥15 events/hr for our OSA+ group. 
Although our study did not find any significant association between AHI and DR, we showed 
that the degree of hypoxaemia, determined by minimum oxygen saturation during sleep, was 
associated with the development of DMac. This association, however, was not seen with DR. 
As the OSA group was more hypoxaemic than the group without moderate-to-severe OSA, 
this may explain why the OSA+ had a higher prevalence of DMac. The relationship between 
OSA and diabetic retinal disease is important given the risk of blindness.
273
 The Oxford study 
of 118 DM male patients reported several findings.
269
 They reported that OSA individuals 
(mean ODI 20.9±16.6 events/hr vs. 2.8±2.1 events/hr in their control group), was associated 
with DMac (r
2
=0.3, p<0.00001).
269
 In another study by the Japanese researchers of 219 DM 
patients, it was demonstrated that, after adjusting for potential confounders, the lowest oxygen 
saturation and not ODI or %TST<90 significantly correlated with the development of PDR 
(OR: 0.93, 95% CI: 0.88 to 0.99; p=0.02).
271
 It is of note that the diagnosis of OSA for both 
the studies was made on the basis of oxygenation (ODI) and not the recommended breathing 
parameters (AHI) and the severity of obesity as measured by BMI was significantly lower 
than our study.  
 
The findings of our study show that minimum oxygen saturation may be associated with 
DMac supports the findings by Shiba et al. The Japanese researchers found that the risk for 
DR was 7% lower as the minimum oxygen saturation level increased.
271
 Although our study 
measured AHI rather than ODI, the combination of results from our’s and Shiba’s270 studies 
on oxygenation and diabetic eye micro-vascular disease, may indicate that intermittent 
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hypoxaemia and lowest oxygen saturation (and not apnoea/hypopnoea frequency) is 
independently associated with diabetic retinal disease especially DMac. OSA may impact on 
DR indirectly through its effect on glycaemia and other systemic diseases such as 
hypertension or directly from hypoxaemia.  
 
4.5.2.3 Pathophysiology for OSA and diabetic retinopathy 
As discussed in Chapter 3, OSA is associated with insulin resistance and glucose intolerance. 
Excess glucose in turn will cause overproduction of ROS, especially superoxide which has 
been shown to activate the polyol, AGE, protein kinase C and hexosamine pathways.
294
 A 
cascade of oxidative stress and inflammatory processes occur from these pathways causing 
endothelial dysfunction.  
 
The visual process is very energy demanding as evidenced by the greater consumption of 
oxygen by the retina compared to the brain
295
 therefore the retina is very oxygen-sensitive. 
Both animal
296
 and human
297
 studies have shown that chronic intermittent hypoxia is linked to 
a reduction in endothelium relaxation and greater vasoconstriction. This impairs oxygenation 
to retina causing activation of inflammatory and oxidative stress markers. ROS were found to 
be elevated in pathological conditions of both OSA and DR.
298-303
 Studies have found that 
there was a negative correlation between nitrite oxide (NO) levels
298-300
 and OSA as well as a 
positive correlation with ROS such as superoxide
299,300
 and urinary 8-hydroxy-2-
deoxyguanosine (8-OHdG)
301
 with OSA. Similarly in DR, there was a greater level of 8-
OHdG in PDR patients compared to individuals with non-PDR or no DR.
302
 These oxidative 
stress markers from OSA were likely to cause dysfunction in the NO activity and 
subsequently endothelial dysfunction.
303
 The higher levels of ROS were found to induce 
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structural and functional changes in the retinal microvasculature such as thickening of 
basement membrane in the retina leading to alterations in retinal blood flow.
304
 In addition, 
inflammatory markers such as vascular endothelial growth factor (VEGF) were also found to 
be elevated in hypoxic OSA patients
267
 and VEGF has been shown to be associated with the 
neovascularisation process in ischaemic retinal disease.
268
 Further longitudinal studies are 
required to examine the causal effect of hypoxia from OSA on diabetic retinal disease.  
 
Apart from intermittent hypoxaemia, the level of hypoxia is also important. A Chinese study 
examined rats exposed to intermittent hypoxaemia (IH) at varying degrees of oxygenation.
247
 
Group 1 had blood oxygenation of 60%, group 2 was 71% and group 3 was 79%. The 
researchers documented greater levels of glucose, insulin and inflammatory makers in group 1 
compared to groups 2 and 3. The levels of nuclear factor kappa B (NF-кB), a major activator 
of inflammatory markers, were highest in group 1, followed by group 2 and finally group 3 
(p<0.05). Furthermore, hypoxia-inducible factor 1-alpha (HIF-1α), tumour necrosis factor 
alpha (TNFα) and interleukin-6 (IL-6) levels were also all significantly higher in group 1 
compared to groups 2 and 3 (p<0.05). Another study compared IH rats treated with and 
without oxygen also demonstrated that NF-кB level was significantly greater in IH rats with 
hypoxia compared to IH treated with oxygen.
248
 A recent human study compared skin 
biopsies of 12 OSA individuals with oxygen saturation of <75% with 12 OSA of ≥75%, 
showed a greater level of HIF-1α and VEGF gene expression levels suggesting greater 
inflammation in those with lower oxygenation.
249
  
 
On the other hand, it is also plausible that diabetic microvascular complication causes the 
development of OSA. In the majority of the DM patients, microvascular complications occur 
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simultaneously
305
 as DR individuals may also have diabetic neuropathy.
177
 Diabetic 
neuropathy may affect the pharyngeal muscles increasing upper airway collapsibility. In a 
case of one family with Charcot-Marie-Tooth (CMT) disease, 11 out of the 14 family 
members were diagnosed to have CMT. In those with CMT, all had sleep apnoea (9 had OSA, 
2 had central sleep apnoea). The researchers also found that CMT correlated highly with OSA 
(r=0.69, p=0.029).
306
 Likewise, DM patients with autonomic neuropathy (AN) were found to 
have a greater risk of OSA compared to those without AN in several studies.
307,308
 Therefore, 
the relationship between OSA and DR is likely to be bi-directional.
309
 
 
4.5.3 Hypertension and diabetic retinopathy 
OSA could also mediate the progression of DR through other systemic diseases such as 
hypertension.
158
 Hypertension is strongly associated with OSA as shown in results of large 
epidemiology studies.
81,158
 The Wisconsin Sleep Cohort Study examined 709 participants 
over 4 years and found a step wise increase in odds for hypertension for those with mild, 
moderate and severe OSA.
158
 The SHHS examined a total of 6132 participants reported odds 
of 1.37 (95% CI: 1.03 to 1.83) for hypertension in those with AHI ≥30 events/hr compared to 
<1.5 events/hr.
81
  
 
Although not statistically significant, systolic BP for our OSA+ patients was higher compared 
to OSA-. In the univariate analysis, the individuals with no previous history of hypertension 
had lower levels of DMac. This is unsurprising as it is well-recognised that BP plays an 
important role in DR progression as shown in the UKPDS studies.
287,310
 In the UKPDS study, 
1148 patients were randomised to receive tight BP control (BP ≤150/85mmHg) or non-tight 
BP control (BP <180/105mmHg) for the hypertension trial in 1987.
310
 Two-thirds (n=758) 
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received tight BP control while 390 had lax BP control.
310
 After a median follow-up of 7.4 
years, the researchers found that there was a 34% (95% CI: 0.50 to 0.89) reduction in the risk 
of retinopathy as the number of patients requiring photocoagulation treatment decreased and a 
47% (95% CI: 0.30 to 0.93) reduction in the risk of deterioration in vision (defined as ≥3 lines 
of the early treatment of diabetic retinopathy study chart) in in tight BP control group.
310
 The 
researchers also examined retinal photography results and found that after 6 years of follow-
up, there was a dose-response relationship between systolic BP and DR.
287
 Those with 
systolic BP of between 125 and 139mmHg had a RR of 1.5 (95% CI: 1.2 to 2.6) while 
systolic BP ≥140mmHg had a RR 2.8 (95% CI: 2.2 to 3.5) for a new diagnosis of DR.287  
 
Other cohort and observational studies have also demonstrated the relationship between 
hypertension and DR. The Hoorn Study that randomly selected individuals followed-up 233 
DM and non-DM individuals over 9 years, reported that those who developed new onset DR 
had at least a 2-fold increase in risk (OR 2.36, 95% CI: 1.02 to 5.49) for hypertension.
311
 The 
Barbados Eye study followed up 324 Africans with DM over 9 years and showed a reduction 
in DR risk in those with anti-hypertensive treatment (RR: 0.5, 95% CI: 0.3 to 0.9) and a 30% 
increase in risk (RR: 1.3, 95% CI: 1.1 to 1.4) for every 10mmHg increase in systolic BP.
312
 
The NHANES study was a cross sectional study of 1006 DM participants reported a 3% 
increase in risk (OR: 1.03, 95% CI: 1.02 to 1.03) for every 1mmHg increase in systolic BP
276
 
while the Singapore Malay Eye Study, another cross sectional observational study of 757 
Malay DM patients reported OR of 1.85 (95% CI: 1.04 to 3.30) for DR in those with 
hypertension compared to disease free individuals.
313
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4.5.4 Glycaemic control and diabetic retinopathy 
Other than hypertension, glycaemic control is also an important risk factor in the progression 
of DR. Our study reported a 33% increase in risk for DR for each 1% increase in HbA1c after 
adjustment for age, gender and BMI. However, the relationship was lost after further 
adjustment for hypertension, insulin use and duration of DM. We also found significant 
relationship between HbA1c and DMac. Similarly, the association became non-significant 
after further adjustment.  
 
Major cohort studies have showed the link between glycaemia control and DR. The UKPDS 
researchers followed-up 3867 newly diagnosed DM individuals for 10 years and showed that 
intensive glycaemic control (HbA1c 7.0%, 95% CI: 6.2 to 8.2) resulted in 25% (95% CI: 7 to 
40) reduction in micro-vascular end points and a 21% reduction in DR compared to 
conventional control (HbA1c 7.9%, 95% CI: 6.9 to 8.8 %).
314
 The WESDR study followed-up 
955 type 1 diabetes patients over 25 years and found that the risk for each unit increment in 
HbA1c level was a 38% increase in risk for progression to proliferative DR (95% CI: 1.31 to 
1.46),
315
 17% increase in risk for DMac (95% CI: 1.10 to 1.25)
316
 and 28% increase in risk for 
visual impairment (95% CI: 1.04 to 2.83).
317
 The Hoorn study demonstrated that for those 
with HbA1c between 5.8 to 13.1%, the OR for DR was 2.36 (95% CI: 1.02 to 5.49) compared 
to those with HbA1c <5.8%.
311
 The Barbados Eye study reported a 3% increase in risk (95% 
CI: 1.2 to 1.5) for every 1% increase in HbA1c.
312
 The non-significant association from our 
study was likely due to insufficient sample size as this study was not powered to examine 
effects of glycaemia and diabetic retinal disease. 
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Studies have reported that some of the main risk factors for DR are duration of DM and 
insulin treatment.
276,318
 Our study found an increase in risk of DR per year for DM diagnosis 
in the univariate analysis. It remained significant after adjustment for age, gender and BMI. 
However, the association diminished after further adjustment for hypertension, insulin 
treatment and HbA1c. Other studies have shown a positive relationship between years of DM 
and DR. A study on 120 consecutive DM individuals with a median age of 74 years found 
that severity of DR was associated with duration of DM (OR: 3.37, 95% CI: 2.34 to 4.85) 
after adjustment for gender, age, HT and HbA1c.
318
 Similarly, the NHANES study also 
reported greater risk of DR with higher DM duration (OR: 1.06, 95% CI: 1.03 to 1.10 per year 
increase in DM).
276
  
 
Insulin treatment is sometimes used as a surrogate marker for a greater severity of DM and 
has been found to have a significant impact on DR.
312
 In our study, a greater proportion in 
OSA+ group was treated with insulin and no insulin treatment was protective of DR as well as 
DMac. This is unsurprising as there is an association between greater insulin resistance and 
impaired glucose metabolism with severity of OSA.
80,319
 Both the Barbados Eye study
312
 and 
the NHANES study
276
 results reflect the significance of insulin treatment as an indication of 
greater severity of DM on diabetic retinal disease. The Barbados Eye study reported a 6 fold 
increase in risk (95% CI: 1.8 to 24.1)
312
 while the NHANES study showed 3 fold (95% CI: 
1.99 to 5.26) higher risk of retinal disease in diabetic patients who are on insulin treatment.
276
 
Admittedly our study did not demonstrate that HbA1c or DM duration were associated with 
diabetic retinal disease, insulin treatment has been shown to be significant and this suggests 
that in obese DM patients, insulin requirement may be a better indicator of greater DM 
severity compared to HbA1c or DM duration.  
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4.5.5 Benefits and limitations of the study 
Apart from cardiovascular risk factors, our study also examined creatinine and eGFR levels. 
There was a significantly higher creatinine level and a non-significant lower eGFR in OSA+ 
group. These findings reassured that the greater risk in the early development of diabetic 
retinal disease as part of DM micro-vascular complications in our OSA+ group. The effect of 
OSA treatment on diabetes micro-vascular complications remains unknown but a study 
recently by Mason et al. examined the impact of CPAP on 35 OSA patients (defined as ODI 
>10 events/hr or AHI >15 events/hr) with macular oedema showing no improvement, but 
interestingly, some improvement in visual acuity occurred after 6 months of treatment in both 
high (p=0.0009) and low (p=0.0001) CPAP compliers.
320
 Our study benefits from well-
matched groups that are representative of the severely obese population and the ethnic 
diversity of our local population. The OSA+ and OSA- groups were well-matched for BMI, 
co-morbidities, diabetes duration, and glucose-lowering medications. The OSA+ group had 
more men and was older than the OSA- but these differences were accounted for when 
undergoing statistical analyses. Also, in our analyses, we observed the expected and 
previously reported factors associated with diabetic retinal disease.  
 
The limitations of our study include its cross-sectional design and lack of information 
regarding other factors such as smoking although the association between DR and smoking is 
still unclear. A multicentre study of 636 Type 1 DM in Germany followed up for 6 years 
showed an association between DR and cigarette smoking during DM (OR 1.36, 95% CI: 
1.02 to 1.81 for diabetes duration cigarette pack years).
321
 The WESDR study (25 years 
follow-up) however, showed that there was no association between smoking and PDR
315
 as 
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well as DMac.
316
 However, WESDR study did find that cigarette smoking had an adverse 
effect on visual impairment (OR 1.63, 95% CI: 1.01 to 2.61).
317
 On the other hand, the 
UKPDS study showed that smoking status was protective of the incidence (RR 0.63, 95% CI: 
0.48 to 0.82) and progression (RR 0.50, 95% CI: 0.36 to 0.71) of DR.
287
 These studies 
showed that the relationship between smoking and DR seems to be inconsistent therefore the 
lack of smoking information in our study may not have major impact on our results. Visual 
acuity data were also not available as our study aimed to assess impact of OSA on DR rather 
than visual impairment.  
 
The major limiting factor for our study was the unavailability of information on anti-
hypertensive and lipid-lowering treatment agents. Information on the use of angiotensin-
converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) on the renin-
angiotensin system (RAS) were also not available. The Eurodiab Controlled Trial of 
Lisinopril in Insulin-Dependent Diabetes (EUCLID) trial showed that lisinopil, a drug which 
affect the RAS system, seems to have a protective effect on PDR progression (OR 0.18, 95% 
CI: 0.04 to 0.82) independent of BP effect.
322
 DIabetic REtinopathy Candesartan Trial 
(DIRECT-Protect-2) has also shown that candesartan may regress DR in type 2 DM (DR 
Improvement OR 1.17, 95%: 1.05 to 1.30).
323
 Fenofibrate, a peroxisome proliferator-activated 
receptor alpha (PPAR-α) agonist, is a cholesterol-lowering agent. It has been shown in the 
Action to Control Cardiovascular Risk in Diabetes (ACCORD) eye study group that 
fenofibrate in addition to simvastatin had significantly lower the risk for the progression of 
DR (OR 0.60, 95% CI: 0.42 to 0.87).
324
 The Fenofibrate Intervention and Event Lowering in 
Diabetes (FIELD) study also demonstrated a lower risk for laser treatment (HR 0.69, 95% CI: 
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0.54 to 0.84) in the fenofibrate-treated group.
325
 These studies suggest a possible effect of 
these agents on DR.  
Finally, an important limitation in this study was the relatively small number of outcome 
events. As there were only 36 participants with DR, the lack of association observed between 
OSA and DR may be attributed to lack of power.  
 
 
4.6 Conclusions 
Our study of severely obese patients with DM found no association between OSA and DR but 
there was a higher prevalence of DMac in those with moderate to severe OSA. Further 
analysis suggests that the severity of hypoxaemia, particularly minimum oxygen saturation 
has an independent association with the development of maculopathy but the exact 
mechanism for this remains unclear.  As this OSA group was more hypoxaemic, it is 
hypothesised that hypoxaemia and not apnoea/hypopnoea frequency per se is the key factor in 
developing diabetic micro-vascular complications. The other likely potential mechanisms 
were levels of greater systemic hypertension and severity of DM in OSA. The impact of 
CPAP on micro-vascular retinal complications in OSA patients remains undetermined, but 
further RCTs may be warranted to specifically look at the hypoxaemic OSA group.  
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CHAPTER 5 – THE IMPACT OF OBSTRUCTIVE SLEEP APNOEA 
ON DIABETIC KIDNEY DISEASE IN EXTREMELY OBESE 
PATIENTS WITH TYPE 2 DIABETES MELLITUS  
 
5.1 Introduction  
The increasing worldwide prevalence of obesity has led to a parallel rise in type 2 diabetes 
mellitus (T2DM). T2DM is associated with micro and macro-vascular complications with 
significant impact on morbidity and mortality. A common micro-vascular T2DM 
complication is diabetic kidney disease (DKD). DKD is characterised by the presence of 
persistent albuminuria, elevation of arterial blood pressure and decline in renal function in 
DM individuals. Indeed, DM is a major risk factor for the development of chronic kidney 
disease (CKD) and subsequent end stage renal disease (ESRD) needing renal replacement 
treatment (RRT).
326
 The UK Prospective Diabetes Study (UKPDS) found that in patients 
with T2DM, over 10 years, the cumulative-incidence of micro-albuminuria was 24.9%, 
macro-albuminuria prevalence was 5.3%, and the incidence of those with creatinine above 
175µmol/l or needing RRT was 0.8%.
327
 DKD is also especially important because of the 
association with excess mortality risk.
328
 A recent NHANES III study on the 10 year 
cumulative standardised all-cause mortality for DM and non-DM was 19.1% (95% CI: 15.5 
to 22.7) and 8.6% (95% CI: 7.9 to 9.3), respectively.
328
 The study also found that DM 
individuals without DKD had similar mortality compared to non-DM individuals (absolute 
risk difference was 3.4% (95 CI: -0.3 to 0.7). However, in DM with DKD, the absolute risk 
difference compared to non-DM was 23.4% (95% CI: 17.2 to 29.6) after adjusted for 
confounders. Therefore, one can argue that the excess mortality risk in DM may be 
associated with DKD (through its effects in the cardiovascular system). 
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5.1.1 The natural history of diabetic nephropathy  
It is useful to understand the natural history of DKD to help to tackle the problem of excess 
mortality in this group. The classic text book description of the natural history of diabetic 
nephropathy (DN) can be characterised based on its structural or functional changes. Table 5-
1 summarises the stages of DN. Structurally, a diabetic kidney begins with hypertrophy of the 
glomeruli followed by thickening of the glomerular basement membrane (GBM).
329
 GBM 
thickening is caused by the accumulation of fibronectin, laminin and collagen types IV. The 
thickness of GBM increases with DM duration. Subsequently, mesangial expansion or 
diabetic glomerulosclerosis occur and this can be mild or severe. Mesangial expansion is 
described as an enlarged mesangium with a diameter exceeding 2 mesangial cell nuclei. The 
expansion occurs following the accumulation of extracellular proteins and other materials in 
the mesangium. Kimmelsteil-Wilson lesion is the next stage representing nodular sclerosis 
and the final stage of DN is advanced diabetic glomerulosclerosis.
329
  
 
 
Table 5-1: Stages of diabetic nephropathy 
Stage Structural change Functional change 
Pre Glomerular hypertrophy Increased in GFR 
I GBM thickening Micro-albuminuria 
II Mesangial expansion Micro-albuminuria 
III Nodular sclerosis Proteinuria 
IV Advanced diabetic glomerulosclerosis  End stage renal failure 
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Functionally, DN begins with hyperfiltration due to hypertrophy of the glomeruli.
330
 
Glomerular filtration rate is increased at this stage. Next, incipient DN with micro-
albuminuria develops. Pathological findings which accompany this stage are thickened GBM 
and mesangial expansion. Consequently, overt proteinuria occurs at the Kimmelsteil-Wilson 
stage. Finally, end stage renal failure develops.
330
 The changes in the glomerular filtration 
function (GFR) of the hyperfiltration, micro-albuminuria and proteinuria stage was 
demonstrated by Nelson and colleagues.
331
 They followed-up 194 Pima Indians at different 
stages of T2DM: normal glucose tolerance, impaired glucose tolerance, newly-diagnosed 
T2DM, T2DM with normo-albuminuria, T2DM with micro-albuminuria; and T2DM with 
macro-albuminuria for four years. The researchers found that in the newly-diagnosed T2DM 
group, GFR increased by 18% after 4 years (p=0.008). The GFR in T2DM with normo-
albuminuria and micro-albuminuria remained stable over similar time period. However, in 
those with macro-albuminuria, there was a decline in renal function by 35% (p<0.001). The 
mean change in GFR from baseline in those with newly-diagnosed T2DM, micro-albuminuria 
and macro-albuminuria groups over 4 years were illustrated in Figure 5-1.
331
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Figure 5-1: Mean (± standard error) change in the glomerular filtration rate from baseline 
during four years of follow-up in participants with newly-diagnosed diabetes mellitus (DM), 
DM with micro-albuminuria and DM with macro-albuminuria 
331
. Reproduced with 
permission from Nelson RG et al. N Engl J Med 1996;335:1636-1642, Copyright 
Massachusetts Medical Society 
 
 
In reality, the progression of DKD does not necessary follow the stages described above. 
Patients with a decline in GFR may not necessarily have albuminuria. For example, the 
UKPDS found that after 15 years of follow-up, 28% of participants had an estimated GFR 
(eGFR) <60ml/min/1.73m
2
 or chronic kidney disease (CKD) Stage 3 and above.
332
 However, 
over half (51%) of the UKPDS participants with CKD Stage 3 and above did not develop 
albuminuria. Similarly, the Diabetes Control and Complications Trial (DCCT) reported that 
6.2% of type 1 diabetes mellitus (T1DM) individuals developed CKD Stage 3 and above but 
24% of these participants did not develop albuminuria after 19 years of follow-up.
333
 The 
ADVANCE (Action in Diabetes and Vascular disease: preterAx and diamicroN modified 
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release Controlled Evaluation) trial had 10,640 participants and reported that 19% of the 
participants had eGFR <60ml/min/1.73m
2
 but only 38% had albuminuria.
334
 This may be 
because, apart from hyperglycaemia, atherosclerosis may also play a role. This is evidenced 
by the study of 608 Japanese DM individuals followed-up over 7.5 years. At baseline, the 
participants had magnetic resonance imaging (MRI) to assess for cerebral infracts. Those with 
subclinical cerebral infarcts, defined as infarcts detected by MRI without a history of stroke or 
transient ischaemic attack (n=177), had a greater risk of needing RRT or doubling of serum 
creatinine (26.0%) compared with those without subclinical infarcts (5.6%, HR 4.79, 95% CI: 
2.72 to 8.46) after 7.5 years after adjustment for confounders.
335
 However, the subclinical 
cerebral infarct group had no increase in the risk of progression to albuminuria at study end 
(39.5% vs. 27.1%, HR 1.23, 95% CI: 0.88 to 1.73).  
 
5.1.2 Obesity, obstructive sleep apnoea and diabetic kidney disease  
Apart from ischaemic nephropathy, obesity is also a risk factor for renal disease. The Kaiser 
Permanente Study consisted of 320,252 participants who had health check-ups performed 
between 1946 and 1985.
336
 The researchers matched the participants to the U.S. Renal Data 
Registry for ESRD until year 2000. In 8,347,955 person years of follow-up, there were a total 
of 1471 ESRD cases. After correcting for confounding factors, the researchers found a step-
wise increased in the risk of ESRD as BMI increased. The risks reported compared to normal 
BMI (between 18.5 and 24.9 Kg/m
2
) was RR 1.87 (95% CI: 1.64 to 2.14) for overweight 
individuals; RR 3.57 (95% CI: 3.05 to 4.18) for those with BMI between 30 and 34.9Kg/m
2
; 
RR 6.12 (95% CI: 4.97 to 7.54) for those with BMI between 35 and 39.9Kg/m
2
 and RR 7.07 
(95% CI: 5.37 to 9.31) for those above BMI 40Kg/m
2
.  
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The effect of obesity on CKD is further confirmed by a systematic review and meta-analysis 
of 3 cohort studies in the general population reported a pooled-RR of 1.26 (95% CI: 1.10 to 
1.45) for overweight individuals and a pooled-RR 1.34 (95% CI: 0.86 to 2.09) in obese 
individuals for CKD when compared with individuals with normal BMI.
337
 For ESRD, there 
were only 2 cohort studies available for the meta-analysis and the pooled-RR was 1.68 (95% 
CI: 1.49 to 1.90) in overweight and 4.07 (95% CI: 2.87 to 5.76) in obese individuals 
compared with normal BMI individuals. Furthermore, a study by researchers at the Cleveland 
Clinic Bariatric and Metabolic Institute examined T2DM patients after median of 6 years 
follow-up post Roux-en-Y gastric bypass surgery (RYGB), a type of bariatric surgery.
338
 A 
total of 59 patients had both baseline and follow-up results on creatinine and urine albumin 
creatinine ratio (ACR). Nineteen patients had albuminuria at baseline and improvement 
occurred in 10 (53%) with the remaining 9 (47%) patients’ ACR status remaining stable 
without any progression at study end. This suggests that correcting obesity may lead to 
improvement in renal function. 
 
OSA may also play a role in DKD. Several studies have attempted to examine the relationship 
between OSA and renal impairment.
339,340
 The Cleveland Family Study observed 496 middle 
aged adults with a mean age of 44.5±17.3 years.
339
 Renal function was assessed using urine 
albumin creatinine ratio (ACR). The log ACR was found to have a positive association with 
severe OSA (β=0.308, standard error [SE]: 0.152, p=0.033) after adjusting for confounders 
(age, gender, ethnicity, BMI, GFR, hypertension and diabetes). Another observational study 
analysed the data on 1,377,427 adult members of the Kaiser Permanente Southern California 
health care system.
340
 This study demonstrated that those with eGFR of >45ml/min/1.73m
2 
(CKD stage 3a) had increased risk of OSA when compared to participants with eGFR 
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>90ml/min/1.73m
2 
(CKD stage 1, normal renal function). They reported a risk of OR 1.21 
(95% CI: 1.17 to 1.25) for eGFR between 75 and 89ml/min/1.73m
2
; OR 1.25 (95% CI: 1.21 
to 1.30) for eGFR between 60 and 74ml/min/1.73m
2
; and OR 1.18 (95% CI: 1.12 to 1.24) for 
eGFR between 45 and 50ml/min/1.73m
2
. Another Japanese study consisting of 119 ESRD 
patients on RRT found that AHI correlated with urea (r=0.490, p<0.01), creatinine (r=0.418, 
p<0.05) and BMI (r=0.489, p<0.01).
341
 These studies showed that OSA is associated with 
greater renal impairment and may be a risk factor for CKD. 
 
Currently, there is no information on the impact of OSA on renal function in T2DM 
individuals with extreme obesity (BMI≥40Kg/m2), an increasingly important clinical 
population. As shown in Chapter 4, nocturnal hypoxaemia parameters other than the AHI may 
also play an important role in diabetic maculopathy, a well-known diabetic microvascular 
complication, amongst extreme obese individuals. We therefore hypothesised that OSA will 
also be associated with greater DKD severity, another well-recognised diabetic microvascular 
complication.  
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5.2 Aim and objectives  
The aim of this chapter is to examine the prevalence of diabetic kidney disease (DKD) and the 
relationship between OSA and DKD in a severely obese population. The following are the 
study’s objectives:  
 
1. To describe the prevalence of DKD amongst DM individuals who are very severely 
obese using 2 estimated glomerular filtration rate (eGFR) equations and, 
2. To examine the relationship between nocturnal hypoxaemia and nephropathy in very 
severely obese DM participants. 
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5.3 Methods 
5.3.1 Study design and study participants 
The methodology has been described in Chapter 2. In brief, anonymised data were collected 
between January 2009 and December 2011 of prospective DM patients. This study was 
carried out over the same time period as those included in Chapters 2 and 4. Data collected 
included: demographic, anthropometry, DM history and co-morbidities. The duration of DM, 
anti-diabetes medication and HbA1c (DCCT-aligned and IFCC) and serum creatinine were 
also obtained. Data on treatment with either angiotensin-converting enzyme (ACE) inhibitor 
or angiotensin receptor blocker (ARB) were also collected.  
 
5.3.2 Measurement for chronic kidney disease  
The estimated glomerular filtration rate (eGFR) was calculated based on recommendations 
from both the National Institute for Health and Clinical Excellence (NICE)
342
 and the 
National Kidney Foundation Kidney Disease outcome Quality Initiative Clinical Practice 
Guidelines
343
 using the abbreviated 4-variable Modification of Diet in Renal Disease 
(MDRD) equation. The MDRD equation used for calculating the eGFR in this study based on 
serum creatinine (S. Creat) (µmol/l) was as follows (S. Creat=serum creatinine):  
 
eGFR=32788 x S. Creat
-1.154
 x Age
-0.203
 x (1.212 if Afro-Caribbean) x (0.742 if female) 
 
In addition, we also used the CKD Epidemiology Collaboration (CKD-EPI) equation for 
regression analysis as it may provide better accuracy compared to the MDRD formula.
344
 The 
comparison between the MDRD and the CKD-EPI formulae will be elaborated further in the 
discussion section. The equations for the CKD-EPI according to gender were as follows:
344,345
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a. Females  
If S. Creat ≤62µmol/l:   eGFR=144 x (S.Creat/88.4/0.7-0.329) x 0.993age  
If S. Creat >62µmol/l:   eGFR=144 x (S.Creat/88.4/0.7
-1.209
) x 0.993
age  
b. Males  
If S. Creat ≤80µmol/l:  eGFR=144 x (S.Creat/88.4/0.9-0.411) x 0.993age  
If S. Creat >80µmol/l:  eGFR=144 x (S.Creat/88.4/0.9
-1.209
) x 0.993
age
  
 
Staging of chronic kidney disease (CKD) was based on eGFR values. Patients with an eGFR 
of >90.0ml/min/1.73m
2 
had CKD stage 1; eGFR of between 60.0 and 89.9ml/min/1.73m
2 
was 
classified as stage 2; eGFR 30.0 to 59.9ml/min/1.73m
2 
was stage 3; eGFR 15.0 to 
29.9ml/min/1.73m
2 
was stage 4; and eGFR <14.9ml/min/1.73m
2 
was stage 5. Patients with 
eGFR of <60ml/min/1.73m
2 
(CKD stage 3 and above) were grouped as having CKD (CKD+) 
while those with eGFR >60ml/min/1.73m
2 
(CKD stage 1 and 2) were categorised as having 
no CKD (CKD-) using both the MDRD and CKD-EPI calculations.  
 
5.3.3 Respiratory sleep monitoring methods 
The respiratory monitoring methods were described in Chapter 2.  
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5.3.4 Statistical analyses 
Statistical analyses were carried out using Stata 13 (StataCorp LP, College Station, Texas). 
Distribution of data was determined using visual inspection and Shapiro Wilk test. When 
eGFR was calculated using CKD-EPI formula, the data was skewed therefore log 
transformation was performed prior to regression analysis. Mean and standard deviation (SD) 
were used to report parametric data while median and interquartile ranges (IQR) were used 
for non-parametric data. Patients were categorised into eGFR of >60ml/min/1.73m
2
 (CKD- 
group) and <60ml/min/1.73m
2 
(CKD+ group). Independent t test, Mann Whitney U test and 
chi square test were used for analysis of normal distributed data, skewed and categorical data 
respectively. Linear regression analysis was used for further analyses. The base model is 
unadjusted, Model 1 was adjusted for age, gender and BMI and Model 2 was adjusted for age, 
gender, BMI, presence/absence of hypertension, presence/absence of CAD, duration of DM, 
presence/absence of insulin treatment and presence/absence of treatment on ACE inhibitor or 
ARB. The factors included in the adjusted models were those that are considered to be 
clinically important, and the rationale for including each factor is discussed elsewhere (see 
table 5-2 below). The results for linear regression analyses using the MDRD eGFR equation 
were reported as beta coefficients with 95% confidence intervals (95% CI). Regression results 
for log transformed eGFR based on CKD-EPI formula were back transformed and were 
reported as percentage change with 95% CI. A p value of less than 0.05 was considered 
statistically significant.  
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Table 5-2: Factors adjusted and the appropriate sections discussing the rationales behind  
Factors Sections 
Age Introduction of Chapter 2 (section 2.1.3) 
Gender Chapter 2’s discussion (section 2.5.5) 
Body mass index Chapter 1 (section 1.3.4) 
Type 2 diabetes  Chapter 3 (section 3.5.2) 
Insulin treatment  Chapter 4 (section 4.5.5) 
Hypertension  Chapter 1 (section 1.3.3) and chapter 4 (section 
4.5.3) 
Coronary artery disease Chapter 1 (section 1.3.3) 
Angiotensin converting enzyme inhibitor or 
Angiotensin receptor blocker 
Sections 5.5.2 and 5.5.3 
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5.4 Results 
5.4.1 Study characteristics  
A total of 121 consecutive obese DM patients were seen at the service between 2009 and 
2011. However, 12 did not have available renal function measures, and respiratory parameter 
measures were not available for 19 patients (Figure 5-2). This resulted in data from 90 eligible 
patients for analysis. None of the patients had a diagnosis of central sleep apnoea.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2: Flow diagram of referrals seen at the HEFT Specialist Weight Management Clinic, and 
those included in the study  
HEFT – Heart of England NHS Foundation Trust 
DM = Diabetes Mellitus 
 
 
Consecutive patients seen at 
HEFT Specialist Weight 
Management Clinic 
(January 2009 to December 2011) 
 
N = 121 DM individuals 
Included patients for analysis 
N = 90 DM individuals 
Excluded:  
 
12   = Creatinine results 
unavailable 
 
19   = Respiratory data 
incomplete 
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The mean age was 51±10 years with slightly more females (57%), and the majority were 
white Europeans (91%). The mean BMI was 46.8±7.7Kg/m
2
 with 61% of patients having 
concomitant hypertension and 10% diagnosed with CAD. Median duration of DM was 6 
years (IQR 2, 10) with HbA1c of 64mmol/mol (IQR 51, 80) or 8.0% (IQR 6.8, 9.5). The 
majority of the patients required at least 2 glucose-lowering medications (53%) and 31% were 
on insulin treatment. The patients had a mean MDRD and CKD-EPI eGFR of 78.3±25.1 and 
89.9±21.6 ml/min/1.73m
2
, respectively. The median AHI was 15 events/hr (IQR 7, 37), mean 
oxygen saturations of 93% (IQR 92, 95), minimum oxygen saturations 82% (IQR 74, 85), and 
the % of time spent below 90% oxygen saturation (%TST<90%) of 2.9% (IQR 0.7, 15.0). The 
prevalence of OSA based on AHI ≥5 events/hr was 83% (95% CI: 74 to 90) and the 
proportion with moderate-to-severe OSA (AHI ≥15 events/hr) was 51% (95% CI: 41 to 61). 
Of those with a diagnosis of OSA, 22.7% and 13.3% had MDRD and CKD-EPI eGFR of 
≤60ml/min/173m2, respectively.  
 
5.4.2 Prevalence of chronic kidney disease  
Twenty-nine percent of the DM individuals (n=26) did not suffer with CKD (MDRD eGFR 
>90ml/min/1.73m
2
) while 49% (n=44) had CKD stage 2. A total of 20 patients had MDRD 
eGFR <60ml/min/1.73m
2 
(22%, 95% CI: 15 to 32). None of the patients had CKD stage 5 and 
only 1 had stage 4 CKD. Using the CKD-EPI equation, a lower proportion (28.9%, n=26) had 
CKD stage 2, 10% had stage 3 (n=9) whilst 1 patient had stage 4, and none had stage 5 CKD. 
A summary table of the characteristics of 90 DM patients is shown in Table 5-3.  
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5.4.3 Comparisons of CKD and non-CKD patients based on MDRD eGFR  
Please refer to Table 5-4 for a summary of the results. Patients in the MDRD CKD+ group 
were older with a mean age of 57±11 years compared to those in the MDRD CKD- group 
(50±9years, p=0.003). No significant differences were found in ethnicity between the groups 
(p=0.207). There were also significantly more females (80%) in CKD+ group compared to 
CKD- (50%, p=0.017) and greater adiposity in CKD+ group with BMI of 50.6±8.7Kg/m
2
 
compared to 45.7±7.1Kg/m
2
 in CKD- group (p=0.012).  Systolic BP was significantly higher 
in CKD+ group (p=0.037) but this was not the case for diastolic BP. Although no difference 
was found in the proportion with hypertension between the two groups, there was at least a 3 
fold higher CAD in the MDRD CKD+ group (25% vs. 7%, p=0.025).  
 
There were no significant differences in DM duration and HbA1c levels between the two 
groups. Insulin usage was at least 2-fold higher in the MDRD CKD+ group (p=0.009). A 
greater proportion of patients were treated with either ACE inhibitor or ARB in the MDRD 
CKD+ group (p=0.021). No significant differences were found in OSA prevalence based on 
AHI ≥5 events/hr or in the proportion of moderate-to-severe OSA. AHI and minimum oxygen 
saturation levels were also not significantly different between the groups. However, there was 
a significant difference in the mean oxygen saturation (p=0.043) and at least 3-times higher in 
%TST<90% in the MDRD CKD+ patients (p=0.046).  
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Table 5-3: Characteristics of 90 Type 2 diabetes mellitus patients 
 
N Mean ± SD or Median (IQR) 
Age (years) 90 51 ± 10 
Females (%) 90 57% 
Ethnicity (%) 
White Europeans 
South Asians 
Afro-Caribbean 
64 
19 
7 
91% 
27% 
8% 
Body Mass Index (Kg/m
2
) 90 46.8 ± 7.7 
Systolic BP (mmHg) 67 143 ± 20 
Diastolic BP (mmHg) 68 84 ± 11 
Co-morbidities  
Hypertension (%) 
Coronary artery disease (%) 
 
55 
10 
 
61% 
10% 
DM parameters 
DM Duration (years) 
Insulin (%) 
87 
28 
6 (2, 10) 
31% 
HbA1c (%) 88 8.0 (6.8, 9.5) 
HbA1c (mmol/mol) 88 64 (51, 80) 
Number of DM Medications (%) 
0 
1 
2 
>3 
18 
24 
37 
11 
20% 
27% 
41% 
12% 
AHI (events/hour) 90 15 (7, 37) 
Mean O2 sats (%) 90 93 (92, 95) 
Minimum O2 sats (%) 90 82 (74, 85) 
Time under 90% sats (%) 83 2.9 (0.7, 15.0) 
MDRD eGFR (ml/min/1.73m
2
) 90 78.3 ± 25.1 
MDRD eGFR < 60 
ml/min/1.73m
2
 20 22.2% 
CKD stages 
1 
2 
3 
4 
26 
44 
19 
1 
29% 
49% 
21% 
1% 
CKD-EPI eGFR (ml/min/1.73m
2
) 90 89.9 ± 21.6 
CKD-EPI eGFR < 60 
ml/min/1.73m
2
 10 11.1%  
CKD stages  
1 
2 
3 
4 
54 
26 
9 
1 
60% 
29% 
10% 
1% 
BP = blood pressure, DM = diabetes mellitus, AHI = apnoea-hypopnoea index, O2 = oxygen, sats = 
saturations, MDRD = Modification of Diet in Renal Disease, eGFR = estimated glomerular filtration 
rate, CKD = Chronic Kidney Disease, CKD-EPI = Chronic Kidney Disease Epidemiology 
Collaboration, HbA1c=glycosylated haemoglobin A1c 
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Table 5-4: Sample characteristics of patients with and without at least chronic kidney disease stage 3 
(CKD 3) based on Modification of Diet in Renal Disease (MDRD) formula 
 N   CKD+ 
N=20 
N CKD- 
N=70 
p value 
Age (years) 20 57 ± 11 70 50 ± 9 0.003 
Female 16 80% 35 50% 0.017 
Ethnicity  
White Europeans 
South Asians 
Afro-Caribbean 
 
17 
3 
0 
 
85% 
15% 
0% 
 
47 
16 
7 
 
67% 
23% 
10% 
0.207 
BMI (kg/m
2
) 20 50.6 ± 8.7 70 45.7 ± 7.1 0.012 
Systolic BP (mmHg) 17 152 ± 26 50 140 ± 17 0.037 
Diastolic BP (mmHg) 17 88 ± 17 50 83 ± 8 0.0954 
Co-morbidities 
Hypertension 
Coronary artery disease 
 
15 
5 
 
75% 
25% 
 
40 
5 
 
57% 
7% 
 
0.149 
0.025 
      
ACE-I or ARB  
ACE inhibitor  
15 
6 
75.0% 
30.0% 
32 
23 
57.5% 
18.6% 
0.021 
0.809 
ARB 9 45.0% 13 18.6% 0.015 
      
DM parameters      
DM Duration  20 9 (4, 13) 67 6 (2, 10) 0.149 
HbA1c (%) 19 7.5 (6.8, 9) 69 8.1 (6.9, 9.7) 0.503 
HbA1c (mmol/mol) 19 58 (51, 75) 69 65 (52, 83) 0.503 
Insulin 11 55% 17 24% 0.009 
Number of DM 
medications 
None 
1 
2 
>3 
 
 
3 
5 
10 
2 
 
 
15% 
25% 
50% 
10% 
 
 
15 
19 
27 
9 
 
 
21% 
34% 
39% 
13% 
 
0.814 
 
Respiratory parameters 
    
OSA (AHI ≥ 5)  17 85%  58 83% 0.821 
      
AHI ≥ 15 10 50% 36 51% 0.910 
      
AHI (events/hr) 20 17 (7, 63) 70 15 (7, 31) 0.600 
Mean O2 sats (%) 20 92 (91, 94) 70 93 (92, 95) 0.043 
Minimum O2 sats (%) 20 81 (73, 84) 70 83 (74, 85) 0.268 
Time under 90% sats (%) 19 8.6 (1.1, 33.3) 64 2.5 (0.5, 12.1) 0.046 
 
Data are presented as mean ± standard deviation, percentage or median (interquartile range).  
CKD+ = presence of chronic kidney disease stage 3 and below; CKD- = absence of chronic kidney 
disease stage 3 and below; BMI = body mass index; BP = blood pressure; DM = type 2 diabetes 
mellitus; AHI = apnoea-hypopnoea index; O2 = oxygen; sats = saturation, HbA1c=glycosylated 
haemoglobin A1c. p values were calculated using either independent t test, Mann Whitney U test or 
chi square test.  
 
 
 141  
 
5.4.4 Comparisons of CKD and non-CKD patients based on CKD-EPI eGFR 
Please refer to Table 5-5 for a summary of the results. Comparisons were also made between 
the CKD+ and CKD- using the CKD-EPI formulae. Similar to the MDRD equation, there was 
a significant difference in age between the CKD+ (63.3±9.2years) compared to the CKD- 
(49.9±9.5years, p<0.0001) group. No significant differences were found for gender, ethnicity 
and BMI. Although systolic BP was 12mmHg higher in the CKD+ compared to the CKD-, 
this was not statistically significant. Similarly, there was no difference in diastolic BP 
(3mmHg difference), proportion of hypertensive individuals (80.0% vs, 58.8%) and coronary 
artery disease (20.0% vs. 10.0%), HbA1c level (1.3% or 14mmol/mol higher in the CKD+ 
group) as well as number of DM medications used. The duration of DM was significantly 
longer for CKD+ (10 [IQR: 7, 14] vs. 6 [IQR: 2, 10] years, p=0.042) and proportion needed 
for insulin was also significantly higher (80.0% vs. 25.0%, p<0.001). The proportions of 
individuals receiving either ACE inhibitor or ARB were not statistical significant (p=0.062).  
 
There was no difference in the proportion of individuals with OSA between the CKD groups 
(p=0.134). However, the proportion of individuals with moderate-to-severe OSA almost 
reached statistical significance and was greater in the CKD+ group (80.0% vs. 47.5%, 
p=0.053). Therefore, unsurprisingly, there was a significant difference in AHI. Median AHI 
for the CKD+ group was 45 events/hr (IQR: 19, 74) compared to 14 events/hr (IQR: 6, 31) in 
the CKD- group (p=0.033). The CKD+ group also spent at least 5 fold greater in % time spent 
below 90% oxygen saturation (%TST<90) (13.8% [IQR: 2.0, 91.0] vs. 2.7% [IQR: 0.7, 12.0], 
p=0.046) whilst there were no significant difference in mean and minimum oxygen 
saturations between the 2 groups.  
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Table 5-5: Sample characteristics of patients with and without at least chronic kidney disease stage 3 
(CKD 3) based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula 
 N   CKD3+ 
N=10 
N CKD3- 
N=80 
P value 
Age (years) 10 63.3 ± 9.2 80 49.9 ± 9.5 <0.0001 
Female 6 60.0% 51 63.8% 0.821 
Ethnicity  
White Europeans 
South Asians 
Afro-Caribbean 
 
8 
1 
1 
 
80.0% 
10.0% 
10.0% 
 
56 
18 
6 
 
70.0% 
22.5% 
0.08% 
0.652 
BMI (Kg/m
2
) 10 49.6 ± 9.1 80 46.5 ± 7.5 0.2337 
Systolic BP (mmHg) 8 154 ± 26 59 142 ± 19 0.1060 
Diastolic BP (mmHg) 8 87 ± 23 59 84 ± 9 0.4716 
Co-morbidities 
Hypertension 
Coronary artery disease 
 
8 
2 
 
80.0% 
20.0% 
 
47 
8 
 
58.8% 
10.0% 
 
0.1940 
0.3430 
      
ACE-I or ARB 8 80.0% 39 48.8% 0.062 
ACE inhibitor 3 30.0% 26 32.5% 0.873 
ARB 5 50.0% 17 21.3% 0.046 
      
DM parameters      
DM Duration  10 10 (7, 14) 77 6 (2,10) 0.0418 
HbA1c (%) 9 9.2 (8.1, 10.1) 79 7.9 (6.7, 9.4) 0.0619 
HbA1c (mmol/mol) 9 77 (65, 87) 79 63 (50, 79) 0.0619 
Insulin 8 80.0% 20 25.0% <0.001 
Number of DM 
medications 
None 
1 
2 
>3 
 
 
1 
3 
6 
0 
 
 
10.0% 
30.0% 
60.0% 
0.0% 
 
 
17 
21 
31 
11 
 
 
21.3% 
26.3% 
38.8% 
13.8% 
 
0.398 
 
Respiratory parameters 
     
AHI (events/hr) 10 45 (19, 74) 80 14 (6, 31) 0.0325 
Mean O2 sats (%) 10 92 (85, 95) 80  93 (92, 95) 0.2878 
Minimum O2 sats (%) 10 78 (71, 83) 80 82 (76, 86) 0.1300 
Time under 90% sats (%) 10 13.8 (2.0, 91.0) 80 2.7 (0.7, 12.0) 0.0460 
      
OSA (AHI ≥ 5) 10 100% 65 81.3% 0.134 
      
AHI ≥ 15 8 80.0% 38 47.5% 0.053 
      
Data are presented as mean ± standard deviation, percentage or median (interquartile range).  
CKD+ = presence of chronic kidney disease stage 3 and below; CKD- = absence of chronic kidney 
disease stage 3 and below; BMI = body mass index; BP = blood pressure; DM = type 2 diabetes 
mellitus; AHI = apnoea-hypopnoea index; O2 = oxygen; sats = saturation, HbA1c=glycosylated 
haemoglobin A1c. p values were calculated using either independent t test, Mann Whitney U test or 
chi square test.  
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5.4.5 Multivariate regression analysis  
Pearson correlation analyses found no significant correlations between AHI, mean and 
minimum oxygen saturations and the MDRD eGFR. However, there was a significant 
correlation between the MDRD eGFR and %TST<90% (r=-0.24). This was confirmed with 
univariate linear regression analyses with a 0.27% reduction in the MDRD eGFR for every 
1% increase in %TST<90% (95% CI: -0.51 to -0.03). No significant results were found for 
AHI (β=-0.06, 95% CI: -0.25 to 0.13), minimum (β=-0.01, 95% CI: -0.54 to 0.52) and mean 
oxygen saturations (β=1.41, 95% CI: -0.06 to 2.89) with the MDRD eGFR as shown in Table 
5-6. However, using the CKD-EPI calculation for eGFR, all 4 respiratory parameters were 
significantly associated with the CKD-EPI eGFR as shown in Table 5-7.  A unit increase in 
AHI resulted in 30% (95% CI: -0.52 to -0.08) whilst %TST<90 52% (95% CI: -0.79 to -0.25) 
reduction in the CKD-EPI eGFR. Similarly, higher mean (β=3.15, 95% CI: 15.26 to 4.90) and 
minimum (β=0.74, 95 CI: 0.13 to 1.36) oxygen saturations resulted in a greater CKD-EPI 
eGFR.  
 
In Model 1 of the multivariate linear regression analyses using the MDRD eGFR as the 
outcome, the inverse association between %TST<90% remained significant (β=-0.25, 95% 
CI: -0.45 to -0.06) after adjusting for age, gender and BMI. Similarly, an increase in the AHI 
also resulted in a reduction in renal function (β=-0.21, 95% CI: -0.35 to -0.05) and a higher 
mean oxygen saturation was associated with better renal function (β=1.49, 95% CI: 0.25 to 
2.74) in Model 1 based on the MDRD formula. No significant association was found for 
minimum oxygen saturations and the MDRD eGFR (β=0.20, 95% CI: -0.24 to 0.65). The 
CKD-EPI eGFR regression models revealed similar results as for the MDRD eGFR and this is 
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shown in Table 5-6. Apart from minimum oxygen saturation (β=0.44, 95% CI: -0.16 to 1.05), 
AHI (β=-0.27, 95% CI: -0.47 to -0.67), mean oxygen saturation (β=2.10, 95% CI: 0.38 to 
3.86) and %TST<90 (β=-0.38, 95% CI: -0.65 to -0.11) maintained statistical significance.  
 
Table 5-6: Linear regression analysis assessing associations between Modification of Diet in Renal 
Disease (MDRD) eGFR and respiratory parameters 
Predictors Models           
Reported as beta coefficients (95% Confidence Intervals) 
 Unadjusted Model 1 Model 2 
AHI  -0.058 (-0.247 to 0.130) -0.207 (-0.353 to -0.061) -0.170 (-0.316 to -0.024) 
 
Min O2 sat 
 
-0.011 (-0.539 to 0.516) 
 
0.202 (-0.241 to 0.645) 
 
0.053 (-0.388 to 0.495) 
 
Mean O2 
 
1.413 (-0.0638 to 2.890) 
 
1.494 (0.247 to 2.741) 
 
1.191 (-0.039 to 2.420) 
 
%TST<90% 
 
-0.272 (-0.512 to -0.032) 
 
-0.254 (-0.453 to -0.055) 
 
-0.215 (-0.406 to -0.023) 
    
Age* -0.848 (-1.332 to -0.363) -0.937 (-1.305 to -0.569) -0.821 (-1.199 to -0.442) 
    
Male* 28.149 (19.324 to 36.975) 35.307 (26.703 to 43.911) 36.904 (28.434 to 45.375) 
 
BMI* 
 
-0.606 (-1.285 to 0.073) 
 
0.254 (-0.278 to 0.787) 
 
0.279 (-0.244 to 0.803) 
 
Hypertension* 
 
-6.358 (-17.101 to 4.385) 
 
Not applicable 
 
3.204 (-6.316 to 12.723) 
 
CAD* 
 
-10.670 (-27.312 to 5.972) 
 
Not applicable 
 
-6.580 (-18.953 to 5.792) 
 
DM duration* 
 
-0.819 (-1.668 to 0.029) 
 
Not applicable 
 
0.259 (-0.467 to 0.986) 
 
Insulin* 
 
-17.954 (-28.702 to -7.206) 
 
Not applicable 
 
-17.309 (-27.273 to -7.344) 
 
ACE/ARB* 
 
-6.524 (-16.999 to 3.952) 
 
Not applicable 
 
1.421 (-7.657 to 10.498) 
    
Unadjusted: univariate models 
Model 1: adjusted for age, gender, body mass index 
Model 2: further adjusted for hypertension, coronary artery disease and duration of type 2 diabetes 
mellitus, insulin treatment and angiotensin-converting enzyme inhibitor or angiotensin receptor 
blocker treatment.  
*Adjusted for apnoea-hypopnoea index only to avoid multi-collinearity 
eGFR = estimated glomerular filtration rate; AHI = apnoea-hypopnoea index; Min O2 sat = minimum 
oxygen saturation; Mean O2 = mean oxygen saturation; %TST<90% = time spent under 90% oxygen 
saturation, BMI = Body mass index, CAD = coronary artery disease, DM = type 2 diabetes, 
ACE/ARB = angiotensin-converting enzyme inhibitor or angiotensin receptor blocker treatment 
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In Model 2, the associations remained significant after further adjustment for hypertension, 
CAD, DM duration, insulin treatment and treatment for ACE inhibitor or ARB. For AHI, 
there was a 0.17% reduction in the MDRD eGFR (95% CI: -0.32 to -0.02) for each increase in 
event/hr and a 0.22% reduction in the MDRD eGFR for each increase in % of %TST<90% 
(95% CI: -0.41 to -0.02). As with Model 1, there were no significant association between 
minimum oxygen saturations and the MDRD eGFR. The mean oxygen saturation and the 
MDRD eGFR was no longer significant (β=1.19, 95% CI: -0.04 to 2.42) after adjustment for 
the additional variables. Regression models based on the CKD-EPI calculation revealed that 
only %TST<90 (β=-0.30, 95% CI: -0.56 to -0.03) was significantly associated with a 
reduction in renal function as shown in Table 5-7. Model 3 also showed that AHI (β=-0.19, 
95% CI: -0.04 to 0.01) was approaching statistical significance based on the CKD-EPI 
calculation. Both minimum (β=0.16, 95% CI: -0.44 to 0.76) and mean (β=1.50, 95% CI: -0.21 
to 3.22) oxygen saturations were not significant.  
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Table 5-7: Linear regression analysis assessing associations between Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) eGFR and respiratory parameters 
Predictors Models 
Reported as percentage change (95% Confidence Intervals) 
 Univariate models Model 1 Model 2 
AHI   -0.300 (-0.517 to -0.082) * -0.268 (-0.468 to -0.669) * -0.189 (-0.391 to 0.013) 
 
Min O2 sat 
 
0.744 (0.128 to 1.363) * 
 
0.439 (-0.164 to 1.046) 
 
0.159 (-0.443 to 0.764) 
 
Mean O2 
 
3.152 (15.257 to 4.903) * 
 
2.105 (0.377 to 3.862) * 
 
1.495 (-0.206 to 3.225) 
 
%TST<90% 
 
-0.524 (-0.794 to -0.254) * 
 
-0.381 (-0.651 to -0.111) * 
 
-0.296 (-0.562 to -0.029) * 
 
Age* 
 
1.600 (1.090 to 2.108) 
 
1.540 (1.040 to 2.037) 
 
1.540 (1.040 to 2.037) 
 
Male* 
 
-3.924 (-18.049 to 8.511) 
 
-12.614 (-26.776 to -0.034) 
 
-13.889 (-28.061 to -1.285) 
 
BMI* 
 
0.408 (-0.416 to 1.225) 
 
0.051 (-0.685 to 0.781) 
 
0.093 (-0.634 to 0.814) 
 
Hypertension* 
 
15.248 (3.965 to 25.206) 
 
Not applicable 
 
2.397 (-11.355 to 14.451) 
    
CAD* 23.998 (7.839 to 37.324) Not applicable 11.488 (-5.052 to 25.424) 
 
DM Duration* 
 
1.174 (0.174 to 2.164) 
 
Not applicable 
 
-0.297 (-1.311 to 0.707) 
 
Insulin* 
 
25.574 (15.957 to 34.091) 
 
Not applicable  
 
20.291 (8.499 to 30.563) 
 
ACE/ARB* 
 
 
11.071 (-0.691 to 21.459) 
 
Not applicable 
 
-5.020 (-19.086 to 7.384) 
Univariate models: unadjusted 
Model 1: adjusted for age, gender, body mass index 
Model 2: further adjusted for hypertension, coronary artery disease and duration of type 2 diabetes 
mellitus, insulin treatment and angiotensin-converting enzyme inhibitor or angiotensin receptor 
blocker treatment 
*Adjusted for apnoea-hypopnoea index only to avoid multi-collinearity 
eGFR = estimated glomerular filtration rate; AHI = apnoea-hypopnoea index; Min O2 sat = minimum 
oxygen saturation; Mean O2 = mean oxygen saturation; %TST<90% = time spent under 90% oxygen 
saturation, BMI = Body mass index, CAD = coronary artery disease, DM = type 2 diabetes, 
ACE/ARB = angiotensin-converting enzyme inhibitor or angiotensin receptor blocker treatment 
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5.5 Discussion 
5.5.1 Prevalence of diabetic kidney disease (DKD)  
Our study found that the proportion of DM with diabetic kidney disease was 22% based on 
the MDRD or 10% based on the CKD-EPI calculations. Several factors can influence the 
prevalence rates. These include population selection, characteristics of the population as well 
as the definition of CKD.  
 
5.5.1.1 Prevalence of diabetic kidney disease (DKD) based on the MDRD eGFR 
Several UK studies have reported that the prevalence of DKD was between 18% and 31.3% 
based on the MDRD criteria for CKD Stage 3 and below in people with diabetes.
346-349
 A 
lower prevalence rate was reported by Dreyer and colleagues;
349
 and Tahrani and 
colleagues.
348
 Dreyer and colleagues extracted data from 148 GP practices of three deprived 
areas in Britain: Newham, Tower Hamlets and City & Hackney.
349
 These are all socially 
deprived areas located in London. The crude prevalence of DKD was reported as 18%. 
Tahrani and colleagues reported a prevalence of 16.5% based on the MDRD eGFR 
<60ml/min/1.73m
2
. The socio-economic status (SES) of our study population was similar to 
that study of Dreyer and colleagues
349
 and was almost identical with the study by Tahrani and 
colleagues.
348
 This was because one of the 2 centres of recruitment by Tahrani and colleagues 
was HEFT (our centre).  
 
About 40% of the Birmingham’s population was living in the most deprived 10% area in 
England; additionally, part of HEFT (our service) also covers the area within the most 
deprived 1% in the UK.
150
 Deprivation and low SES have been shown to be associated with 
late and more severe presentations of CKD.
350
 Therefore, a greater number of patients with 
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DKD might present to the combined DM-renal or the renal clinics instead of the weight 
management service meaning our observation might have underestimated the true prevalence 
of DKD for our population. Furthermore, selection bias may occur in our patient population. 
HEFT specialist weight management service offers bariatric surgery, and bariatric surgery has 
been shown to result in remission of DM especially in ‘mild’ DM patients.154 This may have 
resulted in selective referral of patients who were considered to have ‘less severe’ DM by GPs 
in order to achieve greatest clinical success, as well as being cost effective for the NHS.  
 
The higher DKD prevalence was reported by the NEw Opportunities for Early Renal 
Intervention by Computerised Assessment (NEOERICA) study.
346
 The study compiled 
databases of 17 general practice (GP) practices in Kent, Greater Manchester and West Surrey 
over 13 years. Of a total of 4139 DM patients with eGFR results, 31.3% had DKD. This was 
much greater than our observation. This may be partly because of the clinical management in 
GP practices as general practitioners may have a tendency to assess renal function more 
frequently in older patients (age >65years).
351
 Indeed, Kent, a part of south-east England, has 
a greater proportion of older adults (13.8%) compared with the UK national average 
(11.5%).
351
 Age is a well-known risk factor for CKD
352
 therefore the study may have 
identified a greater prevalence rate compared to our result. Apart from this, no research has 
validated the MDRD equation in older adult (>70 years) populations. Therefore, reliability 
and accuracy of the DKD diagnosis in the NEOERICA study might be an issue. The age 
influence on DKD was also demonstrated by Middleton and colleagues, who analysed the 
Electronic Patient Record of DM individuals (GP practices) from Salford, Greater 
Manchester.
347
 Although they found that 27.5% had DKD, the prevalence was only 16% in 
those <70 years compared to 49% in patients >70 years (p>0.05).  
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5.5.1.2 Prevalence of diabetic kidney disease (DKD) based on the CKD-EPI eGFR 
The CKD-EPI is a relatively new estimation of the GFR and to date, has not been widely used 
in the UK. Therefore, the majority of the prevalence studies based on the CKD-EPI formula 
were results from the US. Three studies using the National Health And Nutrition Examination 
Survey (NHANES) data reported that the prevalence of DKD was between 13.8% and 
17.7%.
353,354
 The NHANES is a programme of studies conducted in non-institutionalised 
adults by the National Centre for Health Statistics. It aims to assess the health and nutritional 
status of about 5000 US citizens each year as a representative sample of the US population. 
The US and UK has different population characteristics therefore, it is more difficult to 
compare our results with the NHANES result.  
 
DKD in the NHANES studies was defined as the presence of urinary albuminuria of >30mg/g 
or eGFR <60ml/min/1.73m
2
. Looking at the temporal trend of DKD, de Boer and colleagues 
examined NHANES results from three different time periods: from 1988 to 1994, 1999 to 
2004 and 2005 to 2008.
353
 Excluding albuminuria, the prevalence of CKD Stage 3 and above 
was 14.9% (95% CI: 12.1 to 17.8) in 1988 to 1994, 16.7% (95% CI: 14.6 to 18.9) in 1999 to 
2004 and 17.7% (95% CI: 15.2% to 20.2) in 2005 to 2008. The second NHANES study by 
Plantinga and colleagues used data from 1999 to 2006 and compare the prevalence between 
participants with diagnosed and undiagnosed DM.
354
 The researchers found a similar 
prevalence for diagnosed (14.0%, 95% CI: 10.5 to 18.4) and undiagnosed DM (13.8%, 95% 
CI: 10.1 to 18.6) in those with eGFR<60ml/min/1.73m
2
. Based on the NHANES results, the 
prevalence of DKD seems to increase with time and this may be due to the parallel increase in 
the prevalence of diabetes.  
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The slightly greater rates reported by the NHANES studies compared to our result can 
partially be explained by the selection bias in our study as discussed above, and the 
differences in the characteristics of the two populations such as age. The prevalence of DKD 
seems to increase with age. In a subgroup analysis of the NHANES study, de Boer and 
colleagues
353
 reported that the prevalence of CKD ≥Stage 3 in those between the age of 20 
and 65 years was 4.5% (95% CI: 2.0 to 7.1) for the period 1988 to 1994; 5.8% (95% CI: 3.9 
to 7.6) for period 1999 to 2004 and 6.0% (95% CI: 3.9 to 8.2) for period 2005 to 2008.
353
 For 
those age >65 years, the prevalence was 31.2% (95% CI: 27.3 to 35.1) for period 1988 to 
1994; 35.5% (95% CI: 31.4 to 39.4%) for period 1999 to 2004 and 37.4% (95% CI: 31.5 to 
43.3%) for period 2005 to 2008.  
 
Both the NHANES and our study reported the crude prevalence rates for DKD. However, the 
subgroup analysis from the NHANES result suggests that the prevalence of DKD increases 
with age. Apart from the age influence, the NHANES studies consist of Hispanics (8%) and a 
greater proportion of Afro-Caribbeans (17%). Studies comparing the renal function between 
these two ethnicities and white Caucasians have shown that white Caucasians have a slower 
decline in renal function.
355,356
 Therefore, the discrepancies in ethnicities will also contribute 
to the difference in prevalence rates.  
 
5.5.1.3 Comparison between the MDRD and CKD-EPI eGFR prevalence 
In comparison to the MDRD formula, utilising the CKD-EPI equations revealed lower 
prevalence rates in the current study. The MDRD formula was first developed in 2006 based 
on a population of individuals with renal impairment only.
344
 Subsequently, the CKD-EPI was 
developed in 2009 to provide a better prediction in individuals with GFR >60ml/min/1.73m
2 
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compared to the MDRD formula.
344
 This is because the CKD-EPI research development 
group included both individuals with and without renal impairment. A total of 8254 
participants’ data were used: 5504 participants’ data were used for the development of the 
formula and 2750 for internal validation. All the participants had results on urinary clearance 
of iothalamate to measure actual GFR. An additional 3896 participants’ data from 16 other 
studies were used for external validation of the CKD-EPI eGFR formula. During the external 
validation process, the accuracy of the CKD-EPI and MDRD equations within 30% of the 
measured GFR (P30) was found to be 84.1% and 80.6%, respectively. The study also found 
that the CKD-EPI formula performed as well as the MDRD equation in those with eGFR 
<60ml/min/1.73m
2 
and is more accurate in the subgroup with eGFR >60ml/min/1.73m
2 
(please refer to Figure 5-2).
344
  
 
 152  
 
 
Figure 5-3: The accuracy of the MDRD and CKD-EPI equations in estimating the measured 
glomerular filtration rate. Reproduced with permission from Levey AS et al. Annals of 
Internal Medicine 2009;150:604-612, Copyright American College of Physicians. 
 
 
As mentioned above, the majority of our patients were referred to be considered for bariatric 
surgery may have ‘mild’ DM without renal complications, so our patients may be more likely 
to have an eGFR >60ml/min/1.73m
2
. If so, does this may mean that using the CKD-EPI 
formula is more accurate in estimating the DKD prevalence for our population? Two other 
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studies compared the formulae in other diabetic populations and did not report any differences 
in the performance of both the formulae.
357,358
 Silveiro and colleagues used 
51
Cr-EDTA to 
measure the isotope GFR (iGFR), which provides an accurate value of GFR for DM 
individuals with GFR >60ml/min/1.73m
2
.
357
 Compared to the measured iGFR of 
103±23ml/min/1.73m
2
, CKD-EPI calculated eGFR was 83±15ml/min/1.73m
2
 and MDRD 
eGFR was 78±17ml/min/1.73m
2
. The P30 accuracy of CKD-EPI (67%, 95% CI: 58-74) was 
found to be similar to the MDRD eGFR (64%, 95% CI: 56-75).  
 
Similarly, Camargo and co-workers used 
51
Cr-EDTA to measure iGFR in 52 T2DM 
patients.
358
 The bias rate was similar for the CKD-EPI and MDRD equations 
(24ml/min/1.73m
2
 vs. 26ml/min/1.73m
2
), as was the P30 accuracy rate (66% vs. 64%). Due to 
the inconsistencies in the performance of both formulae in the DM populations compared to 
the general populations, more researches are needed before conclusion can be drawn in 
identifying a superior formula for the DM population. Additionally, both formulae have not 
been validated in extreme obese populations.  
 
5.5.2 Obstructive sleep apnoea and diabetic kidney disease 
5.5.2.1 OSA (defined by AHI/ODI) and DKD 
The association between chronic nocturnal hypoxemia and renal function has been examined 
by several studies with contradictory results.
340,359-364
 In a small study of 52 DM patients with 
sleep symptoms, the authors found no correlation between urinary ACR and AHI.
359
 The 
small sample of patients and lack of control group were the main limitations of the study. 
Another study from Germany assessed 58 Type 1 diabetes and 498 Type 2 diabetic patients  
and reported a significant difference in the proportions of DKD based on the severity of AHI 
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(<5 events/hr, between 5 and 14.9 events/hr and those >15 events/hr) (p=0.001).
361
 Although 
the study recruited 715 participants, only 556 individuals’ data was used (30% excluded) due 
to issues with sleep recording and missing data. Another limitation was that researchers used 
a 2 hour sleep recordings rather than the commonly used minimum of 4 hours for sleep 
analysis. As mentioned in the discussion of Chapter 3, longer sleep recordings are better at 
diagnosing OSA because apnoea and hypopnoea episodes are higher during REM sleep.
218
 
The study also did not adjust for confounders and used a Level IV sleep device (ApneaLink) 
which lacks information on respiratory effort. Furthermore, the study’s definition of OSA was 
AHI >15 events/hr. If, rather than comparing those with no, mild and moderate-to-severe 
OSA (as reported by the researchers); we used the study’s conservative definition for the 
diagnosis of OSA, the association was no longer found to be significant (unadjusted OR 1.25, 
95% CI: 0.72 to 2.14, own statistical calculation).  
 
In contrast, an observational study in 513 diabetic patients by Furukawa and colleagues using 
pulse oximetry reported significant associations between ODI and albuminuria. The 
researchers employed ODI as a diagnosis of OSA (defined as ≥5 events/hr based on at least 
3% ODI). This Japanese group found that those with OSA had up to a threefold increase in 
the risk for macro-albuminuria (OR 2.97, 95% CI: 1.36 to 6.9) and almost twofold increased 
risk for micro-albuminuria (OR 1.84, 95% CI: 1.16 to 2.96) after adjusting for confounders 
(age, gender, BMI, hypertension, dyslipidaemia, smoking, alcohol, cardiovascular 
medications, DM duration and HbA1c level).
360
 This study used a screening device (pulse 
oximetry) rather than polysomnography to diagnose OSA. Additionally, the researchers used 
the proprietary software accompanying the oximetry to analyse the oximetry data and this was 
not confirmed by a sleep physiologist or sleep expert. This suggests that artefacts and other 
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situations such as disconnection might not have been excluded from the analysis implying 
potential issues in the validity of the oximetry analysis.  
 
Another study of 224 diabetic participants by Tahrani and colleagues demonstrated an almost 
three-fold higher risk of diabetic nephropathy in patients with OSA compared to non-OSA 
individuals (OR: 2.64, 95% CI: 1.13 to 6.16) after adjusting for multiple confounders.
348
 In 
addition, they followed-up the individuals for 2.5±0.7 years. At the end of the study, 196 
individuals had complete baseline and follow-up results. Regression analysis performed 
confirmed that OSA was a significant risk factor for study end MDRD eGFR (β=-3.8, p=0.04) 
after adjusting for age, DM duration, ethnicity, BMI, sex, smoking, mean arterial pressure, 
HbA1c, insulin, total cholesterol, triglyceride, lipid-lowering, anti-diabetic, anti-hypertensive 
and anti-platelet medications. Using AHI instead of OSA in the analysis also showed a similar 
finding (β=-4.6, p=0.02). The researchers also did a sensitivity analysis. They replaced the 
lost to follow-up study-end MDRD eGFR values with baseline values; and the results 
remained similar for both OSA (β=-3.89, p=0.02) and AHI (β=-3.45, p=0.04) as an 
independent predictor for MDRD eGFR decline at the end of the study. The cross-sectional 
analyses of the data make it difficult to infer causality. Although the short-term follow-up 
may suggest a potential causal effect, this need to be confirmed in future prospective 
controlled interventional trials.  
 
Our initial analysis did not find any significant differences in the AHI, as well as the 
prevalence and classification of OSA between CKD+ and CKD- individuals. However, after 
adjusting for potential confounders, we found that the AHI was inversely associated with 
eGFR based on the MDRD calculation. This association almost reached statistical 
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significance using the CKD-EPI formula. We postulated that the negative impact of the AHI 
on the glomerular function is mediated through episodic nocturnal intermittent hypoxemia. 
The AHI captures disordered breathing events with and without desaturation. Since this was a 
service evaluation and our local protocol was to evaluate AHI, we do not have data on ODI. 
Although AHI is not a measurement of nocturnal intermittent hypoxaemia, the repetitive long-
term apnoeic and hypopnoeic episodes are significantly correlated with oxygen 
desaturation.
365
 A recent Canadian study on 475 pre-surgical patients with a mean BMI of 
31±7Kg/m
2
 reported a correlation coefficient of 0.886 (95% CI: 0.865 to 0.904) between AHI 
(using an Embletta device) and ODI (using a PULSOX-300i device).
365
 Another small study 
of 38 Mexican reported a correlation coefficient of 0.89 (p<0.05),
366
 whilst a third study of 18 
participants showed a correlation coefficient of 0.78 (p<0.0001) between AHI and ODI.
367
  
 
5.5.2.2 Duration of nocturnal hypoxaemia and DKD  
Apart from the AHI, we also found that the %TST<90% had an inverse impact on the renal 
function of DM patients based on both the MDRD and CKD-EPI formulae. Only a few 
studies have explored the relationship between the %TST<90% and renal function.
363,364,368
 
Unruh and colleagues compared 46 dialysis patients matched with 137 individuals (matched 
for gender, ethnicity, BMI and age) with normal renal function from the SHHS study.
363
 They 
found that the renal patients were 4 times more likely to have nocturnal hypoxemia compared 
to matched individuals (%TST<90 7.2% vs. 1.8%, p<0.0001).
363
 A major limitation for the 
SHHS study is that dialysis patients are frequently volume overloaded and nocturnal rostral 
fluid shift possibly to the pharyngeal area has been shown to worsen OSA in ESRD 
patients.
369
 Furthermore, the SHHS study did not perform further adjustment for any 
cardiovascular confounders.
363
 Another study by Nicholl and colleagues used the CKD-EPI 
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equation to calculate eGFR.
368
 Participants were classified into 3 groups: 55 non-CKD (eGFR 
>60ml/min/1.73m
2
), 124 CKD (eGFR ≤60ml/min/1.73m2); and 75 ESRD patients, who were 
those on RRT. A total of 254 participants were recruited with at least 6 hours of sleep 
recording and 4% ODI ≥15 events/hr were used to diagnose OSA. Sleep analysis was 
performed by a sleep physician blinded on the participant’s renal function. Nocturnal hypoxia, 
defined as %TST<90 ≥12% were demonstrated to be associated with CKD (OR 3.37, 95% CI: 
1.04 to 10.90) after adjusting for age, sex, BMI, neck circumference, congestive cardiac 
failure, CAD, stroke, DM, sedatives, anti-depressants, narcotics and ODI. This study 
consisted of ESRD patients and carried out a sleep study on dialysis-free day representing a 
higher risk of fluid accumulation therefore the issue of rostral fluid shifts remained with the 
potential reverse causation of renal failure leading to longer duration of nocturnal hypoxia.  
 
A recent study by Ahmed and colleagues evaluated the rate of renal decline in 858 
participants in the general population. Two creatinine results were used: a) one year prior to 
the sleep study; and b) at the same time of the sleep study. The MDRD equation was used to 
calculate the eGFR. Accelerated decline in renal function was defined as a rate of decline 
>4ml/min/1.73m
2
 per year. Ahmed and colleagues reported that the %TST<90% of more than 
12% per night increased the risk for accelerated renal decline by threefold (OR 2.89, 95% CI: 
1.25 to 6.67) after adjusting for AHI, age, BMI, DM and heart failure.
364
 The study did not 
report on the duration of the sleep study. Additionally, the three studies above
363,364,368
 
included both DM and non-DM participants. The majority of the participants in the study by 
Ahmed and colleagues were non-DM individuals (80.4%)
364
 while the SHHS only had 14.8% 
of DM participants
363
 and Nicholl et al.
368
 had 37% DM individuals. Therefore, it is difficult 
to generalise to the DM populations. All three studies also did not adjust for hypertension, a 
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well-known risk factor for CKD and well-recognised to be associated with OSA. Long-term 
cohort studies are needed to explore if prolonged exposure to nocturnal hypoxaemia results in 
accelerated progression of DKD.  
 
5.5.2.3 Pathophysiology of OSA and DKD 
Case reports have documented that OSA may cause focal glomerulosclerosis
370,371
 and in one 
case, complete recovery of proteinuria after bi-level positive airway pressure treatment 
despite the patient remaining morbidly obese.
370
 It is therefore unsurprising that our results 
showed that apnoeic and hypopnoeic episodes as well as the duration of nocturnal hypoxemia 
were associated with renal function in diabetic patients. Several factors may explain the 
association between AHI, as well as %TST<90%, and eGFR. It has been shown in animal 
models that prolonged exposure to intermittent hypoxemia results in the activation of the 
renin-angiotensin-aldosterone receptor system (RAAS).
372
 In addition, intermittent awakening 
and sleep fragmentation from OSA activates the sympathetic nervous system leading to 
higher levels of adrenaline and noradrenaline.
136,214,373
 Both the RAAS and elevation in stress 
hormones ultimately cause a rise in BP, which can have an adverse impact on renal function. 
We attempted to correct for these effects by adjusting for hypertension as well as treatment 
with ACE inhibitors and ARB. The results for the association between AHI and %TST<90% 
with eGFR remained significant. This suggests the possibility of other mediators being 
involved such as inflammation and oxidative stress although it is also possible that we might 
not have fully adjusted for the effects of RAAS.   
 
Both OSA and diabetic nephropathy have been shown to be associated with increased 
inflammatory markers such as interleukin-6 (IL-6) and tumour necrosis factor-alpha 
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(TNFα).374-377 These markers are not only associated with cardiovascular disease,378 they also 
have an impact on the renal vasculature through the activation of oxidative stress pathways. 
Reactive oxygen species (ROS) affects the bioavailability of nitric oxide (NO)
379
 causing 
vasoconstriction and reduction in renal blood flow affecting renal function. Vasoconstriction 
also impacts on BP and eventually systemic hypertension develops and exerts further adverse 
effects on the kidneys. Additionally, hypoxaemia from OSA leads to the activation of 
hypoxia-inducible factor-1 (HIF-1)
380
 and nuclear factor-kappa B (NK-кB).381,382 Both the 
HIF-1 and NK-кB control a huge number of processes including the expression for adhesion 
molecules.
383,384
 These adhesion molecules have been shown to cause endothelial dysfunction 
and ultimately atherosclerosis
385
 therefore causing ischaemia to the highly vascular renal 
organ.  
 
Advanced glycation end products (AGEs) are well known to be elevated in DM 
individuals.
386
 Interestingly, individuals with OSA also have elevated AGE levels.
386
 This is 
important because AGE formation has been associated with alterations in the renal 
architecture as well as the decline in renal function.
387,388
 In addition, OSA has also been 
found to up-regulate the protein kinase C (PKC) pathway. PKC is associated with the 
activation of transforming growth factor-beta (TGFβ) that promotes glomerulosclerosis and 
subsequently DKD.
389
 Apart from AGEs and PKC, humoral factors such as leptin may also 
contribute to the deterioration of renal function. It has been found that patients with diabetic 
nephropathy have higher levels of leptin after adjusting for important confounders including 
obesity (waist-hip-ratio),
390
 as do those with OSA.
391
 The combined effect of both OSA and 
DM on inflammation, oxidative stress, AGEs, PKC and the endocrine system however, has 
not been comprehensively examined and may have a synergistic detrimental effect on renal 
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function. On the other hand, as discussed in Chapter 4, it is also plausible that diabetic 
microvascular complications in particular, diabetes neuropathy which can occur alongside 
DKD may lead to the development of OSA.  
 
5.5.2.4 CPAP treatment and DKD  
Only the study by Tahrani and colleagues assessed effect of CPAP on DKD after 2.5±0.7 
years  of follow-up.
348
 A subgroup of 47 (81%) patients with moderate-to-severe OSA were 
treated with CPAP but only 16 were compliant with using more than 4 hours per night for at 
least 70% of the days (34% in total). The authors found that CPAP-treated patients have a 
significantly slower decline in eGFR. The eGFR results reported were as follows: -1.4% (-
7.7% to 5.2%) in non-OSA group vs. -5.3% (16.5% to 2.7%) in mild OSA vs. -7.7% (-15.9% 
to -1.8%) in moderate-to-severe OSA compliant to CPAP treatment vs. -10.0% (-17.2% to 
2.3%) in moderate-to-severe OSA non-compliant to CPAP (p=0.01 for trend). The study has 
several limitations. Apart from a small sample size and has no control group, the researchers 
also did not adjust for important confounders such as reno-protective treatment with ACE 
inhibitors or ARB. The participants who were CPAP-compliant might also be more likely to 
be compliant to other diabetic management such as better dietary adherence, self-monitoring 
of glucose levels and compliant with glucose-lowering, as well as other medications. These 
measures can curtail the progression of renal decline and was not assessed in the study. Due to 
the limited studies available describing the effect of CPAP in DKD, well-designed adequately 
powered RCTs are needed to establish the benefits of CPAP treatment.  
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5.5.3 Limitations and benefits of the study  
There are several limitations in our study. This was a cross-sectional study, which showed a 
significant association between hypoxemia and diabetic nephropathy, but cannot infer 
causality. Additionally, we reported the crude prevalence DKD rate in an extreme obese 
population and it is difficult to compare prevalence rates from other populations due to the 
variations in the populations’ characteristics. Although we adjusted for several important 
confounders, we did not take into account others such as smoking and alcohol status. 
Smoking has been found to be associated with greater progression of nephropathy in DM 
patients compared to non-smoker.
127,392
 Alcohol has been found to have an U shape 
association with DKD in Type 1 diabetes patients.
393
 Therefore, future studies should take 
into account both the effect from smoking and alcohol.  
 
Using validated formulae to calculate estimated GFR are advantageous because it is non-
invasive and inexpensive in comparison with other methods. However, both the MDRD and 
CKD-EPI equations have not been validated in the extremely obese population. Due to the 
nature of this study, which was a part of a service evaluation, more intrusive tests have not 
been carried out. Nevertheless, it is important to point out that all of the renal function tests 
were undertaken by HEFT biochemistry department and calibration of equipment is 
performed regularly. Creatinine results for our study were therefore reliable.  
 
Data on albuminuria was also not included in the study, which may indicate that we missed a 
greater number of patients with diabetic nephropathy. We also did not assess volume status as 
this is difficult to assess accurately based on clinical examination for extremely obese 
 162  
 
individuals. As our population only includes extremely obese individuals, the results should 
be interpreted with caution in the general DM population without extreme obesity. 
 
Our study adjusted for multiple confounders; in particular, we adjusted for drugs affecting the 
RAAS system. A recent systematic review and meta-analysis examined 28 studies with 
134,912 DM participants compared the treatment of using either ACE inhibitor or ARB with 
other anti-hypertensive drugs.
394
 It showed that the RAAS drugs reduced serum creatinine 
with pooled relative risk (RR) of 0.66 (95% CI: 0.52 to 0.83). This suggests that reno-
protective effect of the RAAS drugs is not only on BP-lowering. In fact, the effects of RAAS 
inhibition are likely to be complex as it caused a reduction in GFR initially through 
haemodynamic changes, however, in the long-term, RAAS drugs may protect the kidney 
through restriction of angiotensin activity which is associated with the prevention of renal 
parenchymal injury.
395
 
 
5.6 Conclusion 
This study showed that not only are apnoea and hypopnoea episodes potentially important in 
DKD, the duration of exposure of nocturnal hypoxemia also appears to play a significant role 
in the decline in renal function amongst extreme obese DM patients. Further studies should 
examine the factors mediating the effect of hypoxemia on renal function and the long-term 
impact of nocturnal hypoxemia on the progression on DM nephropathy, as well as the 
treatment of OSA on diabetic nephropathy still warrants further investigation.  
 
 
 
 163  
 
CHAPTER 6 – THE EFFECT OF OBSTRUCTIVE SLEEP APNOEA 
ON DIABETIC RETINAL AND KIDNEY DISEASES: A 
SYSTEMATIC REVIEW AND META-ANALYSIS  
 
6.1 Introduction  
Obstructive sleep apnoea (OSA) is a chronic sleep disorder characterised by recurrent 
complete or partial episodic collapse of the upper airway resulting in chronic intermittent 
nocturnal hypoxemia (CIH), arousal, and sleep fragmentations. OSA is prevalent among 
people with diabetes and has been proposed to alter glycaemic control. A recent meta-analysis 
of cohort studies reported that moderate to severe OSA has a 63% increase in risk for diabetes 
[DM] (RR 1.63, 95% confidence interval [CI]: 1.09 to 2.45).
80
 Additionally, the CIH that 
accompanies OSA results in the activation of oxidative stress and inflammatory pathways 
such as increased advanced glycation end products (AGEs)
386
 that have also been implicated 
in the pathogenesis of diabetes vascular complications.
396
  
 
As illustrated in Chapters 4 and 5, there were inconsistencies in the results for both diabetic 
retinal and kidney diseases.  The differences may be due to methodological variations, such as 
the definition of OSA used, or the population under study, or may be masking small effects 
that are not identified within single studies.  
 
6.2 Aim and objectives 
Due to the inconsistency in the literature, we conducted a systematic review to summarise the 
association between chronic nocturnal hypoxemia caused by OSA and the risk of diabetes 
retinal disease (retinopathy and maculopathy) and diabetic kidney disease (DKD). The 
measures employed to assess OSA can include the apnoea-hypopnoea index (AHI), the 
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oxygen desaturation index (ODI), time spent below 90% oxygen saturations at night 
(%TST<90), mean oxygen saturation, and minimum oxygen saturation. By using the different 
measures to assess OSA, we aimed to further understand the pathophysiological pathways 
mediating the impact of OSA on diabetic retinopathy (DR), diabetic maculopathy and DKD.  
 
 
6.3 Methods 
The systematic review was conducted according to the recommended Preferred Reporting 
Items for Systematic Review and Meta-analysis (PRISMA) statement
397
 and the Meta-
analysis of Observational Studies in Epidemiology (MOOSE) statement.
398
 The protocol is 
registered in Prospero database (registration number was CRD42014008757).  
 
6.3.1 Eligibility criteria 
The full inclusion and exclusion criteria for the systematic review are summarised in Table 6-
1. The review had no language restrictions and the following inclusion criteria were used:  
 
Participants: Adults with either type 1 or type 2 diabetes mellitus (DM) are included. 
Therefore, non DM individuals, children and adolescents with DM, pregnant females, 
gestational DM or DM secondary to other causes such as maturity onset diabetes of the young 
(MODY) and latent autoimmune diabetes of adulthood (LADA) were excluded.  
 
Exposure: DM individuals must have had a diagnosis of obstructive sleep apnoea. The 
diagnosis may or may not have been based on the American Academy of Sleep Medicine 
(AASM) guidance
75
 of using AHI obtained from polysomnography. We also included studies 
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which used oxygen desaturation index (ODI) from pulse oximetry as a diagnostic measure of 
OSA. We excluded studies, which used screening questionnaires such as the Berlin 
questionnaire or Epworth Sleepiness Score as a diagnosis of OSA. Other respiratory 
disorders, which may induce hypoxia or hypoxaemia including central sleep apnoea, heart 
failure, chronic obstructive pulmonary disease or pulmonary fibrosis, were also excluded.  
 
Comparator: People with no OSA were the comparator.  
 
Outcomes: The primary outcome was the risk of development or progression of diabetic 
retinopathy (DR), diabetic maculopathy (DMac) and diabetic kidney disease (DKD). DR has 
been categorised into overall DR and advanced DR. Advanced DR is defined as either pre-
proliferative or proliferative DR. DMac consists of both macular oedema and ischemia. For 
DKD, renal function assessed using either estimated glomerular filtration rate (eGFR), serum 
creatinine or albuminuria, which included both micro- and macro-albuminuria were included. 
Any studies reporting other diabetic eye diseases or eye diseases from other causes such as 
glaucoma, cataract, retinal vein or artery occlusion, were excluded. Furthermore, chronic 
renal failure or nephropathy secondary to causes other than DM was also excluded.  
 
Study design: Only observational studies, which consisted of either cross-sectional, cohort or 
case-control studies, were included. This excluded all intervention studies such as randomised 
controlled trials, non-human studies, experimental studies, case reports, and studies with less 
than 10 participants. Due to the small number of studies available, which examine the 
relationship between OSA and diabetes retinal disease, we also included OSA prevalence 
studies (n=6) if data on diabetes microvascular complications were available.
292,320,399-402
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Table 6-1: Eligibility criteria for the systematic review 
Inclusion criteria Exclusion criteria 
Participants:  
All adults with type 1 or type 2 diabetes 
mellitus (DM) 
 
Children and adolescents (age below 18 years) 
Pregnant females 
Gestational diabetes mellitus 
Maturity onset diabetes of the young 
Latent autoimmune diabetes of adulthood 
No type 1 or type 2 DM 
Exposure:  
Those with obstructive sleep apnoea (OSA) 
or chronic intermittent hypoxemia (CIH) 
 
Hypoxemia secondary to other respiratory 
disorders 
Chronic obstructive pulmonary disease 
Central sleep apnoea 
Heart failure 
Asthma  
Comparator:  
Adults without OSA or CIH 
 
 
Outcomes:  
Diabetic retinopathy (background, pre-
proliferative and proliferative) 
Diabetic maculopathy or diabetic macular 
oedema 
 
Diabetic kidney disease (micro- and macro-
albuminuria and chronic kidney disease 
assessed using glomerular filtration rate) 
 
Retinopathy from non DM causes 
Glaucoma, cataract, retinitis, retinal vein occlusion, 
retinal artery occlusion 
Optic neuritis 
 
Renal impairment secondary to non DM causes 
Study designs:  
Cross sectional study 
Cohort study  
Case series 
 
Non-human studies 
Single case reports 
Sample size < 10 participants 
Randomised controlled trials 
Intervention studies 
Experimental studies 
Systematic reviews/reviews 
Editorials 
Protocol papers 
Letters 
Guidelines/consensus statements 
Language:  
All 
 
None 
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6.3.2 Search strategy  
Both indexed term such as medical subject headings (MeSH) and free text were used to 
capture a wider aspect of the literature. The MeSH terms used for the searches are described 
in Table 6-2. Furthermore, no restriction was applied to any of the database searches. 
Searches were performed from the inception until January 2014 of the following electronic 
databases: MEDLINE, Excerpta Medica DataBase (EMBASE) and Cochrane Central Register 
of Controlled Trials. In addition, OpenGrey and Zetoc were also searched for grey literature 
such as conference abstracts. For OpenGrey, the following free text was used: “obstructive 
sleep apnoea” or “obstructive sleep apnea”. The search term for Zetoc included “obstructive 
sleep apnoea/apnea and diabetes” as well as “apnoea/apnea and diabetes”. Finally, we hand 
searched citations from included papers.  
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Table 6-2: The search terms for MEDLINE, EMBASE and Cochrane Database 
Search terms for diabetic retinopathy 
1. Diabet$.mp. 
2. Respiratory system/ or breathing disorder/ or snoring/ or hypoventilation/ or sleep/ or 
polysomnography/ or sleep apnea syndrome/ or breathing/ or sleep disordered breathing/ or 
sleep disorder/ 
3. Hypoxemia/ or respiratory function disorder/ or anoxia/ or hypoxia/ 
4. Somnolence/ or apnea/ or apnea hypopnea index/ or hypopnea.mp. 
5. 2 or 3 or 4 
6. 1 and 5 
7. Diabetic retinopathy/ or retinopathy/ proliferative retinopathy/ or retinopathy.mp. 
8. Maculopathy.mp. or retina maculopathy/ 
9. Macular edema.mp. or retina macula edema/ 
10. Eye disease.mp. or eye disease/ 
11. 7 or 8 or 9 or 10 
12. 6 and 11 
Search terms for diabetic kidney disease 
1. Diabet$.mp. 
2. Respiratory system/ or breathing disorder/ or snoring/ or hypoventilation/ or sleep/ or 
polysomnography/ or sleep apnea syndrome/ or breathing/ or sleep disordered breathing/ or 
sleep disorder/ 
3. Hypoxemia/ or respiratory function disorder/ or anoxia/ or hypoxia/ 
4. Somnolence/ or apnea/ or apnea hypopnea index/ or hypopnea.mp. 
5. 2 or 3 or 4 
6. 1 and 5 
7. Nephropathy.mp. or kidney disease/ 
8. Albuminuria.mp. or proteinuria/ or albuminuria/ 
9. $albuminuria.mp. 
10. Renal failure.mp. 
11. Kidney function/ 
12. Diabetic nephropathy/ or nephropa$.mp. or chronic kidney failure/ 
13. 7 or 8 or 9 or 10 or 11 or 12 
14. 6 and 13 
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6.3.3 Study selection  
Two authors independently reviewed the titles and abstracts to select eligible studies. This 
was followed by the review of full texts of the eligible studies. This process was 
accomplished independently by two authors again. Disagreements were resolved through 
discussion and if no consensus reached, a third author arbitrated. In cases whereby several 
duplicate or ‘kin’ studies were found, we chose the most recent study with the most complete 
data (especially results on adjusted odds ratios) available. 
 
6.3.4 Data extraction  
Prior to formal data extraction, a standardised form was designed based on the STrengthening 
the Reporting of OBservational studies in Epidemiology (STROBE) statement.
403
 The 
standardised data extraction form was piloted on a sample of five studies and improvements 
were made before formal use. Data extraction was performed by one author and checked by 
other authors. When additional information was missing or needed, authors from the studies 
were contacted for unreported adjusted odds ratios with 95% confidence intervals (CI) or 
frequency data. A sample of the data extraction form is available in the appendix section.  
 
6.3.5 Assessment of the quality of the study 
 A revised quality assessment form to assess the risk of bias for individual studies for both DR 
and DKD studies has been devised based on the Newcastle Ottawa Scale for nonrandomised 
studies in meta-analyses.
404
 The quality of the study was assessed according to five 
components and they were study methods, selection bias, respiratory measurement, blinding 
of the assessor performing DR or sleep analyses and statistical analysis (Table 6-3). Each 
component had a set of criteria and each criterion was rated ‘yes’, ‘no’ or ‘unclear’. An 
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overall judgement was made for each component to assess if the study was either ‘weak’, 
‘moderate’ or ‘strong’. Subsequently, an overall judgement was rated again with either as 
‘weak’, ‘moderate’ or ‘strong’. This is in accordance with the recommendations by the 
Cochrane Collaboration.
405
 This was carried out independently by two reviewers, and any 
discrepancies were resolved by discussion. The form was piloted on known studies and 
necessary modifications were made. A copy of the quality assessment form is available in the 
appendix section.  
Table 6-3: Criteria to assess risk of bias in individual studies 
Selection bias 
1. Does the study address an appropriate and clearly focused question?  
2. Was consecutive patients recruited?  
3. Was the cases and controls taken from comparable populations?  
4. Were the exclusion criteria the same for both cases and controls?  
5. Was the participant representative of the patient population? 
6. If applicable, was the control group comparable to cases (consider suitability, 
recruitment and baseline characteristics)? 
7. Was it clear that controls are not cases (in case control)? 
Overall Judgment for selection bias (Weak / Moderate /Strong) 
Respiratory measurement 
1. Was a suitable measurement for OSA used? (PSG/oximetry measured in standard, 
valid and reliable way) 
2. Was the scoring of the respiratory measures based on guidelines / consensus 
guidelines eg. AASM guidelines?  
3. Was there a clear definition of OSA used?  
Overall Judgment for measurement (Weak / Moderate / Strong) 
Blinding  
1. Blinding of assessor performing sleep analysis 
2. Blinding of assessor of retinal photographs 
Overall Judgment for measurement (Weak / Moderate / Strong) 
Study methods 
1. Were participant attrition rates /missing data documented? 
2. Were reasons given for drop outs / missing data? 
3. Is this retrospective / prospective design?  
Overall Judgment for study design (Weak / Moderate / Strong) 
Analysis  
1. Were all outcomes reported? 
2. Were confounding variables adjusted for? 
Overall Judgment for analysis (Weak / Moderate /Strong) 
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6.3.6 Data synthesis and analysis 
After data extraction and quality assessment, the findings were synthesised and summarised 
according to studies which reported on overall DR, advanced DR, DMac and DKD.  
Statistical analysis was carried out using Stata 13 (StataCorp LP, College station Texas). For 
the review on diabetic retinopathy, we performed meta-analyses on adjusted odd ratios (OR) 
for the effect of OSA on advanced DR, effect of ODI, and the effect of minimum oxygen 
saturation on DR. For the review on DKD, we performed a meta-analysis on studies which 
reported unadjusted OR on the effect of OSA on DKD. We also meta-analysed studies, which 
only reported adjusted ORs to minimise the influence of potential confounders. All meta-
analyses were performed using both random and fixed effects model analyses.  
 
For DR, due to the limited number of studies, no meta-analysis was carried out for mean 
oxygen saturation and %TST<90. Similarly, for DKD, meta-analysis was not performed for 
effect of mean and minimum oxygen saturation as well as percentage of time spent below 
90% oxygen saturation (%TST<90) on DKD because only a limited number of studies were 
available. Funnel plots were utilised to assess publication bias and small study effects for 
meta-analysis which contained >5 studies.  
 
We also carried out kappa statistics for to measure the agreement between the two authors. 
For DR, the kappa statistics were 0.95 (98% agreement, p<0.001) for study selection and 0.79 
(88% agreement, p<0.0001) for quality assessment. For DN, the kappa statistics were 0.71 
(87% agreement, p<0.0001) for study selection and 0.80 (89% agreement, p<0.0004) for 
quality assessment.  
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6.4 Results  
6.4.1 Diabetic retinopathy and maculopathy  
6.4.1.1 Study characteristics 
The initial search identified 851 studies (814 from databases and 37 from grey literature). 
After the removal of duplicates, there were 731 records and 678 were excluded based on title 
and abstract screening. A total of 53 full-text articles were obtained and 37 were excluded. Of 
those excluded, 15 studies were duplicates or ‘kin’ studies, 11 did not have OSA as exposure, 
two studies did not assess DR or DMac as outcomes, one study did not have DM as the 
population, and eight were studies with other study designs. Therefore, 16 studies were 
included in the systematic review (please refer to Figure 6-1 for PRISMA flow chart).  
 
The characteristics of the included studies, study population, methods of assessing OSA and 
the outcome measures used are summarised in Table 6-4. Out of the 16 included studies, four 
were conference abstracts.
406-409
 Only one study was longitudinal,
406
 and the remainder was 
cross-sectional. The majority of the studies were from European countries (10 studies) with 
three studies from Japan, one from India and two studies from the US. There are a total of 
2731 DM participants (2636 with T2DM). Only two studies recruited community DM 
participants.
400,410
 Gender proportions,
292,407,408,411
 mean BMI
406-408,411
 and the mean duration 
of DM
292,406-408
 were not reported in 4 studies while mean age and HbA1c, were not reported 
in 3 studies.
406-408
 The studies included were predominantly males except the study by 
Banerjee et al.
224
 Mean ages for the studies ranged between 43 and 67 years. One study only 
included extreme obese individuals with a mean BMI of 47.3Kg/m
2 224
 whilst the mean BMI 
from other studies ranged from 24.2 to 35.5Kg/m
2
. Mean HbA1c levels and DM duration 
ranged from 6.5% to 9.2% and 7.6 to 23.0 years, respectively.  
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Figure 6-1: PRISMA flow chart on study selection for diabetic retinopathy. 
OSA=obstructive sleep apnoea; DR=diabetic retinopathy; DM=diabetes mellitus; 
sat=saturation; DMac=diabetic maculopathy 
*Other languages=1 study in Russian and 1 study in Czech language 
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Table 6-4: Characteristics and results of included studies for diabetic retinopathy and diabetic maculopathy 
Study ID 
(country) 
Study 
design 
Patients Demographics  OSA 
assessment 
Results 
Storgaard 
2014
ǁ 
(Denmark) 
CS 180 
T2DM 
Setting = Diabetes outpatient 
Mean age = 59 years* 
Females = 42%* 
Mean HbA1c = 7.4%* 
Mean DM duration = 8.2 years* 
Mean BMI = 32.2 Kg/m
2 
* 
Berlin Q then 
Level III sleep 
test 
(ApneaLink) +/- 
Level IV sleep 
test (Embletta)
#
 
Univariate analysis for DR 
- No difference in DR between OSA (26.4%) vs. non-OSA 
(19.4%) (p>0.05) 
- No difference in AHI between DR 17±20 vs. non-DR 
17±25 events/hr (p>0.05) 
 
 
 
Nishimura 
2013
a 
(Japan) 
CS 136 
T2DM  
Setting = Unclear 
Mean age = NA 
Females = NA 
Mean HbA1c = NA 
Mean DM duration = NA 
Mean BMI = NA 
NA Univariate analysis for DR 
- No significant difference in ODI for DR 17.1±15.2 vs. 
non-DR 15.4±14.7 events/hr (p=0.54).  
- No significant difference in AHI for DR 17.8±15.1 vs. 
non-DR 15.2±13.6 events/hr (p=0.33) 
 
Multivariate analysis for DR 
- Association between min O2 sat and DR (OR 0.89, 
95% CI: 0.83 to 0.95). 
Adjusted for HbA1c, DM duration, history of CVD. 
 
Furukawa 
2013 
(Japan) 
CS 513 
T2DM 
Setting = Multicentre diabetes 
outpatients 
Mean age = 62 years 
Females: 43% 
Mean HbA1c = 7.3% 
Mean DM duration = 11.7 years 
Mean BM = 25.2 Kg/m
2 
 
Oximetry 
(PULSOX-3Si)
#
 
Multivariate analysis for DR 
- No association between OSA and DR (OR 1.00, 95% CI: 
0.60 to 1.68)  
Adjusted for age, sex, BMI, hypertension, hyperlipidaemia, 
smoking status, alcohol (regular or not), current 
medications for stroke, ischaemic heart disease, DM 
duration and HbA1c.  
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Banerjee 
2013 
(UK) 
CS 93 T2DM Setting = Specialist weight 
management clinic  
Mean age = 52 years 
Females = 59% 
Mean HbA1c = 8.1% 
Mean DM duration = 7.6 years 
Mean BMI = 47.3 Kg/m
2
 
Level III sleep 
test 
(Embletta)
#
~ 
Multivariate analysis for DR 
- No association between OSA and DR (OR 1.00, 95% CI: 
0.98 to 1.02) 
- No association between min O2 sat and DR (OR 0.93, 
95% CI: 0.67 to 1.02) 
- No association between mean O2 sat and DR (OR 0.93, 
95% CI: 0.86 to 1.01)  
- No association between %TST<90 and DR (OR 1.03, 
95% CI: 1.00 to 0.06) 
- No association between OSA and advanced DR (OR 
1.01, 95% CI: 0.97 to 1.04 – unpublished data) 
Adjusted for age, sex, BMI, ethnicity, DM duration, 
insulin, HbA1c, hypertension and coronary artery disease. 
 
 
Multivariate analysis for DMac 
- No association between OSA and DMac (OR 1.01, 95% 
CI: 0.98 to 1.04) 
- No association between mean O2 sat and DMac (OR 
0.80, 95% CI: 0.59 to 1.07) 
- Association between min O2 sat and Dmac (OR 0.79, 
95% CI: 0.65 to 0.95) 
- No association between %TST<90 and DMac (OR 1.03, 
95% CI: 1.03, 95% CI: 0.99 to 1.08) 
Adjusted for age, sex, BMI, ethnicity, DM duration, 
insulin, HbA1c, hypertension and coronary artery disease. 
 
Altaf 2013
a 
(UK) 
Cohort 199 
T2DM 
Setting = Diabetes outpatient 
Mean age = NA 
Females = 43% 
Mean HbA1c = NA 
Mean DM duration = NA 
Mean BMI = NA 
Level III sleep 
test (Alice 
PDX)
#
~ 
Multivariate analysis for advanced DR 
- Association between OSA and advanced DR (OR 3.90, 
95% CI: 1.02 to 15.30)  
- Followed-up for 4.4 years, OSA independently 
associated with progression of advanced DR (OR 6.60, 
95% CI: 1.20 to 13.10) 
Adjusted for age, gender, ethnicity, BP, HbA1c, total 
cholesterol, triglycerides, diabetes duration, smoking, 
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alcohol, renal function, WC, anti-platelet, anti-diabetes, 
lipid-lowering and anti-hypertensive treatments 
 
Multivariate analysis for DMac 
- Association between OSA and DMac (OR 4.5, 95% 
CI: 1.8 to 11.4) 
- Follow-up 4.4 years, OSA not associated with 
progression of DMac (effect size not reported) 
Adjusted for age, gender, ethnicity, BP, HbA1c, total 
cholesterol, triglycerides, diabetes duration, smoking, 
alcohol, renal function, WC, anti-platelet, anti-diabetes, 
lipid-lowering and anti-hypertensive treatments 
 
Rudrappa 
2012 
(UK) 
CS 31 T2DM Setting = Diabetes outpatient 
Mean age = 55 years 
Females = 0% 
Mean HbA1c = 9.2% 
Mean DM duration = 11.0 years 
Mean BMI = 35.3 Kg/m
2
 
Inpatient PSG 
(Visilab) 
Multivariate analysis  
- Association between total retinopathy scores and OSA 
(p=0.008) 
- No association between OSA and advanced DR (OR 
12.6, 95% CI: 0.62 to 255.76) 
- No association between OSA and DMac (effect size not 
reported) 
Adjusted for potential confounders including novel serum 
biomarkers for diabetic retinopathy and inflammation 
 
 
Mehta 
2012
a 
(India) 
CS 80 T2DM Setting = Outpatient retinal 
clinic 
Mean age = NA 
Females = NA 
Mean HbA1c = NA 
Mean DM duration = NA 
Mean BMI = NA 
 
 
Inpatient PSG Multivariate analysis for DR 
- No association between OSA and DR (effect size not 
reported) 
Did not report on factors adjusted 
Mason 
2012  
CS 80 T2DM 
with 
Setting = Macular oedema 
outpatient  
Level IV sleep 
testing 
Univariate analysis for DR 
- No associated between OSA and DR (p=0.32) 
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(UK) macular 
oedema 
Mean age = 65 years 
Females = 50% 
Mean HbA1c = 7.8% 
Mean DM duration = 15.0 years  
Mean BMI = 30.2 Kg/m
2
 
(Apnealink)
ǂ
~  
Univariate analysis for DMac 
- No association between macular thickness and AHI  
- No association between macular thickness and %TST<90 
- No dose response association between severity of ODI 
and macular thickness 
 
 
Kosseifi 
2012
ǁ 
(US) 
CS 98 T2DM Setting = Outpatient sleep clinic 
Mean age = 61  
Females = NA 
Mean HbA1c = 6.5% 
Mean DM duration = NA 
Mean BM = 33.7 Kg/m
2
 
Level III sleep 
test (NovaSom 
QSG) 
Univariate analysis for DR 
- AHI in DR group (44.2) higher than non-DR group 
(22.7) (p<0.05) 
 
 
 
West 2010 
(UK) 
CS 118 
T2DM 
Setting = 1 diabetes outpatient 
and 5 primary care centers 
Mean age = 67 years* 
Females = 0% 
Mean HbA1c = 8.0%* 
Mean DM duration = 10.0 
years* 
Mean BMI = 30.2 Kg/m
2
* 
Oximetry and in 
some level III 
sleep test 
(Embletta)~ 
Multivariate analysis  
- Retinopathy scores associated with OSA (r
2
=0.19, 
p<0.0001) 
- OSA associated with DMac (r
2
=0.30, p<0.0001) 
Did not report on factors adjusted 
 
 
 
 
 
Shiba 2010 
(Japan) 
CS 219 
T2DM 
Setting = Hospital inpatient (eye 
disease) 
Mean age = 63 years* 
Females = 43% 
Mean HbA1c = 7.3% 
Mean DM duration = 11.5 years 
Mean BMI = 24.2 Kg/m
2
 
Oximetry 
(PMP-200G) 
Multivariate analysis for advanced DR 
- Association between advanced DR with 
neovascularisation and OSA (OR 1.09, 95% CI: 1.01 to 
1.16) 
Adjusted for insulin treatment, ODI, DM duration, sex, 
mean oxygen saturation and %TST<90 
 
 
- Association between min O2 sat and advanced DR 
(OR 0.93, 95% CI: 0.88 to 0.99) 
Adjusted for age, HbA1c, hypertension, ODI and %TST<90 
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- No association between %TST<90 and advanced DR 
(effect size not reported) 
 
- No difference in mean O2 sat between OSA (97.6%±1.2) 
and non-OSA (97.3%±1.5) (p=0.14) 
 
Schober 
2010
ǁ 
(Germany) 
CS 58 T1DM 
& 
498 
T2DM 
Setting = 14 primary care 
centres 
Mean age = 60 years 
Females = 48% 
Mean HbA1c = 7.6% 
Mean DM duration = 9.3 years 
Mean BMI = 31.9 Kg/m
2
 
Level IV sleep 
test 
(ApneaLink)
ǂ
~ 
Univariate analysis for DR 
- No difference in DR between OSA (13.9%) vs. non-OSA 
(11.5%) (p=0.45) 
 
 
 
 
 
Borel 2010
ǁ 
(France) 
CS 37 T1DM Setting = Diabetes outpatient 
Mean age = 43 years 
Females = 32% 
Mean HbA1c = 7.8% 
Mean DM Duration = 23.0 years 
Mean BMI = 24.7 Kg/m
2
 
Oximetry Univariate analysis for DR 
- Significant difference in DR between pathological 
recording (73.3%) vs. borderline recording (11.1%) 
(p<0.05) 
 
 
 
 
Unver 2009 
(US) 
CS 44 DM Setting = Outpatient retinal 
clinic 
Mean age = 60 years* 
Females = NA 
Mean HbA1c = 7.5%* 
Mean DM duration = 16.3 
years* 
Mean BMI = NA 
 NA Univariate analysis for DR 
- Significant difference between DR and OSA (OR 
143.18, 95% CI: 7.41 to 2767.79) 
- 10 eyes had pan-retinal photocoagulation in OSA 
group vs. 1 in non-OSA group  
 
Univariate analysis for DMac 
- Association between OSA and DMac (OR 14.44, 95% 
CI; 2.34 to 147.60) 
- 7 OSA patients had laser treatment for macular edema 
and most worsened after treatment with some needing ≥2 
treatment. 9 non-OSA patients had laser treatment for 
macular oedema and majority resolved without further 
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progression 
 
 
Laaban 
2009
ǁ 
(France) 
CS 303 
T2DM 
Setting = Hospital inpatient 
(DM)  
Mean age = 61 years 
Females = 49% 
Mean HbA1c = 9.2% 
Mean DM duration = 14.5 years 
Mean BMI = 32.0 Kg/m
2
 
Level IV sleep 
test (CID 102)~ 
Univariate analysis for DR 
- Significant association between OSA and DR (OR 
0.56, 95% CI: 0.35 to 0.92) 
 
 
 
 
 
 
 
 
Merritt 
2007
a 
(UK) 
CS 44 T2DM Setting = Diabetes outpatient 
Mean age = 61 years 
Females = 32% 
Mean HbA1c = 8.0%* 
Mean DM Duration = 16.5 
years* 
Mean BMI = 30.4 Kg/m
2
* 
Oximetry 
(Minolta 
300i®)
 
Univariate analysis for advanced DR 
- No significant difference in ODI between advanced DR 
(15.4±14.7) vs. non-advanced DR (17.1±15.2) (p=0.54) 
- Significant difference in %TST>90% between 
advanced DR (12.6%±19.7) and non-advanced DR 
(1.8%±2.6) (p=0.03) 
 
CS = cross-sectional study, NA = information not available, HbA1c = glycosylated haemoglobin A1c, BMI = body mass index, T1DM = Type 1 diabetes 
mellitus, T2DM = Type 2 diabetes mellitus, OSA = obstructive sleep apnoea, PSG = polysomnography, Berlin Q = Berlin questionnaire, AHI = apnoea-
hypopnoea index, ODI = oxygen desaturation index, O2 = oxygen saturation, %TST<90 = percentage time spent under 90% oxygen saturation. DR = 
diabetic retinopathy, DMac = diabetic maculopathy, OR = odds ratio, 95% CI = 95% confidence intervals. Bolded texts indicate significant results. 
#
Minimum 4 hours recording; 
$
Veteran study with low female participants; *Average values of the 2 groups; 
a 
Conference abstracts; 
ǁ 
Prevalence studies 
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6.4.1.2 Respiratory methodology and OSA diagnosis  
Only two studies carried out an in-hospital overnight sleep study.
407,412
 Six studies conducted 
portable home sleep studies
224,292,320,400,401,406
 while four studies used pulse 
oximetry.
360,399,409,413
 Of those that utilised portable sleep studies, 3 studies used a level III 
device with data on respiratory effort, air flow, oxygen saturation and heart rate; 3 studies 
used a level IV device with no data on respiratory effort. Two studies used a mixed method: 
one utilised oximetry followed by a portable sleep study in a subset the participants
410
 and 
another study identified at risk individuals using the Berlin questionnaire followed by a 
portable sleep study.
402
 Two studies did not report on the equipment used for OSA 
assessment
408,411
 as shown in Table 6-4.  
 
There was a high level of heterogeneity in the sleep studies and diagnosis of OSA (Table 6-5). 
Of the 14 studies using either a pulse oximetry, an overnight sleep device or a mixed 
method,
224,320,360,399-402,406,407,409,410,412-414
 ten studies
224,320,360,399-401,406,409,410,413
 provided 
information on the definitions of apnoea, hypopnoea or oxygen desaturation. Of those 10 
studies, only 2 studies were in line with the AASM criteria.
224,406
 AASM guidelines
75
 define 
apnoea as complete cessation of airflow for at least 10 seconds whilst hypopnoea as at least 
30% reduction in airflow for at least 10 seconds accompanied by at least a 4% oxygen 
desaturation. One study
400
 defined apnoea as at least 80% reduction in airflow for at least 10 
seconds and hypopnoea as 50-80% reduction in airflow for at least 10 seconds with a 4% 
oxygen desaturation. Another study
401
 that carried out sleep study using a Level IV device 
defined apnoea as an increased variation in suprasternal pressure with no airflow for at least 
10 seconds. Two studies defined hypopnoea as a 50% reduction in airflow accompanied by 
≥4% oxygen desaturation for ≥10 seconds.320,401 Five studies performed pulse oximetry; one 
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study used 3% desaturation
360
 while the other 4 studies used 4% oxygen 
desaturation
320,409,410,413
 as the cut-point. 
 
Based on the AASM guidelines,
75
 an AHI of ≥5 events/hr is diagnostic of OSA. Mild, 
moderate and severe OSA are defined as AHI between 5.0 and 14.9 events/hr, between 15.0 
and 29.9 events/hr and >30.0 events/hr, respectively.
75
 The definition for OSA diagnosis was 
available in 10 studies.
224,320,360,400-402,406,410,412,413
 Of the six studies which used AHI to 
diagnose OSA, four used an AHI cut-point of ≥5 events/hr401,402,406,412 while 2 used AHI ≥15 
events/hr.
224,400
 In addition, Storgaard and co-workers defined OSA as AHI ≥5 events/hr with 
the presence of sleep symptoms.
402
 Two studies used an ODI cut point of ≥5 events/hr360,413 
and another study utilised ODI ≥10 events/hr as OSA diagnosis.410 Mason et al. defined OSA 
using both ODI ≥10 events/hr and AHI ≥15 events/hr.320 The remainder of the studies (n=6) 
did not report on the criterion used for OSA diagnosis.
292,399,407-409,411
  
 
6.4.1.3 Definition of diabetic retinopathy 
As for the diagnosis of DR, the 4 studies from the UK used information from the English 
National Screening Program for Diabetic Retinopahty (ENSDPR).
224,406,410,412
 The study by 
West et al. (UK study) had two independent trained ophthalmology graders to review the 
digital retinal photographs of all the participants.
410
 Merritt et al.,
409
 Storgaard et al.,
402
 and 
Mason et al.
320
 also performed digital retinal photography. In addition, Mason et al.
320
 
measured macula thickness using dual laser spectral-domain optical coherence tomography 
and had an ophthalmologist with a special interest in the retina to interpret the data. Furukawa 
et al.
360
 carried out florescence fundoscopy performed by ophthalmology specialists in all the 
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participants. Two studies obtained information on DR from medical records.
407,413
 The 
remaining six studies did not quote their source for the diagnosis of DR.
292,399-401,408,411
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Table 6-5: Criteria used for the diagnosis of obstructive sleep apnoea and diabetic retinopathy assessment as reported by the included studies  
Study  Definition of apnoea/hypopnoea or oxygen desaturation 
(OD)  
OSA diagnosis Min 
recording  
DR assessment 
Storgaard 2014 NA AHI ≥5 events/hr with 
sleep symptoms 
4 hours Digital photograph  
Nishimura 2013 NA NA NA NA 
Furukawa 2013 OD ≥3% ODI 3% ≥5 events/hr 4 hours Florescence 
fundoscopy  
Banerjee 2013 AASM criteria* AHI ≥15 events/hr 4 hours Digital photograph 
Altaf 2013 AASM criteria* AHI ≥5 events/hr 4 hours Digital photograph 
Rudrappa 2012 NA AHI ≥5 events/hr NA Digital photograph 
Mehta 2012 NA NA NA Medical records 
Mason 2012 Apnoea = complete cessation in airflow ≥10 seconds; hypopnoea 
= 50% reduction in airflow with ≥4% desaturations for ≥10 
seconds; and OD ≥4% 
ODI 4% ≥10 events/hr 
and AHI ≥15 events/hr 
NA Digital photograph + 
spectral domain 
optical coherence 
tomography  
Kosseifi 2012 NA NA NA NA 
West 2010 OD ≥4% ODI 4% ≥10 events/hr NA Digital photograph 
Shiba 2010 OD ≥4% ODI 4% ≥5 events/hr Mean ≥6 hr Medical records 
Schober 2010 Apnoea = 80% reduction in airflow ≥10 seconds; hypopnoea = 
50-80% reduction in airflow with ≥4% desaturations for 
≥10seconds 
AHI ≥15 events/hr NA NA 
Borel 2010 Normal = no oxygen fluctuations; borderline = ‘oxygen 
saturation fluctuations limited in amplitude / appeared during 
limited periods of time; pathological = fluctuations in oxygen 
desaturation and re-saturation  
Normal vs. borderline 
vs. pathological 
NA NA 
Unver 2009 NA NA NA NA 
Laaban 2009 Apnoea = increased variation in suprasternal pressure with no 
airflow for ≥10 seconds; Hypopnoea = ≥50% reduction in 
airflow with ≥4% desaturation for ≥10 seconds 
AHI ≥5 events/hr NA NA 
Merritt 2007 OD ≥4%  NA NA Digital photograph 
OD = oxygen desaturation, min = minimum, OSA = obstructive sleep apnoea, hr = hour, NA = not available, *AASM = American Academy of Sleep 
Medicine criteria: apnoea = complete cessation of airflow for ≥10 seconds; hypopnoea = ≥30% reduction in airflow ≥4% drop in oxygen desaturation 
for ≥10 seconds. 
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6.4.1.4 Quality assessment for studies on diabetic retinopathy  
Table 6-6 summarises the quality assessment for the 16 studies. The overall quality of the 
studies were low-to-moderate (n=14). Only two studies were rated as high quality. The 
majority of studies were rated as either moderate or high for study methods (n=11). Selection 
bias was an issue in the majority of the studies (n=10 rated as low). Methods of recording 
sleep data were not presented in several studies (n=7 were weak), in particular, the criterion 
used for the diagnosis of OSA was poorly described. Only two studies blinded the sleep 
record assessor, while seven studies blinded the DR assessment.  
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Table 6-6: Quality assessment of included studies for diabetic retinopathy 
  Components  
Study  Selection bias Methods and 
measurement 
Blinding Study design Analysis  Overall 
Storgaard 2014 Weak Moderate Weak Strong Weak Weak 
Nishimura 2013 Moderate Weak Weak Moderate Moderate Moderate 
Furukawa 2013 Weak Moderate Moderate Weak Strong Weak 
Banerjee 2013 Strong Strong Strong Moderate Strong Strong 
Altaf 2013 Weak Strong Weak Weak Moderate Moderate 
Rudrappa 2012 Weak Weak Moderate Strong Moderate Moderate 
Mehta 2012 Weak Weak Weak Moderate Moderate Weak 
Mason 2012 Weak Moderate Moderate Strong  Weak Moderate 
Kosseifi 2012 Weak Weak Weak Moderate Weak Weak 
West 2010 Moderate Moderate Strong Strong Strong Strong 
Shiba 2010 Moderate Moderate Moderate Weak Strong Moderate 
Schober 2010 Weak Moderate Weak Strong Weak Weak 
Borel 2010 Weak Weak Weak Moderate Weak Weak 
Unver 2009 Moderate Weak Weak Weak Weak Weak 
Laaban 2009 Moderate Strong Moderate Moderate Weak Moderate 
Merritt 2007 Weak Weak Moderate Weak Weak Weak 
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6.4.1.5 The association between OSA and DR 
The results from the studies are detailed in Table 6-4 and the overall summary of the 
results for all outcomes is presented in Table 6-7. Eight studies (n=1134) reported on the 
effect of OSA on overall DR;
224,320,400-402,407,411,414
 six studies carried out univariate 
analysis
320,400-402,411,414
 and two studies performed multivariate regression analysis.
224,407
 
The majority of studies, which carried out univariate analysis, were prevalence 
studies.
292,320,399-401
 Schober and colleagues recruited 715 diabetic participants in 
Germany.
400
 However, 217 participants (30%) were excluded due to issues with sleep 
recording and missing data. Therefore, only 556 (51 T1DM and 498 T2DM) participants’ 
data were analysed. Apart from the high attrition rate, the portable sleep study (Apnealink) 
performed was missing data on respiratory effort and the researchers used a minimum of 2 
hours recording instead of the commonly used 4 hours sleep recording. The diagnosis of 
apnoea and hypopnoea were also not in line with AASM. OSA was diagnosed if AHI was 
≥15 events/hr. DR was present in 13.9% of OSA individuals and 11.3% in non-OSA 
participants (p=0.45). Mason et al.
320
 also used the Apnealink device (no effort data) on 
their participants. The minimum sleep recording time was not reported and the participants 
were recruited from the Oxford Eye Hospital (Oxford, UK) database. All participants had 
had laser treatment for macular oedema.  Of a total of 208 possible participants, 80 were 
recruited. No significant difference in DR between OSA and non-OSA groups was found 
(p=0.32).  
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Table 6-7: Summary of the results categorised according to diabetic retinopathy outcomes 
 Overall Diabetic retinopathy (DR) Retinopathy score / Advanced DR Diabetic maculopathy 
OSA  
(based on 
AHI) 
8 studies (n=1134) 
Adjusted: (+) 0 studies; (-) 2 studies 
  
Unadjusted : (+) 2 studies; (-) 4 studies 
Pooled OR not calculated^ 
(I
2
=79%)  
(5 studies, see Figure 6-2)  
Retinopathy score (2 studies, n=149) 
Adjusted: (+) 2 studies; (-) 0 studies 
 
Advanced DR (4 studies, n=367) 
Adjusted: (+) 1 study; (-) 2 studies 
Pooled OR (2 studies – see Figure 
6-7) 
1.05, 95% CI: 0.95 to 1.16, I
2
= 
73.2% 
 
Unadjusted: (+) 1 study; (-) 0 studies 
 
6 studies (n=565) 
Adjusted: (+) 1 study; (-) 1 study 
 Pooled OR not calculated^ 
(I
2
=90%)  
(2 studies, see Figure 6-8) 
 
Unadjusted : (+) 2 studies; (-) 4studies 
OSA  
(based on 
ODI) 
5 studies (n=949) 
Adjusted: (+) 1 study; (-) 1 study 
Pooled OR (2 studies – see Figure 
6-4) 
1.09. 95% CI: 1.02 to 1.17 I
2
= 
0.0% 
 
Pooled OR (4 studies, combined 
AHI & ODI as OSA diagnosis – 
see Figure 6-5) 
1.05, 95% CI: 0.95 to 1.16, I
2
= 
65.9% 
 
 
Unadjusted: (+) 1 study; (-) 2 studies 
 
 
 
 
 1 study (n=80) 
Adjusted: (+) 0 study; (-) 1 study 
 
Unadjusted: (+) 0 study; (-) 1 study 
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%TST<90 3 studies (n=356) 
Adjusted: (+) 0 study; (-) 2 studies 
 
Unadjusted: (+) 1 study; (-) 0 study 
 2 studies (n=173) 
Adjusted: (+) 0 study; (-) 1 study 
 
Unadjusted: (+) 0 study; (-) 1 study 
 
Mean O2 2 studies (n=312) 
Adjusted: (+) 0 study; (-) 1 study 
 
Unadjusted: (+) 0 study; (-) 1 study 
 
 1 study (n=93) 
Adjusted: (+) 1 study; (-) 0 study 
OR 0.80, 95% CI: 0.59 to 1.07 
 
Unadjusted:  no data 
 
Minimum O2 3 studies (n=448) 
Adjusted: (+) 2 studies; (-) 1 study 
Pooled OR  (3 studies – Figure 6-
6): 
 0.91, 0.87 to 0.95, I
2
=0% 
 
Unadjusted: no data 
 
 1 study (n=93) 
Adjusted: (+) 1 study;(-) 0 study 
OR 0.79, 95% CI: 0.65 to 0.95 
 
Unadjusted:  no data 
(+): reported significant association; (-): reported no significant associations; shaded cells indicate that no study reported data for the exposure-outcome 
combination. DR = diabetic retinopathy; OSA = obstructive sleep apnoea; AHI = apnoea-hypopnea index; ODI = oxygen desaturation index; O2 = 
oxygen saturation, n = total number of participants 
^Due to high level of heterogeneity    
*Only one study provided quantitative data 
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A prevalence study from Denmark recruited 180 T2DM participants.
402
 The patients were 
first screened using the Berlin questionnaire and high-risk individuals were investigated 
using ApneaLink device with a minimum of 4 hour respiratory recording. A subset of 
participants had confirmatory portable sleep study using an Embletta device. No significant 
difference in DR was found between OSA (26.4%) and non-OSA (19.4%) individuals 
(p>0.05). Furthermore, the AHI was similar in DR (17±20 events/hr, n=74) compared to 
non-DR (17±25 events/hr, n=25) individuals. Another European study by Laaban and 
colleagues
401
 recruited poorly controlled French T2DM inpatients over a 6-month period. 
An overnight sleep study was performed and diagnosis of OSA was in accordance with 
AASM guidelines. However, the minimum required sleep recording for analysis was not 
reported. Out of a total of 362 participants, 191 had OSA. Sixty-six per-cent of non-OSA 
had DR compared to 48% with mild OSA, 53% with moderate OSA and 68% in the severe 
OSA group. No statistical significant difference was found between non-OSA group and 
mild, moderate as well as severe OSA group (p>0.05). Overall, 52% of OSA individuals 
had DR.  
 
A U.S. veteran study recruited 98 well-controlled T2DM (HbA1c<6.5%) with OSA.
292
 All 
participants underwent three consecutive overnight sleep studies. Neither the minimum 
sleep recording time nor the criteria used for OSA diagnosis was reported. Also, the 
criteria used for the diagnosis of OSA were not reported. The study demonstrated a higher 
mean AHI in OSA participants (44.2 events/hr) with DR compared to those without DR 
(AHI 27.2 events/hr, p<0.05). Another U.S. study was conducted on 22 obese individuals 
with OSA matched with 22 obese T2DM for age, weight and duration of DM.
411
 The 
participants were recruited consecutively from a retinal referral practice. The methods used 
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for sleep study and the diagnosis of OSA were not reported. The study found that all OSA 
individuals had DR with multiple nerve-fibre-layer infarcts compared with 14 participants 
in the non-OSA group (unadjusted RR 4.4, 95% CI: 2.04 to 9.51). Also, fluorescein 
angiography was performed and OSA participants were more likely to have widespread 
areas of capillary non-perfusion compared to non-OSA individuals (effect size not 
reported).  
 
Mehta and co-workers
407
 observed 80 T2DM patients presented to their eye clinic in India. 
They performed in-hospital sleep study. Fifty DR individuals were compared to 30 non-
DR participants. Greater risk of OSA was observed in DR group compared to non-DR 
group (OR 2.91, 95% CI: 1.14 to 7.42). However, this did not remain significant after 
adjustment for confounders, although the confounders examined were not detailed. In 
addition, the study did not report the minimum sleep recording time as well as the criteria 
used for OSA diagnosis.  
 
Banerjee and co-workers
224
 reported on consecutive participants from the specialist weight 
management clinic in Birmingham, UK. Portable sleep studies were carried out as part of 
routine patient assessment. The AASM guidelines were followed for sleep analysis. OSA 
was diagnosed if AHI was ≥15 events/hr. At least 4 hours of sleep recording were available 
for all participants. A total of 93 individuals’ sleep data was analysed after excluding 
participants with incomplete data. No significant association was reported in the 
unadjusted and adjusted regression models. The final model, which was adjusted for age, 
gender, ethnicity, DM duration, insulin treatment, hypertension, HbA1c and coronary artery 
disease, reported OR 1.00 (95% CI: 0.98 to 1.02). However, the researchers could not 
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adjust for smoking, a potential important factor. The study also only included an extreme 
obese population, which is difficult to generalise to the wider populations.  
 
6.4.1.5.1 The association between OSA and DR: summary and meta-analysis 
Overall, the majority of the studies, which carried out univariate analysis, did not report 
any significant association between OSA and DR (n=4). Only two studies from the 
U.S.
292,411
 demonstrated significant associations. However, these were unadjusted models 
and therefore exposed to multiple confounders such as gender and BMI. Two studies, 
which performed multivariate regression analysis, reported no significant association 
between OSA and DR. A meta-analysis was performed on six studies
224,400-402,407,411
 that 
reported on the effect of OSA on overall DR in unadjusted models. Due to a significant 
level of heterogeneity (I
2
=79%), pooled results were not presented as the results may be 
misleading. We, however, presented a forest plot of the reported ORs on all seven six as 
shown in Figure 6-2. A funnel plot was also carried out as shown in Figure 6-3. The funnel 
plot suggests an imbalance in small sample studies with negative results. Therefore, 
overall, there was no convincing evidence that OSA is associated with DR in T2DM 
populations. No study had examined the association between OSA and DR in T1DM. 
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Figure 6-2: Forest plot on studies which reported unadjusted odds ratios and 95% confidence 
intervals on the effect of obstructive sleep apnoea on overall diabetic retinopathy.  
 
 
Figure 6-3: Funnel plot on studies which reported effect of obstructive sleep apnoea on overall 
diabetic retinopathy. 
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6.4.1.6 The association between oxygen desaturation index and diabetic retinopathy  
Five studies (n=949) utilised oximetry to assess the effect on DR. A French study recruited 
T1DM (n=37) and participants were classified into normal, borderline and pathological 
recording groups.
399
 Normal recording was defined as no oxygen fluctuations; borderline 
was defined as ‘oxygen saturation fluctuations were limited in amplitude or appeared 
during limited periods of time’; and pathological was defined as fluctuations in oxygen 
desaturation and re-oxygenation.
399
 Minimum sleep recording was not reported. Of those 
with pathological recordings, 73% had DR compared to 11% in borderline group and 33% 
in normal oximetry group. Comparing the three groups, significant difference was only 
detected between pathological and borderline groups (p<0.05) and no difference was found 
between pathological and the normal recording groups.  
 
Merritt and colleagues
409
 reported a significant difference in ODI between those with 
advanced DR (mean 13.6 events/hr) and those without advanced DR (mean 3.8 events/hr, 
p=0.03). Merritt and co-workers recruited overweight and obese participants from the UK 
with T2DM diagnosed >5 years. Overnight oximetry recording was carried out. No 
information was available for the minimum required sleep recording and no regression 
analysis was performed. 
 
A Japanese study that recruited consecutive T2DM who had had a sleep study did not 
observe any significant difference in AHI for DR and non DR participants.
408
 They 
excluded participants with heart failure, chronic pulmonary disease and those on 
haemodialysis; therefore 136 participants’ data were analysed. The researchers did not 
report on the methods used for sleep study as well as the minimum sleep recording time. 
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No significant difference in ODI (17.1 events/hr vs. 15.4 events/hr, p=0.544) as well as 
AHI (17.8 events/hr vs. 15.1 events/hr, p=0.325) between DR and non-DR participants was 
reported.  
 
Similarly, another multi-centred Japanese study (513 T2DM) also did not observe 
significant association between ODI and DR.
360
 All the participants had a minimum of 4 
hours sleep recording. OSA was diagnosed when 3% ODI occurred at least 5 times per 
hour. Both univariate and multivariate (OR 1.00, 95% CI: 0.60 to 1.68) regression analyses 
were not significant. Factors adjusted for in the multivariate analysis were age, gender, 
BMI, hypertension, hyperlipidaemia, smoking and alcohol status, medications for stroke 
and heart disease, DM duration and HbA1c levels. The researchers, however, did not adjust 
for the usage of any DM medications especially insulin treatment.  
 
Another Japanese study by Shiba et al.
413
 recruited consecutive 219 T2DM Japanese 
inpatients who underwent eye surgery (cataract, glaucoma, retinal detachment or vitreous 
surgery) in a single centre. Sixty-eight had non-proliferative-DR (NPDR) and 151 had 
proliferative-DR (PDR). Pulse oximetry was utilised and OSA was diagnosed if 4% ODI 
>5 events/hr was present. The mean sleep recording time was at least 6 hours. No 
significant associations were found between OSA and PDR with multivariate logistic 
regression analysis (effect size not reported). Factors adjusted for included age, HbA1c, 
hypertension, 4% ODI, minimum oxygen saturation and % time spent under 90% oxygen 
saturation.  
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However, in a subgroup analysis of 151 PDR individuals, 37 had iris and/or angle 
neovascularisation whilst 114 did not;
415
 the researchers demonstrated a significant 
association between ODI and neovascularisation group (OR 1.09, 95% CI: 1.01 to 1.16) 
after adjusting for confounders (gender, DM duration, insulin treatment, mean oxygen 
saturation, 4%ODI, minimum oxygen saturation and percentage time spent under 90% 
oxygen saturation). Important factors such as age, BMI and smoking status were not 
included in the regression model.  
 
6.4.1.6.1 The association between oxygen desaturation index and diabetic retinopathy: 
summary and meta-analysis 
In summary, one study consists of T1DM
399
 and another study in a T2DM population
415
 
reported  significant associations between ODI and DR. We undertook a meta-analysis on 
the two studies,
360,415
 which reported on the adjusted ORs of the effect of OSA diagnosed 
using ODI criteria on DR. The results showed a significant association (pooled-OR 1.09, 
95% CI: 1.02 to 1.17, I
2
=0.0%, Figure 6-4). However, the majority of the analytical weight 
was derived from the study by Shiba and colleagues
415
 (97%). To address this that, we 
combined the studies that reported adjusted ORs using either AHI
224,406
 or ODI
360,413
 as 
criteria for OSA diagnosis. The result became non-significant (pooled-OR 1.05, 95% CI: 
0.95 to 1.16) with a significant level of heterogeneity (I
2
=65.9%, Figure 6-5). Therefore, 
the evidence on the effect of ODI on DR was inconclusive in T2DM, and there was 
insufficient evidence of the effect in T1DM as only one study was available.
399
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Figure 6-4: Forest plot on the effects of obstructive sleep apnoea diagnosed using oxygen 
desaturation index on diabetic retinopathy using results from studies which reported adjusted odds 
ratios only.  
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Figure 6-5: Forest plot on the effects of obstructive sleep apnoea diagnosed using oxygen 
desaturation index or apnoea-hypopnoea index on diabetic retinopathy using results from studies 
which reported adjusted odds ratios only.  
6.4.1.7 The association between diabetic retinopathy and other respiratory parameters 
Apart from ODI and AHI, sleep studies also recorded % time spent under 90% oxygen 
saturation (%TST<90), mean and minimum oxygen saturation levels. Only four studies 
reported the effect of these sleep parameters on DR.
224,408,409,413
 However, not all the 
studies reported on all these three parameters. Two studies (n=312) reported on the effect 
of mean oxygen saturation.
224,415
 Banerjee et al.
224
 found no association between mean 
oxygen saturation using a multivariate logistic regression (OR 0.83, 95% CI: 0.67 to 1.02) 
nor did Shiba et al.
413
 who performed univariate analyses between advanced DR 
(97.3%±1.5) and non-advanced DR group (97.6%±1.2, p=0.14).   
 
Three studies (n=356) reported results on %TST<90.
224,409,413
 Merritt and colleagues
409
 
found a significant difference between advanced DR and non-advanced DR (mean 
%TST<90 12.6% vs. 1.8%, p=0.03). Two studies, which carried out regression analysis, 
did not find any significant association after adjusting for potential confounders,
224,413
 with 
only one study reported the effect size  (OR 1.03, 95% CI: 1.00 to 1.06).
224
 The factors 
adjusted in the respective models were described above.  
 
In total, three studies (n=448) examined the effect of minimum oxygen saturation on DR 
using multivariate regression analysis.
224,408,413
 Banerjee et al.
224
 reported no association 
(OR 0.93, 95% CI: 0.67 to 1.02). On the other hand, Nishimura et al. adjusting for HbA1c 
levels, DM duration and cardiovascular disease demonstrated significant association 
between minimum oxygen saturation and DR (OR 0.89, 95% CI: 0.83 to 0.95).
408
 Shiba et 
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al. also found significant results between minimum oxygen saturation and advanced DR 
(OR 0.93, 95% CI: 0.88 to 0.99).
413
  
 
6.4.1.7.1 The association between diabetic retinopathy and other respiratory parameters: 
summary and meta-analysis 
A meta-analysis was also performed on the effect of minimum oxygen saturation on DR 
using multivariate regression analysis. The result was significant with low level of 
heterogeneity (pooled-OR 0.91, 95% CI: 0.87 to 0.95, I
2
=0.0%) as shown in Figure 6-6. In 
summary, there was no evidence that mean oxygen saturation or %TST<90 were 
associated with DR. However, there was evidence from both our narrative synthesis and 
meta-analysis that minimum oxygen saturation had an impact on DR. Due to the limited 
available studies which reported on the effects of minimum oxygen saturation on DR, 
publication bias may be present.  
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Figure 6-6: Forest plot on the pooled estimates of the effect of minimum oxygen saturation on 
diabetic retinopathy using results from studies which reported adjusted odds ratios only. 
 
 
6.4.1.8 The association between OSA and retinopathy scores/advanced DR 
Five studies examined the association between OSA and retinopathy scores including 
advanced DR.
224,406,410-412
 To recap, advanced DR is defined as pre-proliferative or 
proliferative DR. Two studies
410,412
 (n=149) reported a significant association between 
OSA and total retinopathy scores through multivariate regression analysis in males (both 
studies only recruited males) while four studies
224,293,406,411
 (n=367) examined the 
relationship between OSA and advanced DR. West and co-workers
410
 carried out overnight 
oximetry studies on 118 men. Information on minimum required sleep recording and the 
criteria used for diagnosis of OSA were not described. The retinopathy scores explained 
19% of OSA variance (r
2
=0.19, p<0.0001) in a multivariate-linear regression analysis.  
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Rudrappa and colleagues
412
 performed overnight in-hospital sleep studies on 31 T2DM 
obese males, and OSA was diagnosed if AHI was ≥5 events/hr. In a multiple regression 
analysis, OSA was found to be a risk factor for retinopathy scores (p=0.008). Rudrappa 
also reported a significantly higher prevalence of advanced DR cases (n=4) in the OSA 
group compared to the non-OSA (n=0) group. However, in an unadjusted model, no 
significant association was found between OSA and advanced DR (OR 12.6, 95% CI: 0.62 
to 255.76). The study is clearly underpowered thus the observations should be treated with 
caution. Banerjee et al.
224
 also did not demonstrate any significant association in their 
univariate and multivariate analyses (unpublished data - OR 1.01, 95% CI: 0.97 to 1.04).  
 
On the other hand, Unver and colleagues
411
 described a difference in advanced DR 
between OSA and non-OSA individuals. They found that 10 of the eyes of the participants 
with OSA needed pan-retinal photocoagulation for proliferative-DR compared to one 
individual in the matched non-OSA group. Furthermore, the OSA participants who had 
photocoagulation, neovascularisation of vessels persisted despite treatment compared with 
resolution in non-OSA group. In addition, a UK study carried out by Altaf et al.
406
 on 
T2DM reported that OSA was a risk factor for advanced DR (OR 3.9, 95% CI: 1.02 to 
15.3) using multivariate regression analysis. The factors adjusted in the model were age, 
gender, ethnicity, smoking, alcohol, waist circumference, blood pressure, HbA1c, DM 
duration, total cholesterol, triglycerides, renal function, anti-platelets agents, lipid lowering 
agents and medications for DM and hypertension. Participants had overnight portable sleep 
monitoring performed, diagnosis of OSA was in accordance with AASM criteria and the 
minimum period of sleep recording was 4 hours. An AHI ≥5 events/hr was considered 
diagnostic of OSA.  
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Moreover, Altaf and co-workers
406
 followed-up their participants for 4.4±1 years and 
found that OSA participants were more likely to progress from no or background DR status 
to advanced DR state (15%) compared to non-OSA participants (3%, p=0.01). They also 
reported that OSA predicted the development of advanced DR (OR 6.6, 95% CI: 1.2 to 
35.1, p=0.03) after adjusting for confounders (age, gender, ethnicity, smoking, alcohol, 
waist circumference, blood pressure, HbA1c, DM duration, total cholesterol, triglycerides, 
renal function, anti-platelets, anti-diabetes, lipid lowering and anti-hypertensive 
treatments).   
 
6.4.1.8.1 The association between OSA and retinopathy scores/advanced DR: summary 
and meta-analysis 
A meta-analysis on three studies
224,406,415
 that reported on adjusted ORs for advanced DR 
(one study used ODI as OSA diagnosis
415
), the pooled estimates did not show a significant 
association between advanced DR and OSA (pooled-OR 1.05, 95% CI: 0.95 to 1.16) with a 
significant level of heterogeneity (I
2
=73.2%, Figure 6-7). In conclusion, from our narrative 
review, there was some evidence that OSA was associated with greater severity of DR as 
well as advanced DR amongst T2DM populations. The meta-analysis performed for the 
cross-sectional studies, however, did not support this notion. However, a significant level 
of heterogeneity as well as a small number of studies mean that the pooled results may not 
be reliable and needed to be interpreted with caution. No study has explored the 
association between OSA and severity of DR as well as advanced DR in T1DM 
populations.  
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Figure 6-7: Forest plot on the effects of obstructive sleep apnoea on advanced diabetic retinopathy 
using results from studies which reported adjusted odds ratios only.  
 
 
 
6.4.1.9 Association between diabetic maculopathy (DMac) and other respiratory 
parameters 
Limited studies have explored the impact of OSA and DMac (n=949).
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 Mason et al.
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obese non-OSA group, only nine had macular oedema without evidence of capillary non-
perfusion (unadjusted OR 14.44, 95% CI: 2.34 to 147.60). In addition, seven of the 
participants in the OSA required laser treatments for macular oedema and the majority of 
the participants' oedema worsened with greater leakage and infarcts despite laser treatment. 
In the non-OSA group, nine participants required laser treatment and the majority (n=8) 
resolved without further progression. 
 
Three studies (n=410) carried out multivariate regression analysis.
224,406,410
 Banerjee et 
al.
224
 did not observed that AHI was a risk factor for DMac (OR 1.01, 95% CI: 0.98 to 
1.04). In contrast, West et al.
410
 reported that OSA explained 30% of the variance of DMac 
(p<0.0001). The final study by Altaf et al.
406
 found that OSA (AHI ≥5 events/hr) was 
significantly associated with DMac (OR 4.5, 95% CI: 1.8 to 11.4, p=0.002). However, 
after 4 years of follow-up, OSA was not found to be a risk factor for the development of 
DMac (effect size not reported). A meta-analysis was performed for the two studies
224,406
 
which reported adjusted odd ratios. There was a significant level of heterogeneity 
(I
2
=90.1%) therefore, pooled estimates were not presented (Figure 6-8). 
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Figure 6-8: Forest plot on studies which reported adjusted odds ratios on the effect of obstructive 
sleep apnoea on diabetic maculopathy. 
 
Two studies (n=173) examined the effect of %TST<90 on DMac.
224,320
 Mason et al.
320
 
performed univariate analysis and did not find any significant relationship between macula 
thickness with %TST<90 (effect size not reported). Similarly, Banerjee et al. reported no 
association between %TST<90 and DMac (OR 1.03, 95% CI: 0.99 to 1.08) in their 
regression model. In addition, Banerjee and co-workers also reported non-significant 
findings on the effect of mean oxygen saturation on DMac (OR 0.80, 95% CI: 0.59 to 
1.07). However, minimum oxygen saturation was observed to be an independent predictor 
of DMac (OR 0.79, 95% CI: 0.65 to 0.95). Only the study by Mason and colleagues 
examined the effect of ODI on DMac and this was found to be non-significant (effect size 
not reported). In conclusion, there was some evidence that OSA appeared to be associated 
with DMac. However, there was insufficient evidence to draw conclusions on the effect of 
mean oxygen saturation, %TST<90, minimum oxygen saturation and ODI on DMac.  
 
Altaf 2013
Banerjee 2013
ID
Study
4.50 (1.80, 11.40)
1.01 (0.98, 1.04)
OR (95% CI)
  1.0877 11.4
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6.4.2 Diabetic kidney disease 
6.4.2.1 Study characteristics 
Our initial searches identified a total of 1163 studies (1129 from databases and 34 from 
grey literature). After excluding obvious duplicates, there were 1062 studies and 1030 were 
subsequently removed after title and abstract screening. Thirty-two full text articles were 
retrieved and 9 studies were included in our narrative synthesis. We excluded 23 articles 
because of the following: ten studies did not include DM populations, nine were duplicate 
studies, two did not include participants with OSA, one study did not have DKD as an 
outcome and one study was a review article. Figure 6-9 showed the PRISMA flow chart 
for study selection.  
 
The majority of the studies had a cross-sectional study design except the study by Tahrani 
and colleagues
348
 which included a follow-up component.  Most studies were from 
European countries (6 studies), two studies from Japan and one from the US. There were a 
total of 2920 DM participants (2862 T2DM) across all studies. The mean age of 
participants ranged from 51 to 62 years and proportion for females ranged from 33% to 
73%. The study by Kosseifi and co-workers
414
 did not report on gender distribution but it 
described US veterans therefore consisted of a high proportion of males. The mean HbA1c 
and DM duration ranged between 6.5 and 9.2% and between 7.5 and 14.5 years, 
respectively. One study only included extreme obese individuals with a mean BMI of 
46.8Kg/m
2
.
225
 The remainder of the studies mean BMI ranged from 25.2 to 33.7Kg/m
2
.  
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Figure 6-9: PRISMA flow chart on study selection for diabetic kidney disease. 
OSA = obstructive sleep apnoea; DKD = diabetes kidney disease; DM = diabetes mellitus; ODI = 
oxygen desaturation index 
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Full-text articles assessed 
for eligibility  
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Review   (n=1) 
 
 
 
Studies included in 
qualitative synthesis 
(n=9) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
 
OSA and DKD  (n=7) 
ODI and DKD   (n=2) 
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Table 6-8: Characteristics and results of included studies for systemic review on diabetic kidney diseases 
Study ID 
(country) 
Study 
design 
Participants Demographics OSA assessment Results  
Buyukaydin 
2012 
(Turkey) 
CS 52 T2DM Setting = Diabetes clinic 
Mean age = 56 years 
Females = 73% 
Mean HbA1c = 7.9% 
Mean DM Duration = 12.8 years 
Mean BMI = 32.4 Kg/m
2
 
Inpatient PSG 
(Compumedics E 
3142)  
Univariate analysis 
- No difference in albuminuria between OSA 
(21.9%) and non-OSA (29.4%) groups. 
- No difference in AHI between micro-
albuminuria 9.0±14.6 vs. no micro-albuminuria 
10.5±10.0 events/hr (p>0.05) 
 
Furukawa 
2013 (Japan) 
CS 513 T2DM Setting = Multi-centre diabetes 
clinics 
Mean age = 62 years 
Females = 43% 
Mean HbA1c = 7.3% 
Mean DM Duration = 11.7 years 
Mean BMI = 25.2 Kg/m
2
 
Oximetry 
(PULSOX-3Si) 
#
 
Multivariate analysis 
- Association between ODI and micro-
albuminuria (OR 1.84, 95% CI: 1.16 to 2.96) 
- Association between ODI and macro-
albuminuria (OR 2.97, 95% CI: 1.36 to 6.90) 
Adjusted for age, sex, BMI, hypertension, 
hyperlipidemia, smoking, alcohol, medications 
for stroke and IHD, duration of DM and HbA1c 
 
Kosseifi 
2012
ǁ 
(US) 
CS 98 T2DM Setting = Sleep clinic 
Mean age = 61 years 
Females = NA
$
 
Mean HbA1c = 6.5% 
Mean DM Duration = NA 
Mean BMI = 33.7 Kg/m
2
 
Level III sleep test 
(NovaSom QSG) 
Univariate analysis  
- No difference in AHI between micro-
albuminuria 33.5 vs. no micro-albuminuria 28.0 
events/hr (p>0.05) 
- Significant difference in oxygen saturation 
in micro-albuminuria 73.0% vs. no micro-
albuminuria 77.4% (p<0.01) 
 
Laaban 
2009
ǁ 
(France) 
CS 303 T2DM Setting = Hospital inpatient 
Mean age = 61 years 
Females = 49% 
Mean HbA1c = 9.2% 
Mean DM Duration = 14.5 years 
Mean BMI = 32.0 Kg/m
2
 
Level IV sleep test 
(CID 102)
 ǂ
~ 
Univariate analysis  
- No difference in albuminuria between groups: 
non-OSA (25%), mild OSA (34%), moderate 
OSA (38%) or severe OSA (39%). 
- Association between OSA and albuminuria 
(unadjusted OR 1.70, 95% CI: 1.01 to 2.85). 
 
 208  
 
 
Leong 2014 
(UK) 
CS 90 T2DM Setting = Specialist weight 
management clinic 
Mean age = 51 years 
Females = 57% 
Mean HbA1c = 8.3% 
Mean DM Duration = 7.5 years 
Mean BMI = 46.8 Kg/m
2
 
Level III sleep test 
(Embletta) 
#
~ 
Multivariate analysis (linear regression) 
- Association between AHI and MDRD 
eGFR(β=-0.17, 95% CI: -0.32 to -0.02). 
- Association between %TST<90 and MDRD 
eGFR (β=-0.22 to 95% CI: -0.41 to -0.02). 
- No association between mean O2 and MDRD 
eGFR (β=1.91, 95% CI: -0.04 to 2.42). 
- No association between minimum O2 and 
MDRD eGFR (β=0.05, 95% CI: -0.39 to 0.50) 
 
- No association between AHI and CKD-EPI 
eGFR (β=-0.19, 95% CI: -0.39 to 0.01) 
- Association between %TST<90 and CKD-
EPI eGFR (β=-0.30, 95% CI: -0.56 to -0.03) 
- No association between minimum O2 and 
CKD-EPI (β=0.16, 95% CI: -0.44 to 0.76) 
- No association between mean O2 and CKD-
EPI (β=1.50, 95% CI: -0.21 to 3.22) 
Adjusted for age, gender, BMI, hypertension, 
IHD, DM duration, insulin treatment, RAS 
treatment. 
 
Schober 
2010
ǁ 
(Germany) 
CS 58 T1DM & 
498 T2DM 
Setting = 14 primary care 
centres 
Mean age = 60 years 
Females = 48% 
Mean HbA1c = 7.6% 
Mean DM Duration = 9.3 years 
Mean BMI = 31.9 Kg/m
2
 
Level IV sleep test 
(ApneaLink) 
ǂ
~ 
Univariate analysis 
- Significant difference between groups: 
AHI<5/hr 13 patients, AHI 5-14/hr 46 
patients, AHI≥15/hr 42 patients (p=0.001). 
- No association between OSA (AHI ≥15/hr) 
and nephropathy (unadjusted OR 1.24, 95% CI: 
0.80 to 1.92). 
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Storgaard 
2014
ǁ 
(Denmark) 
CS 180 T2DM Setting = Diabetes clinic 
Mean age = 59 years* 
Females = 42% 
Mean HbA1c = 7.4%* 
Mean DM Duration = 8.2 years* 
Mean BMI = 32.2 Kg/m
2
* 
 
Berlin Q and 
ApneaLink +/- 
level III sleep test 
(Embletta)
 #
 
Univariate analysis 
- No association between OSA and albuminuria 
(OR 1.38, 95% CI: 0.76 to 2.53). 
Tahrani 
2013 (UK) 
Cohort 224 T2DM Setting = 2 diabetes clinics 
Mean age = 57 years* 
Females = 42% 
Mean HbA1c = 8.2%* 
Mean DM Duration = 10.0 
years* 
Mean BMI = 33.5 Kg/m
2
* 
Level III sleep test 
(Alice PDX)
 #
~ 
Multivariate analysis  
- Association between OSA and nephropathy 
(OR 2.64, 95% CI: 1.13 to 6.16) 
- No association between minimum O2 and 
nephropathy (OR 0.96, 95% CI: 0.93 to 1.00). 
Adjusted for age, sex, ethnicity, DM duration, 
BMI, mean arterial pressure, HbA1c, 
triglycerides, insulin, GLP-1, anti-hypertensive, 
total cholesterol, high-density-lipoprotein 
cholesterol, lipid-lowering treatment, anti-
platelets, oral DM agents, alcohol and smoking 
 
- After 2.5 years follow-up: linear regression 
showed OSA predict study end MDRD eGFR 
(β=-3.8, p=0.04) and AHI associated with 
study end MDRD eGFR (β=-4.6, p=0.02).  
Adjusted for age, DM duration, ethnicity, sex, 
BMI, mean arterial pressure, anti-hypertensive 
agent, HbA1c, insulin, oral DM agents, total 
cholesterol, lipid lowering treatment, antiplatelet 
agents and smoking. 
- No association between minimum O2 and 
study end eGFR (effect size not reported) 
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Tanaka 
2009
a ǁ 
(Japan) 
CS 904 T2DM Setting = Multi-centre diabetes 
clinics  
Mean age = 62 years* 
Females = 33% 
Mean HbA1c = 6.9% 
Mean DM Duration = 10.3 
years* 
Mean BMI = 25.3 Kg/m
2 
 
Oximetry  Multivariate analysis 
- Association between OSA and creatinine 
(OR 2.37, 95% CI: 1.21 to 4.65) 
 
NA=information not available, HbA1c=glycosylated haemoglobin A1c, DM=Diabetes mellitus, BMI=body mass index, CS = cross-sectional study, 
T1DM=Type 1 diabetes mellitus, T2DM=Type 2 diabetes mellitus, OSA=obstructive sleep apnoea, PSG=polysomnography, ODI=oxygen desaturation 
index, AHI=apnoea-hypopnoea index, O2=oxygen saturation, eGFR=estimated glomerular filtration rate, MDRD=modification of Diet in Renal 
Disease, CKD-EPI=chronic kidney disease Epidemiology Collaboration, IHD=ischemic heart disease, RAS=renin-angiotensin system, GLP-
1=glucagon-like peptide-1 
ǂ
PSG data did not have data on effort; 
#
Minimum 4 hours recording; 
$
Veteran study with low female participants; *Average values from 2 groups; 
a 
Conference abstracts; 
ǁ 
Prevalence studies; ~Portable home sleep study  
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6.4.2.2 Respiratory methodologies and OSA diagnosis 
Most of the studies used a 3-channeled ambulatory sleep device (oximetry, air-flow and 
respiratory effort) to assess OSA
225,348,414
 while one performed full polysomnography 
(PSG) with cardiovascular and neurological channels in addition to the 3 respiratory 
channels.
359
 Two studies used a device without data on respiratory effort to diagnose OSA 
(a two-channelled device).
400,401
 One study used a mixed method:
402
 the Berlin 
questionnaire was used to screen participants and high-risk individuals were offer a 2 
channel portable device (pulse oximetry and air-flow using ApneaLink device). A subset 
of the participants also had a 3 channel device (Embletta) sleep study. Finally, two studies 
utilised pulse oximetry for sleep assessment.
360,416
 The characteristics of the studies are 
summarised in Table 6-8.  
 
A small degree of heterogeneity was present for the definition of apnoea and hypopnoea. 
Four studies utilised the AASM criteria for apnoea and hypopnoea.
225,348,359,401
 One study 
which utilised a 2 channel device
400
 defined apnoea as an 80% reduction in airflow for at 
least 10 seconds and hypopnoea as a 50-80% reduction in airflow with a 4% oxygen 
desaturation for more than 10 seconds. Two studies
360,416
 which used pulse oximetry 
employed a 3% drop in oxygen saturation for oxygen desaturation, whilst the other two 
studies
402,414
 did not describe the definition. For diagnosis of OSA, four studies utilised an 
AHI ≥5 events/hr as the diagnosis criterion225,348,359,401 and one study employed AHI ≥15 
events/hr.
400
 Two studies used 3%ODI ≥5 events/hr360,416 whilst the remaining two studies 
did not report on the criteria used to diagnose the condition.
402,414
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Table 6-9: Criteria used for the diagnosis of obstructive sleep apnoea and diabetic kidney disease assessment as reported by the included studies  
Study  Definition of apnoea/hypopnoea or 
oxygen desaturation (OD)  
OSA diagnosis Min 
recording  
DKD test DKD diagnosis  
Buyukaydin 
2012 
AASM criteria* AHI≥5 events/hr NA 24 hour urine 
albumin 
Albuminuria ≥ 30mg/day 
Furukawa 
2013  
OD ≥3% ODI≥5 events/hr 4 hours Early morning urine 
ACR 
Micro-albuminuria 
≥3.4mg/mmol 
Macro-albuminuria ≥ 34.0 
mg/mmol 
Kosseifi 2012 NA NA NA NA Micro-albuminuria 
Laaban 2009 Apnoea =  increased variation in 
suprasternal pressure with no airflow for 
≥10 seconds; hypopnoea = ≥50% 
reduction in airflow with ≥4% 
desaturation for ≥ 10 seconds 
AHI≥5 events/hr NA 24 hour urine 
albumin 
Micro-albuminuria ≥ 30mg/day 
Leong 2014  AASM criteria* AHI≥5 events/hr 4 hours eGFR  eGFR <60min/ml/1.73m2 based 
on MDRD and CKD-EPI 
equations 
Schober 2010 Apnoea = 80% reduction in airflow ≥ 10 
seconds; hypopnoea = 50-80% reduction 
in airflow with ≥ 4% desaturations for ≥ 
10 seconds 
AHI≥15 events/hr NA NA NA 
Storgaard 
2014 
NA AHI≥5 events/hr 4 hours 24 hour urine 
albumin  
Micro-albuminuria 30-300 
mg/day 
Macro-albuminuria > 300mg/day  
(2 out of 3 samples 
Tahrani 2013 AASM criteria* AHI≥5 events/hr 4 hours eGFR & 
urine ACR 
MDRD eGFR 
<60min/ml/1.73m
2 
ACR >3.4 mg/mmol 
Tanaka 2009 OD ≥3% ODI≥5 events/hr NA Creatinine (mg/dl) NA 
OD = oxygen desaturation, min = minimum, OSA = obstructive sleep apnoea, hr = hour, NA = not available, DKD = diabetic kidney disease, eGFR = 
estimated glomerular filtration rate, MDRD = Modification of Diet in Renal Disease, CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration, 
ACR = albumin-creatinine ratio.*AASM = American Academy of Sleep Medicine criteria: apnoea = complete cessation of airflow for ≥10 seconds; 
hypopnoea = ≥30% reduction in airflow ≥4% drop in oxygen desaturation for ≥10 seconds.  
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6.4.2.3 Definition for diabetic kidney disease 
As expected, there were variations in the diagnoses of DKD. Three studies reported 24 
hour urinary albumin results and diagnosed micro-albuminuria as a urine albumin 
concentration of >30mg/day.
359,401,402
  One Japanese study utilised early morning urine 
ACR and diagnosed micro-albuminuria as an ACR>3.4mg/mmol creatinine with macro-
albuminuria as an ACR >34mg/mmol creatinine.
360
  The veteran study reported on micro-
albuminuria but did not describe the diagnosis criteria.
414
 Tahrani and colleagues reported 
on both urinary ACR and eGFR results.
348
 Micro-albuminuria was diagnosed as an ACR 
>3.4mg/mmol with macro-albuminuria ≥30mg/mmol. Estimated GFR was calculated 
based on the Modification of Diet in Renal Disease (MDRD) equation. DKD was 
diagnosed as either presence of micro- or macro-albuminuria or eGFR <60ml/min/1.73m
2
. 
Leong et al.
225
 only used eGFR and this was calculated using the MDRD and the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) formulae. DKD was defined as 
an eGFR <60ml/min/1.73m
2
. Schober and co-workers
400
 used the term ‘nephropathy’ but 
did not report on the test or criteria used to diagnose DKD. Finally, Tanaka and 
colleagues
416
 utilised serum creatinine levels (mg/dl) as a continuous variable. Please refer 
to Table 6-9 for further details.  
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Table 6-10: Summary of the results for diabetic kidney disease 
 Diabetic kidney disease 
OSA  
(based on AHI) 
7 studies (n=1503)  
Adjusted: (+) 2 studies; (-) 0 studies 
  
Unadjusted : (+) 1 studies; (-) 4 studies 
Pooled OR (6 studies – see Figure  6-10) 
1.56. 95% CI: 1.11 to 2.21 I
2
= 37.3% 
 
OSA  
(based on ODI) 
2 studies (n=1317)  
Adjusted: (+) 2 study; (-) 0 studies 
Pooled OR (2 studies – see Figure 6-12) 
2.00. 95% CI: 1.36 to 2.94 I
2
= 0.0% 
 
Pooled OR (3 studies, combined AHI & ODI as OSA diagnosis – 
see Figure 6-13) 
2.10, 95% CI: 1.48 to 2.97, I
2
= 0.0% 
 
Unadjusted: No data 
 
%TST<90 1 study (n=90) 
Adjusted: (+) 1 study; (-) 0 study 
 
Unadjusted: No data 
 
Mean O2 1 study (n=90) 
Adjusted: (+) 0 study; (-) 1 study 
 
Unadjusted: No data 
 
Minimum O2 3 studies (n=491) 
Adjusted: (+) 0 study; (-) 2 studies 
 
Unadjusted: (+) 1 study; (-) 0 study  
 
(+): reported significant association; (-): reported no significant associations; shaded cells indicate 
that no study reported data for the exposure-outcome combination. DR = diabetic retinopathy; OSA 
= obstructive sleep apnoea; AHI = apnoea-hypopnoea index; ODI = oxygen desaturation index; 
%TST<90 = percentage time spent under 90% oxygen saturation; O2 = oxygen saturation, n = total 
number of participants 
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6.4.2.4 Quality assessment 
The quality of the studies was summarised in Table 6-11. Overall, the studies were of 
moderate quality (n=4).
360,400,401,416
 Only 2 studies were rated high quality
225,348
 and 3 were 
of low quality.
359,402,414
 Majority of the studies were at risk of selection bias with six 
studies being rated as weak.
348,359,360,400,402,414
 This was because several studies did not 
perform consecutive participant recruitment nor did they report if the study populations 
were representative of the local patient populations. In addition, only one study performed 
respiratory scoring with an assessor blinded of the participants clinical characteristics.
225
 
Several studies were rated at least moderate for methods of sleep assessment (n=7) in 
particular, many studies did not perform sleep analysis according to the AASM 
recommendations.
225,348,359,360,400,401,416
 The majority of the studies scored reasonably well 
for study methods (n=6) as reasons were provided for any excluded or missing 
data.
225,348,360,400,401,414
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Table 6-11: Quality assessment of included studies for diabetic kidney disease 
  Components  
Study  Selection bias Methods and 
measurement 
Blinding Study design Analysis  Overall 
Buyukaydin 2012 Weak  Strong Weak Weak Weak Weak 
Furukawa 2013 Weak Moderate  Weak Weak Strong Weak 
Kosseifi  2012 Weak Weak Weak Moderate Weak Weak 
Laaban 2009 Moderate Strong Weak Moderate Weak Moderate 
Leong 2014 Strong Strong Strong Moderate Strong Strong 
Schober 2010 Weak Moderate Weak Strong Weak Weak 
Storgaard 2014 Weak Moderate Weak Strong Weak Weak 
Tahrani 2013 Weak Strong Weak Strong Strong Strong 
Tanaka 2009 Moderate Moderate Weak Weak Strong Moderate 
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6.4.2.5 Association between OSA and DKD 
The results from the studies are detailed in Table 6-8 and the overall summary of the 
results for all outcomes is presented in Table 6-10. A total of seven 
studies
225,348,359,361,402,414,417
 (n=1503) examined the effect of OSA on DKD. Five studies 
(n-1189) performed only univariate analysis,
359,400-402,414
 four of which demonstrated no 
significant associations, although the direction of effect for all but one study was of higher 
risk of DKD among patients who have OSA.
359,401,402,414
 Buyukaydin and colleagues
359
 
recruited 52 Turkish T2DM participants from their clinic. Full inpatient PSG was 
performed and the respiratory recording was scored according to AASM criteria.
75
 
Minimum duration of sleep recording was described. Twenty-four hour urinary albumin 
excretion was used to assess DKD. The researchers did not find any significant correlation 
between urine albumin excretion and AHI (r=0.91, p=0.362) nor any significant difference 
in albuminuria between OSA and non-OSA group (OR 0.67, 95% CI: 0.15 to 3.31). 
Similarly, a French study recruited 303 poorly-controlled T2DM inpatients over a 6 month 
period showed no significant difference in micro-albuminuria based on 24 hour urinary 
albumin excretion results between those with no OSA (25%) compared to those with mild 
(34%), moderate (38%) or severe OSA (39%).
401
 Comparing OSA and non-OSA 
individuals made no difference to the result (OR 1.70, 95% CI: 0.98 to 2.97). OSA was 
diagnosed using a level IV sleep device with no data on effort nor any information on 
minimum sleep recording.  
 
A Danish study
402
 recruited 183 participants who were first screened using the Berlin 
questionnaire. High risk individuals were invited for a portable home study using a two-
channel sleep device with minimum of 4 hours respiratory recording. OSA was diagnosed 
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when AHI ≥5 events/hr was present alongside sleep symptoms. Again, 24 hour urine 
albumin excretion was used for the diagnosis of DKD. There were no significant difference 
in micro-albuminuria between OSA (36%) and non-OSA (28%) individuals (p>0.05). 
Likewise, no significant difference in macro-albuminuria was found between the two 
groups (10% vs. 9%, p=0.2). A U.S. veteran study on 98 OSA individuals with well-
controlled T2DM (HbA1c<6.5%) who also suffered with OSA observed a non-significant 
difference in the AHI between those with micro-albuminuria (28.0 events/hr) and those 
without micro-albuminuria (33.5 events/hr, p>0.05).
414
 Participants were predominantly 
males and had a level III device sleep test carried out for three consecutively nights. 
Neither the minimum sleep recording nor criteria used for albuminuria were reported.  
 
Only one study demonstrated a significant difference in diabetic nephropathy between 
OSA and non-OSA individuals.
400
 The study was designed as a prevalence study and was 
sponsored by a pharmaceutical company which provided support on data collection and 
analysis. Although 715 DM participants were recruited from 14 primary care centres in 
Germany, 217 participants was excluded (30%) due to missing sleep or participants’ data. 
Therefore a total of 556 eligible participants (58 T1DM and 498 T2DM). A 2-channel 
ambulatory sleep study was performed with no data on respiratory effort making it difficult 
to distinguish obstructive from central sleep apnoea. In addition, the study adopted a 
minimum of 2 hours sleep recording and not the commonly used 4 hours. On top of that, 
the researchers utilised a conservative AHI ≥15 events/hr as the diagnosis of OSA. Method 
used for the diagnosis of nephropathy was not reported. A significant difference (p=0.001) 
in nephropathy between those without AHI <5evernts/hr (n=13), AHI between 5-14 
events/hr (n=46) and AHI ≥15 events/hr (n=42) was recorded. However, when an AHI ≥15 
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events/hr was used (as per the German study’s definition of OSA), the difference was no 
longer significant (OR 1.24, 95% CI: 0.78 to 1.97).  
 
Univariate and multivariate analyses were carried out by two UK-based studies.
225,348
 
Leong et al. recruited consecutive extremely obese individuals with T2DM from our 
specialist weight management clinic.
225
 Estimated GFR was calculated using MDRD and 
CKD-EPI formulae. Sleep study was performed using a level III sleep device and 
recording were scored by sleep physiologists and confirmed by a sleep physician blinded 
of the renal results. Scoring was done according to the AASM recommendations with a 
minimum of 4 hours sleep recording. Multivariate linear regression analysis demonstrated 
a linear association between AHI and MDRD eGFR results (β=-0.170, 95% CI: -0.316 to -
0.024). However, this was not confirmed using the CKD-EPI formula (β=-0.19, 95% CI: -
0.39 to 0.01). Factors adjusted included age, gender, BMI, hypertension, coronary artery 
disease, DM duration, insulin treatment and drugs for renin-angiotensin-aldosterone 
system.  
 
Tahrani and colleagues
348
 conducted a cohort study on 224 T2DM participants. DKD was 
assessed using both early morning urine ACR (>3.4 mg/mmol) and eGFR 
(<60ml/min/1.73m
2
). MDRD equation was used to calculate eGFR. OSA assessment was 
carried out using a level III device. Analysis of sleep study was performed in accordance 
with the AASM guidelines with at least 4-hour sleep recording. Results demonstrated that 
OSA was an independent predictor for DKD (adjusted OR 2.64, 95% CI: 1.13 to 6.16) 
after adjusted for age, sex, ethnicity, BMI, DM duration, smoking and alcohol status, mean 
arterial pressure (MAP), HbA1c, triglycerides, total cholesterol, high-density-lipoprotein 
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(HDL) cholesterol, insulin, hypoglycaemic agents, anti-hypertensive, lipid lowering agent. 
Moreover, 196 participants were followed-up for 2.5±0.7 years and linear regression 
analysis confirmed that OSA was associated with study-end eGFR result (β=-3.8, p=0.04) 
after adjusting for age, sex, ethnicity, smoking, BMI, DM duration, MAP, total cholesterol, 
triglycerides, anti-hypertensive and lipid lowering agents, HbA1c, insulin and oral diabetes 
medications, antiplatelet agents and baseline eGFR. Substituting OSA with AHI revealed 
similar results (β=-4.6, p=0.02). As for albuminuria, 163 participants’ data were available. 
Excluding 107 who had albuminuria at baseline, a non-significant difference was found 
between OSA (22.6%) and non-OSA (13.3%, p=0.23) group. Combining eGFR and 
albuminuria for the diagnosis of DKD, 169 patients had follow-up results and 76 patients’ 
data were excluded due to known DKD at baseline; 23.1% OSA participants compared to 
12.2% non-OSA participants developed DKD (p=0.18).  
 
A meta-analysis was carried out for six studies which reported unadjusted ORs on the 
effect of OSA on DKD.
225,348,359,400-402
 The pooled estimates showed a small, but 
significant association, with higher risk of DKD in those who have OSA (pooled OR 1.56, 
95% CI: 1.11 to 2.21, I
2
=37.3%, Figure 6-10). Funnel plot of these studies suggest an 
imbalance of small studies with positive results (Figure 6-11). 
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Figure 6-10: Forest plot on the effects of obstructive sleep apnoea on diabetic kidney disease using 
results from studies which reported unadjusted odds.  
 
 
Figure 6-11: Funnel plot on studies which reported unadjusted odds ratios on the effect of 
obstructive sleep apnoea on diabetic kidney disease. 
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6.4.2.5.1 Association between OSA and DKD: summary  
In summary, although there was no significant association between DKD and OSA in 
studies that used only the univariate analysis, pooling of these studies suggests that there is 
a significant association. The studies that did undertake multivariate analysis, and the one 
study which followed up patients longitudinally, all showed that patients with DM who 
have OSA had a higher risk of DKD.  
 
6.4.2.6 Association between DKD and other respiratory parameters 
Two studies (n=1317) from Japan utilised drop in oxygen levels during sleep (3%ODI ≥5 
events/hr) as the diagnostic criterion for OSA.
360,416
 Both reported a significant association 
between ODI and DKD. The Dogo Study was a multi-centre study consisted of 513 
Japanese T2DM.
360
 All participants had overnight pulse oximetry, data was analysed using 
a proprietary software with a minimum of 4 hours sleep recording. DKD was diagnosed as 
either micro-albuminuria (≥3.4mg/mmol) or macro-albuminuria (≥34 mg/mmol) based on 
early morning urine ACR. Multivariate analysis demonstrated that OSA was associated 
with micro-albuminuria (adjusted OR 1.84, 95% CI: 1.16 to 2.69) as well as macro-
albuminuria (adjusted OR 2.97, 95% CI: 1.36 to 6.90). The confounders adjusted for were 
made for age, sex, BMI, hypertension, hyperlipidaemia, smoking and alcohol status, DM 
duration, HbA1c, medications for stroke and ischemic heart disease.  
 
Another multi-centred Japanese study recruited consecutive 904 T2DM individuals.
416
 
DKD was assessed based on creatinine levels. Minimum sleep recording was not reported. 
The researchers reported a significant association between OSA and creatinine levels 
(adjusted OR 2.37, 95% CI: 1.21 to 4.65) after adjusting for age, sex, BMI, heart rate and 
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hypertension. The researchers also observed that a stepwise increase in ODI severity (ODI 
<5 events/hr, ODI between 5 and 15 events/hr and ODI >15 events/hr) was associated with 
a 0.5mg/dl increase in creatinine (adjusted OR 1.54, 95% CI: 1.10 to 2.16) after adjusted 
for similar factors.  
 
We also performed a meta-analysis on these two studies which used ODI criteria for the 
OSA diagnosis.
360,416
 The results were significant (pooled OR 2.00, 95% CI; 1.36 to 2.94, 
I
2
=0.0%, Figure 6-12). Combining the study by Tahrani and colleagues
348
 which used an 
AHI criterion for OSA diagnosis into the model showed similar results (pooled OR 2.10, 
95% CI: 1.48 to 2.97, I
2
=0.0%) as shown in Figure 6-13. However, as all three studies 
reported positive results therefore publication bias cannot be ruled out. 
 
 
Figure 6-12: Forest plot on the effects of oxygen desaturation index on diabetic kidney disease 
using results from studies which reported adjusted odds ratios only. 
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Figure 6-13: Forest plot on the effects of obstructive sleep apnoea on diabetic kidney 
disease using results from studies which reported adjusted odd ratios only. Note: Furukawa 
2013 and Tanaka 2009 diagnosed OSA using 3% ODI ≥5 events/hr whilst Tahrani 2013 diagnosed 
OSA based on AHI ≥5 events/hr.  
 
 
Three studies (n=491) examined the effect of minimum oxygen saturation on 
DKD,
225,348,414
 with only one reporting a significant association.
414
 Leong and co-
workers
225
 did not report any significant association (β=0.053, 95% CI: -0.388 to 0.495) 
after adjusted for confounding factors listed above. This was confirmed by the study by 
Tahrani and co-workers
348
 (adjusted OR 0.96, 95% CI: 0.93 to 1.00). Leong and colleagues 
(n=93) also examined the effect of mean oxygen saturation which was not significant 
(β=1.191, 95% CI: -0.039 to 2.420),225 whereas the association was significant between 
%TST<90 and eGFR using both MDRD (β=-0.215, 95% CI: -0.406 to -0.023) and CKD-
EPI (β=-0.30, 95% CI: -0.56 to -0.03) equations.  
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6.4.2.6.1 Association between DKD and other respiratory parameters: summary 
In summary, our narrative synthesis outlined a likely effect of sleep apnoea as measured by 
ODI on DKD in patients with T2DM, and this was confirmed by our meta-analysis which 
had a low level of heterogeneity. There was insufficient evidence that the level of 
hypoxaemia, %TST<90 and mean oxygen saturation have an impact on the risk of DKD.  
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6.5 Discussion  
6.5.1 Diabetic retinal disease 
There was no convincing evidence from our narrative synthesis that OSA is associated 
with DR especially for non-advanced DR in T2DM populations. The association between 
OSA and DR amongst T1DM was still unclear as only one study was available and it used 
oximetry rather than AHI as diagnosis of OSA. From the narrative synthesis, there 
appeared to be some evidence that OSA was associated with greater severity of DR as well 
as advanced DR amongst T2DM. The majority of the studies were cross-sectional except 
one cohort study, which reported significant association between OSA and the 
development of advanced DR. The meta-analysis performed for cross sectional studies, 
however, did not show any association between advanced DR and T2DM with a significant 
level of heterogeneity. Therefore, the pooled results might not be accurate. No study has 
explored the association between OSA and severity of DR as well as advanced DR in 
T1DM populations. Data on DMac was more limited and inconclusive. Whilst overall, 
larger cross-sectional studies suggested an association with OSA, this was not confirmed in 
a longitudinal study.
406
 This may be due to the relatively short duration of follow-up. 
Therefore, well-designed with good sample size long-term case control or cohort studies 
are required to establish if OSA leads to greater progression of advanced DR as well as 
DMac in both T1DM and T2DM populations.  
 
6.5.1.1 Other respiratory parameters and DR  
The evidence for the effect of ODI on DR was inconclusive from the narrative synthesis as 
only 4 studies were available whereby one of the studies examined effect on advanced DR. 
Although the meta-analysis showed significant association between ODI and OSA, the 
 227  
 
results were mainly from one study and addition of another study which used AHI as OSA 
diagnosis yielded a non-significant results with significant level of heterogeneity.  There 
was insufficient evidence to conclude on the effect of ODI on DMac. There was no 
evidence that mean oxygen saturation or the duration of nocturnal hypoxemia was 
associated with DR. There was also insufficient evidence to conclude on the effect of both 
mean oxygen saturation and %TST<90 on DMac. However, there was evidence from both 
the narrative synthesis and meta-analysis that the level of nocturnal hypoxemia had an 
impact on DR. One study
224
 also found that minimum oxygen saturation was associated 
with DMac. Due to the limited available studies, which report on the effects of minimum 
oxygen saturation on DR, publication bias of positive results might be present. Therefore, 
more studies are needed to examine the effect of minimum oxygen saturation especially 
with DMac. It will be of interest to know if low oxygen saturation in those with mild OSA 
(AHI between 5 and <15 events/hr) has any impact on DR as well as DMac in the long 
term given that this group of individuals are not likely to be offered CPAP treatment 
according to current guidelines and clinical practice.  
 
6.5.1.2 Heterogeneity in respiratory assessment  
There was a high degree of heterogeneity in the studies especially in the devices used to 
record sleep parameters. Majority of the studies used portable home sleep monitoring 
devices. The gold standard for the diagnosis of OSA is the overnight sleep laboratory 
polysomnography with a technician in attendance. Full PSG captures the most complete 
pathophysiological state of OSA using respiratory, cardiovascular, neurological, and 
muscle recordings. However, due to the increasing demand of sleep studies and the limited 
availability of facilities and technicians, portable devices are a useful cost-effective 
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alternative. A recent meta-analysis compared in-hospital PSG and portable sleep devices 
demonstrated that portable devices had good diagnostic performance with the area under 
the curve (AUC) to be between 0.85 and 0.99 depending on the severity of OSA.
418
 In our 
review, the majority of the portable devices used by the researchers of included studies had 
3 channels (airflow, oximetry and respiratory effort) except three studies, which utilised a 
device with only 2 channels (no data on effort).  
 
Apart from portable home sleep device, some studies used pulse oximetry to diagnose 
OSA. A recent study of 475 participants who underwent simultaneous portable PSG 
(Embletta) and pulse oximetry (PULSOX-300i) found that ODI correlated highly with AHI 
(r=0.886, 95% CI: 0.865 to 0.904, p<0.001).
365
 Furthermore, the AUC for ODI for the 
diagnosis of mild, moderate and severe OSA were 0.908 (95% CI: 0.880 to 0.936), 0.931 
(95% CI: 0.909 to 0.952) and 0.958 (95% CI: 0.937 to 0.979), respectively.
365
 Another 
study of 275 participants with OSA reported the accuracy for of using ODI >5 events/hr as 
the basis for diagnosis of OSA was 0.81.
419
 Studies also differed tremendously in the 
definition for apnoea/hypopnoea as well as oxygen desaturation, and the diagnostic criteria 
used for of OSA. The information regarding the minimum sleep recording period was also 
generally unavailable.  
 
Since the majority of the study designs were cross-sectional, it is difficult to infer causality. 
However, the study by Altaf et al. was prospective and they reported significant worsening 
of DR after 4 years of follow-up.
406
 It is likely that OSA resulted in the development and 
greater progression of DR. The possible mechanisms of OSA causing DR had been 
discussed in detailed in Chapter 4. Likewise, plausibility of diabetic microvascular 
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complication leading to the development of OSA had also been covered in Chapter 4. 
Therefore, the association between OSA and DR is likely bi-directional.
309
 
 
6.5.2 Diabetic kidney disease 
Our narrative synthesis demonstrated evidence of a possible association between OSA 
(diagnosed using AHI) and DKD among T2DM populations. This was confirmed by a 
meta-analysis on the studies that carried out univariate analysis. Nevertheless, crude ORs 
are subjected to multiple confounders such as age, gender and BMI and the results may not 
be accurate. Studies which performed multivariate analysis adjusted for important 
confounders such as BMI, gender and DM duration, also demonstrated a significant 
association between OSA and DKD. Additionally, the only longitudinal study with 
medium-term follow-up also showed a significant worsening of eGFR in individuals with 
T2DM and OSA.
348
 In that study, 47 participants were offered continuous positive airway 
pressure (CPAP) treatment, 16 of whom were compliant with CPAP. The eGFR decline 
was slower in the CPAP-compliant group (-7.7%, 95% CI: -15.9% to -1.8%) compared to 
non-compliant group (-10.0%, 95% CI: -17.2% to 2.3%). Although the CPAP results were 
not adjusted for important confounders and has no control group for comparison, it 
suggests that reversing sleep apnoea using CPAP may contribute to decelerating the 
decline in renal function.  
 
One of the excluded studies, the Nutritional Health And Nutrition Examination Survey 
(NHANES) study was published as a conference abstract.
420
 Participants were recruited 
between 2005 and 2008. The study was excluded because only 9.5% of the participants 
were diabetic and it was unclear whether the self-reported sleep apnoea was central or 
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OSA (present in 4.6% of the population). The NHANES researchers carried out 
multivariate regression analysis and demonstrated that when DM and sleep apnoea coexist, 
the risk of micro-albuminuria was three-fold higher (OR 3.4, 95% CI: 1.80, 6.39) and the 
risk for macro-albuminuria was 11-times greater (OR 11.39, 95% CI: 4.60 to 28.42) after 
adjusting for demographics, cardiovascular disease, blood pressure and BMI. Assuming 
the diagnosis of sleep apnoea was OSA in the majority of the participants, this research 
strengthens the evidence of the association between OSA and DKD in T2DM. Currently, 
there is a dearth of information on the effect of OSA on DKD in T1DM populations. 
 
6.5.2.1 Other respiratory parameters and DKD 
We also outlined a likely effect of ODI on DKD in T2DM populations and this was 
confirmed by our meta-analysis with low level of heterogeneity. However, publication bias 
may occur as no ‘neutral result’ study was available. It appears that there was no 
association between the level of hypoxemia and DKD although only two studies were 
available. There was insufficient evidence to conclude on the effect of mean oxygen 
saturation and %TST<90 on DKD. Currently, there is a dearth of information on the effect 
of these respiratory parameters in T1DM populations.  
 
A small degree of heterogeneity was identified in the methods and the criteria used for 
OSA diagnosis. The majority of the studies utilised either a level III or level IV portable 
device probably because it is less labour intensive and less costly as discussed in the above 
section. Differences also occur with DKD diagnosis. Some studies used albuminuria whilst 
others used either eGFR or creatinine level. Only Tahrani and colleagues
348
 used both 
albuminuria and eGFR as a diagnosis of DKD and is likely to provide a better overall 
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assessment of DKD. However, several studies, which used either eGFR or creatinine level, 
still demonstrated a significant association
225,360,416
.  
 
6.5.2.2 Pathophysiology of OSA and DKD  
Almost all the studies were cross-sectional in design and therefore unable to demonstrate 
causality, with only the study by Tahrani and co-workers
348
 longitudinal that reported a 
significant worsening of eGFR after 2.5 years of follow-up.  OSA is likely to impact on 
both the development and progression of DKD directly through intermittent hypoxemia 
(IH) and sleep fragmentations, or indirect via insulin resistance and other systemic 
diseases. IH caused by OSA had been documented to cause greater level of oxidative stress 
response, activation of inflammatory pathways leading to endothelial dysfunction.
247,248
 
Additionally, the intermittent intra-renal hemodynamic changes from recurrent 
sympathetic overdrive secondary to sleep fragmentations can cause ischemia with intra-
renal reperfusion injury leading to intrinsic renal injury.
421
 Case reports on participants 
with OSA have shown secondary focal glomerulosclerosis
370,371
 and in one case, complete 
resolution of proteinuria after bi-level positive airway pressure treatment.
370
  
 
In addition, studies have shown a dose-response relationship between the severity of OSA 
and level of glycaemia.
218
 This is likely to be caused by excess sympathetic activity, 
activation of the hypothalamic-pituitary-adrenal axis, direct insult to beta-cell function and 
activation of deleterious molecular pathways adversely affecting insulin sensitivity.
396
 
Collectively, these mechanisms result in greater insulin resistance among DM participants 
and greater insulin resistance amongst those with T2DM that has been shown to be a 
predictor of the development of micro-albuminuria irrespective of other metabolic 
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profiles.
422
 Furthermore, OSA is a known cause of resistance hypertension,
423
 and 
hypertension is a major risk factor for renal damage.
424
 On the other hand, it is also 
plausible that diabetes microvascular complication causes OSA. This has been illustrated 
in Chapter 5. Therefore, there is likely to be a two-way association between OSA and 
DKD.
309
 
 
6.5.3 Limitations  
Our systematic review has limitations. The reliance on the results from cross-sectional 
studies is a major concern. It is well-documented in the literature that cross-sectional 
studies are usually subject to selection bias.
425
 This was certainly reflected in our quality 
assessment in both selection bias. Most of the studies did not blind either the DKD or DR 
outcome from the assessor who scored the sleep recording reflecting possible measurement 
bias. However, several studies were conference abstracts and some were in the form of 
short reports for the review of DR. Due to the word limit, only limited information was 
available for these studies. Our quality assessment tool may not have completely assessed 
the rigour of these studies. Although several studies adjusted for confounders, the issue 
with residual confounders remained. We also did not examine the possible association 
between sleep apnoea related arousals and DR. The majority of the included studies were 
from European countries, there were a few from Asia and some small studies from North 
America. There were no large studies from the North and South American, African as well 
as Asia-pacific populations. However, the underlying mechanistic effects between OSA 
and diabetic microvascular complications should not differ in other populations therefore 
our results should be generalisable in all T2DM populations. 
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6.6 Conclusion  
6.6.1 Diabetic retinal disease 
Although our review explored the effects of OSA on DR, it is important to note that 
glycaemic control and hypertension are still the greatest risk factors for DR. This 
systematic review revealed key shortfalls in the reporting of the methodology used for 
sleep studies. We recommend that future studies should report the device used for sleep 
assessment, minimum sleep recording time, definition for apnoea/hypopnoea and the 
criteria used for the diagnosis of OSA as a minimum. In addition, several of the respiratory 
sleep parameter results were missing in majority of the studies. This could perhaps be 
avoided if core outcome reporting for sleep studies is introduced for observational studies 
in addition to intervention trials. Another important consideration is blind scoring of 
sleep/retinopathy data. Statistical analyses of such data should also report effect sizes after 
adjustment of major potential confounders. Given the high prevalence of OSA in patients 
with T2DM, the potential association between OSA, intermittent hypoxemia and diabetes 
complications, and plausibility of shared pathophysiological mechanisms between OSA 
and DM, there is a need for future large prospective studies with long term follow-up data 
to examine the long term effects of OSA including sleep apnoea related arousals as well as 
other respiratory sleep parameters on non-advanced as well as advanced DR in both T1DM 
and T2DM populations. Likewise, it is also important to follow-up OSA-free DR 
individuals to determine if DM micro-vascular complications contribute to OSA 
development.   
 
6.6.2 Diabetic kidney disease 
Our systematic review demonstrated that OSA was associated with DKD in T2DM 
populations. There is a dearth of information on the effect of OSA on DKD amongst 
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T1DM. In light of the plausible bi-directional mechanisms between OSA and DKD, there 
is a need for large prospective studies with long term follow-up to determine the long term 
effects of AHI as well as other respiratory parameters on both albuminuria and GFR in 
both T1DM and T2DM populations in the future. Similarly, it is also vital to monitor 
disease free DKD individuals to examine if micro-vascular complications play any role in 
the development of OSA.  
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CHAPTER 7 – CONCLUSIONS  
 
In summary, this thesis demonstrated that the duration and the level of nocturnal 
hypoxaemia are associated with glycaemic control in patients with type 2 diabetes mellitus 
(T2DM). We also reported relationships between the duration of hypoxaemia and the risk 
of diabetic kidney disease (DKD); and the level of nocturnal hypoxaemia and the risk of 
diabetic maculopathy. The latter findings were further confirmed by the systematic review 
in which showed an inverse relationship between minimum oxygen saturation and the risk 
of diabetic retinopathy. Although we could not conclude on the effect of the duration of 
hypoxaemia on DKD, our systematic review demonstrated that the presence of obstructive 
sleep apnoea (OSA) does seem to be associated with the risk of DKD. We also showed that 
OSA is not only more prevalent but also more severe in South Asians compared to white 
Europeans. 
 
The findings of this thesis have important implications in the management of extreme 
obese individuals as well as raising several issues for future researches. Some of the key 
implications include: 1) obesity is a complex disease, 2) the importance of individualised 
care especially in the management of OSA in South Asians, and 3) the reliance of using 
apnoea-hypopnoea index (AHI) in the management of OSA.  
 
7.1 Findings in the context of obesity as a complex disease 
It is well established that obesity is associated with both OSA (chapter 1, section 1.3.4) and 
diabetes mellitus (DM) (chapter 3, section 3.1.1). Other chronic diseases associated with 
obesity are cardiovascular disease, stroke, hypertension, dyslipidaemia and several 
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malignancies (chapter 1, section 1.1.5). Therefore, obesity is a complex disease affecting 
the functions of several organ systems. Our significant findings on the association between 
glycaemic control as well as diabetic microvascular complications and OSA amongst 
extreme obese individuals provide further evidence to support this notion.  
 
Although future longitudinal research is needed to address the causal relationship between 
OSA and microvascular complications, it is likely that obesity will have, at least in part, an 
indirect influence through the effect of OSA (please refer to chapter 4, section 4.5.2 and 
chapter 5, section 5.5.2.3) or DM, on the development and progression of diabetic 
microvascular complications. Therefore, weight management strategies are likely to be 
beneficial in treating OSA, DM and possibly microvascular complications. The ‘Action on 
obesity: comprehensive care for all’ report published by the Royal College of Physicians 
recommended a multidisciplinary team (MDT) approach to weight management.
34
 The 
MDT should be supported by policy makers, acting as the driver for good practice and 
involved in the development and implementation of local and national guidelines. 
Additionally, the team have a role in evaluating and improving their clinical practice as 
well as participation in future research to continually improve care.  
 
7.2 Findings in the context of personalised care  
Most importantly, the team will have the role of optimising individual patient care. The 
National Institute for Health and Care Excellence (NICE) clinical guidance 138: Patient 
experience in adult NHS services: improving the experience of care for people using adult 
NHS services, recommends individualisation of patient care, taking into account the 
variations in which a condition may impact on individuals, and tailoring treatment 
 237  
 
accordingly.
426
 Each patient is different and one distinct characteristic that must be 
considered is ethnic background. Our study found that South Asians, a relatively 
understudies sub-population, suffer from more severe OSA compared with white 
Europeans with extreme obesity.  
 
Future studies are needed to explore the interactions between metabolic risk factors and 
quality of life in these group. There is also a need to have improved insight into the clinical 
presentations of OSA among South Asians patients. The Sleep Heart Health Study (SHHS) 
which consisted of 13,194 participants, demonstrated a difference in OSA symptomology 
amongst Hispanic, Afro-Caribbean and white Caucasians.
427
 However, objective 
assessment of sleep symptoms has not been performed in South Asians populations in the 
UK. In addition, longitudinal studies on the health consequences of OSA among South 
Asians are needed to identify if this ethnic group faces similar risk as their white European 
counterparts. Finally, the effect of OSA treatment whether it is with continuous positive 
airway pressure (CPAP) or with weight reduction strategies, on various health outcomes, 
as well as adherence to treatment, should also be studied by ethnic group.  
 
7.3 Findings in the context of respiratory parameters 
Currently, the American Academy of Sleep Medicine (AASM) recommended that those 
with apnoea-hypopnoea index (AHI) ≥15 events/hr should be considered for CPAP 
regardless of the level of obesity.
75
 This recommendation ignores individuals with AHI 
<15 events/hr, who may have low nocturnal oxygen saturation or those who have long 
durations of nocturnal hypoxaemia. Our results suggests that minimum oxygen saturation 
and percentage of time spent under 90% oxygen saturation (%TST<90) also may have a 
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pivotal role in both glycaemic control and diabetic microvascular complications in DM 
individuals with extreme obesity.  
 
Although our study cannot infer causality, our findings raise questions on the reliance of 
the AHI as a sole criterion for the treatment of OSA. We therefore suggest that further 
research is needed to clarify this. The first step is to confirm if the level and duration of 
nocturnal hypoxaemia are better predictors compared to the AHI for the development 
and/or progression of diabetic microvascular complications in well-designed longitudinal 
studies. If this is true then the second step is to identify if there is a minimum threshold 
which may contribute to the glycaemic control and the development and progression of 
diabetic microvascular complications for both the minimum oxygen saturation and 
%TST<90 regardless of the AHI. Then the third step is to carry out a well-designed 
prospective randomised controlled trial to establish if correcting the level and/or duration 
of hypoxaemia has any beneficial effects on glucose levels and disease progression in 
diabetes mellitus. This is especially important in individuals with AHI <15 events/hr (not 
qualified for CPAP). It is also important to establish if there is any difference in the 
response to the treatment of hypoxaemia according to different ethnic groups such as South 
Asians.  
 
One of the limitations of our study is that we only examined a severely obese T2DM 
population and the effect of OSA on Type 1 diabetes mellitus (T1DM) is not studied. 
Although we did not investigate the effect in T1DM, it is likely that the underlying 
mechanisms will not differ between these two groups. However, studies still needed to 
address if the impact of OSA on vascular complications in T1DM populations is similar to 
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those in T2DM. Future work should also examine if the factors which mediates the effect 
of hypoxaemia on glycaemic control, retinal and renal function in this population. 
 
Our study identifies several gaps in our understanding of the effect of OSA on disease 
outcomes such as whether effects differ by ethnicity (South Asians). Although AHI is the 
recommended tool for diagnosis and treatment of OSA, we demonstrated that other 
nocturnal hypoxaemia parameters may also play a role in glycaemic control and diabetic 
microvascular complications. However, future research is needed to confirm this. Our 
findings also support the current available evidence that obesity is a complex disease.  
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APPENDICES 
Appendix 1: Data extraction form for systematic review chapter 
(Chapter 6) 
Study identifications     
  Study No 
   First author  
   Year of publication 
   Reference 
 
  
Country  
 
 Publication 
characteristics     
  Source of Funding  
   Role of funder 
 
  
Study design 
 
 Methodology Consecutive recruitment? 
   Summary of study aims 
   Setting 
   Selected population  
 
  
Excluded population 
 
 
Respiratory methods 
Sleep study (method, 
device) 
 
  
Definition of 
apnea/hypopnea/oxygen 
desaturation 
 
  
Definition for OSA 
diagnosis 
 
  
Minimum duration of 
recording 
 
 Outcome measures (eg. 
retinopathy score, ACR) Data source 
 
  
Scoring methods (eg. For 
retinopathy) 
 
 Sample size Total Number 
   Attrition/missing data 
   OSA 
   Non OSA 
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Demographics Age 
   Female (%) 
   BMI 
   HbA1c 
 
  
DM duration  
 
 
 Outcome results Outcome 1 
 OSA vs. non-OSA Outcome 2 
   Outcome 3 
   Outcome 4 
   Outcome 5 
   Outcome 6 
   Outcome 7  
 Analysis Method (?multivariate) 
   Result outcome 1 
   Result outcome 2 
   Result outcome 3 
   Result outcome 4 
   Result outcome 5 
   Confounders adjusted  
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Appendix 2: Quality assessment form for systematic review chapter 
(Chapter 6) 
 
Author:                                                        Year:                                     Study ID:                                                         
Reviewer initials: 
 Yes/No/Unclear Supporting 
evidence 
Selection bias 
8. Does the study address an appropriate and clearly focused 
question?  
  
9. Was consecutive patients recruited?    
10. Was the cases and controls taken from comparable 
populations?  
  
11. Were the exclusion criteria the same for both cases and 
controls?  
  
12. Was the participant representative of the patient population?   
13. If applicable, was the control group comparable to cases 
(consider suitability, recruitment and baseline characteristics)? 
  
14. Was it clear that controls are not cases (in case control)?   
Overall Judgment for selection bias (Weak / Moderate /Strong)   
Respiratory measurement 
4. Was a suitable measurement for OSA used? (PSG/oximetry 
measured in standard, valid and reliable way) 
  
5. Was the scoring of the respiratory measures based on 
guidelines / consensus guidelines eg. AASM guidelines?  
  
6. Was there a clear definition of OSA used?    
Overall Judgment for measurement (Weak / Moderate / Strong)   
Blinding  
3. Blinding of assessor performing sleep analysis   
4. Blinding of assessor of retinal photographs   
Overall Judgment for measurement (Weak / Moderate / Strong)   
Study methods 
4. Were participant attrition rates /missing data documented?   
5. Were reasons given for drop outs / missing data?   
6. Is this retrospective / prospective design?    
Overall Judgment for study design (Weak / Moderate / Strong)   
Analysis  
3. Were all outcomes reported?   
4. Were confounding variables adjusted for?   
Overall Judgment for analysis (Weak / Moderate /Strong)   
Overall judgment for the study (Weak, Moderate, Strong)  
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Appendix 3: MOOSE checklist for the systematic review on the effect of 
obstructive sleep apnoea on diabetic retinopathy 
Criteria Brief description of how the criteria were handled in 
the meta-analysis 
Reporting of background should 
include 
 
 Problem definition Obstructive sleep apnoea (OSA) has been found to be 
associated with diabetes mellitus and worsening insulin 
resistance, and thus is likely to be associated with a 
greater risk of development or progression of diabetic 
microvascular complications. However, the current 
evidence on the associations between OSA or chronic 
intermittent hypoxaemia (CIH) and diabetic retinopathy 
(DR) and maculopathy (DMac) has been inconclusive. 
 Hypothesis statement OSA increases the risk of DR and DMac  
 Description of study outcomes Effects on DR and DMac 
 Type of exposure or 
intervention used 
Presence or absence of OSA/CIH 
 Type of study designs used We included prospective cohort and cross-sectional 
studies. We excluded intervention studies.  
 Study population Type 1 or Type 2 diabetes mellitus. Please refer to Table 
6-1 for full eligibility criteria. 
Reporting of search strategy 
should include 
 
 Qualifications of searchers WBL - MBChB, MRCP  
 Search strategy, including time 
period included in the 
synthesis and keywords 
MedLine from inception until January 2014 
EMBASE from inception until January 2014 
Cochrane Database from inception until January 2014 
OpenGrey from Inception until January 2014 
Zetoc from Inception until January 2014 
We used both MeSH/Emtree Headings and free text for 
the search. Please refer to Table 6-2 for search terms. 
 Databases and registries 
searched 
MedLine, EMBASE, Cochrane Database 
Grey literature: OpenGrey and Zetoc  
 Search software used, name 
and version, including special 
features 
OvidSP was used for MEDLINE and EMBASE searches. 
EndNote X5 was employed to combine citations and 
eliminate duplications 
 Use of hand searching We hand-searched citations of all included papers.  
 List of citations located and 
those excluded, including 
justifications 
Please refer to Figure 6-1 of the PRISMA flow chart for 
study selection process. The full citation list is available 
upon request. 
 Method of addressing articles 
published in languages other 
than English 
We included English, Chinese and French language 
papers. Unfortunately, due to limitation on skills and 
budget, we were unable to translate 2 papers (1 Russian 
and 1 Czech language).  
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 Method of handling abstracts 
and unpublished studies 
We contacted the authors of relevant unpublished studies 
(mainly conference abstracts) for additional data.  
 Description of any contact with 
authors 
We contacted authors on number of DR in OSA and non 
OSA groups. When appropriate, we also sought data on 
diabetes maculopathy. 
Reporting of methods should 
include 
 
 Description of relevance or 
appropriateness of studies 
assembled for assessing the 
hypothesis to be tested 
Eligibility criteria are described in the methods section of 
Chapter 6 and summarised in Table 6-1.  
 Rationale for the selection and 
coding of data 
Prior to formal data extraction, a standardised form was 
designed based on the STROBE. The standardised data 
extraction form was piloted on a sample of 5 studies and 
improvements were made before formal use for the 
systematic review. Data extracted include study 
identification, study design, measures for OSA or CIH, 
characteristics of participants, funding, results on DR and 
DMac. 
 Assessment of confounding We meta-analysed results from studies which performed 
multivariate analysis (adjusted ORs and 95% CI) to 
provide a least bias estimate. 
 Assessment of study quality, 
including blinding of quality 
assessors; stratification or 
regression on possible 
predictors of study results 
A revised quality assessment form was devised based on 
the Newcastle Ottawa Scale. An overall judgment of 
either ‘weak’, ‘moderate’ or ‘strong’ were given to study 
based on the rating of 5 components:  study design, 
selection bias, measurement and methods, blinding of the 
assessor performing DR or sleep analysis on participants’ 
characteristics, and analysis. Each components had a set 
of criteria and each criterion was rated as ‘yes’, ‘no’ or 
‘unclear’. 
 Assessment of heterogeneity The I
2
 statistic was employed to assess heterogeneity. 
 Description of statistical 
methods in sufficient detail to 
be replicated 
Stata 13 was used for meta-analysis. Adjusted ORs and 
95% CI were log transformed followed by both fixed and 
random effects models analyses. Pooled results were 
back-transformed and only results from random effects 
model were presented.  
 Provision of appropriate tables 
and graphics 
We included the following in Chapter 6:  
1. Characteristics and results of included studies 
2. Quality assessment of included studies 
3. Figure 6-1: PRISMA flow chart on study selection 
4. Forest plots of pooled estimates 
5. Funnel plot for publication bias. 
We also included:  
1. Eligibility criteria for the systematic review 
2. Search terms for the systematic review 
3. Quality assessment form 
4. Criteria used for OSA and DKD assessment as 
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reported by included studies 
 
Reporting of results should 
include 
 
 Graph summarizing individual 
study estimates and overall 
estimate 
Please refer to Figure 6-2, 6-4, 6-5, 6-6, 6-7 and 6-8 for 
details.  
 Table giving descriptive 
information for each study 
included 
Please refer to Table 6-3 in the manuscript 
 Results of sensitivity testing 
 
Please refer to Figure 6-8. 
 Indication of statistical 
uncertainty of findings 
Pooled-odds ratios with 95% confidence intervals and I
2
 
values
 
were presented for all meta-analyses 
Reporting of discussion should 
include 
 
 Quantitative assessment of bias Funnel plot was employed and risk of publication bias 
was discussed. Limitations of observational studies on 
residual bias was discussed 
 Justification for exclusion We excluded studies that had not reported on our 
outcome of interests or not exposed to OSA.  
 
 Assessment of quality of 
included studies 
Implications on the assessment of conference 
abstracts/short reports on the quality of studies was 
discussed. 
 
Reporting of conclusions should 
include 
 
 Consideration of alternative 
explanations for observed 
results 
We discussed a possible bi-directional association 
between OSA and DR/DMac (Chapter 4) as well as the 
possibility of residual confounders.  
 
 Generalization of the 
conclusions 
We noted a lack of studies from the North and South 
American, African as well as Asia-pacific populations. 
However, the underlying mechanistic effects between 
OSA and DR/DMac should not differ in other populations 
therefore our results should be generalisable in all T2DM 
populations. 
 Guidelines for future research This systematic review found:  
a. Key shortfalls in the reporting of methodology 
used for sleep studies and that this could perhaps 
be avoided if core outcome reporting is introduced 
for observational studies. 
b. Future large prospective studies with long term 
follow-up data to examine the effects of OSA on 
DR/DMac in T1DM and T2DM populations are 
needed. 
c. Likewise, prospective studies to follow up OSA-
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free DR/DMac individuals to determine effect of 
DM micro-vascular complication on OSA 
development. 
 Disclosure of funding source No funding 
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Appendix 4: MOOSE checklist for the systematic review on the effect of 
obstructive sleep apnoea on diabetic kidney disease  
Criteria Brief description of how the criteria were handled in 
the meta-analysis 
Reporting of background should 
include 
 
 Problem definition Obstructive sleep apnoea (OSA) has been found to be 
associated with diabetes mellitus and worsening insulin 
resistance, and thus is likely to be associated with a 
greater risk of development or progression of diabetic 
microvascular complications. However, the current 
evidence on the associations between OSA or chronic 
intermittent hypoxemia (CIH) and diabetic kidney disease 
(DKD) has been inconclusive. 
 Hypothesis statement OSA increases the risk of DKD 
 Description of study outcomes Effects on DKD (renal function or albuminuria) 
 Type of exposure or 
intervention used 
Presence or absence of OSA/CIH 
 Type of study designs used We included prospective cohort and cross-sectional 
studies. We excluded intervention studies.  
 Study population Type 1 or Type 2 diabetes mellitus. Please refer to Table 
6-1 for full eligibility criteria. 
Reporting of search strategy 
should include 
 
 Qualifications of searchers WBL - MBChB, MRCP  
 Search strategy, including time 
period included in the 
synthesis and keywords 
MedLine from inception until January 2014 
EMBASE from inception until January 2014 
Cochrane Database from inception until January 2014 
OpenGrey from Inception until January 2014 
Zetoc from Inception until January 2014 
We used both MeSH/Emtree Headings and free text for 
the search. Please refer to Table 6-2 for search terms. 
 Databases and registries 
searched 
MedLine, EMBASE, Cochrane Database 
Grey literature: OpenGrey and Zetoc  
 Search software used, name 
and version, including special 
features 
OvidSP was used for MEDLINE and EMBASE searches. 
EndNote X5 was employed to combine citations and 
eliminate duplications 
 Use of hand searching We hand-searched citations of all included papers.  
 List of citations located and 
those excluded, including 
justifications 
Please refer to Figure 6-9 of the PRISMA flow chart for 
study selection process. The full citation list is available 
upon request 
 Method of addressing articles 
published in languages other 
than English 
We included English, Chinese and French language 
papers. Unfortunately, due to limitation on skills and 
budget, we were unable to translate 1 Czech paper 
 Method of handling abstracts We contacted the authors of relevant unpublished studies 
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and unpublished studies (mainly conference abstracts) for additional data.  
 Description of any contact with 
authors 
We contacted authors on frequency and adjusted odd 
ratios of DKD in OSA and non OSA groups.  
Reporting of methods should 
include 
 
 Description of relevance or 
appropriateness of studies 
assembled for assessing the 
hypothesis to be tested 
Eligibility criteria are described in the methods section 
and summarised in Table 1 in supplementary materials. 
 Rationale for the selection and 
coding of data 
Prior to formal data extraction, a standardised form was 
designed based on the STROBE. The standardised data 
extraction form was piloted on a sample of 5 studies and 
improvements were made before formal use for the 
systematic review. Data extracted include study 
identification, study design, measures for OSA or CIH, 
characteristics of participants, funding and results on 
DKD. 
 Assessment of confounding We meta-analysed results from studies which performed 
multivariate analysis (adjusted ORs and 95% CI) to 
provide a least bias estimate. 
 Assessment of study quality, 
including blinding of quality 
assessors; stratification or 
regression on possible 
predictors of study results 
A revised quality assessment form was devised based on 
the Newcastle Ottawa Scale. An overall judgment of 
either ‘weak’, ‘moderate’ or ‘strong’ were given to study 
based on the rating of 5 components:  study design, 
selection bias, measurement and methods, blinding of the 
assessor performing sleep analysis on participants’ 
characteristics, and analysis. Each components had a set 
of criteria and each criterion was rated as ‘yes’, ‘no’ or 
‘unclear’. 
 Assessment of heterogeneity The I
2
 statistic was employed to assess heterogeneity. 
 Description of statistical 
methods in sufficient detail to 
be replicated 
Stata 13 was used for meta-analysis. Adjusted ORs and 
95% CI were log transformed followed by both fixed and 
random effects models analyses. Pooled results were 
back-transformed and only results from random effects 
model were presented.  
 Provision of appropriate tables 
and graphics 
We included the following in the manuscript:  
5. Table 6-6: Characteristics and results of included 
studies 
6. Table 6-8: Quality assessment of included studies 
7. PRISMA flow chart on study selection 
8. Forest plot for pooled estimates 
9. Funnel plot for publication bias 
 
We also included:  
10. Eligibility criteria for the systematic review 
11. Search terms for the systematic review 
12. Quality assessment form 
13. Criteria used for OSA and DKD assessment as 
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reported by included studies 
 
Reporting of results should 
include 
 
 Graph summarizing individual 
study estimates and overall 
estimate 
Please refer to Figure 6-10, 6-12, 13 
 Table giving descriptive 
information for each study 
included 
Please refer to Table 6-6 
 Results of sensitivity testing 
 
Figure 6-12 
 Indication of statistical 
uncertainty of findings 
Pooled-odds ratios with 95% confidence intervals and I
2
 
values
 
were presented for all meta-analyses 
Reporting of discussion should 
include 
 
 Quantitative assessment of bias Funnel plot was employed and risk of publication bias 
was discussed. Limitations of observational studies on 
residual bias was discussed 
 Justification for exclusion We excluded studies that had not reported on our 
outcome of interests or not exposed to OSA.  
 
 Assessment of quality of 
included studies 
Implications on the assessment of conference 
abstracts/short reports on the quality of studies were 
discussed. 
 
Reporting of conclusions should 
include 
 
 Consideration of alternative 
explanations for observed 
results 
We discussed a possible bi-directional association 
between OSA and DKD (Chapter 5) as well as the 
possibility of residual confounders.  
 
 Generalization of the 
conclusions 
We noted a lack of studies from the North and South 
American, African as well as Asia-pacific regions. 
However, the underlying mechanistic effects between 
OSA and DKD should not differ in other populations 
therefore our results should be generalisable in all T2DM 
populations. 
 Guidelines for future research This systematic review found:  
d. OSA was associated with DKD in T2DM 
population 
e. Dearth of information on the effect of OSA on 
DKD in T1DM population 
f. Future prospective studies up to determine the 
long term effects of OSA on DKD in T1DM and 
T2DM populations. 
 Disclosure of funding source No funding 
 
